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Thesis Abstract  
 
Background 
Providing optimal care for older adults creates many challenges for healthcare 
providers especially general practitioners (GPs). Appropriate prescribing of 
medications is a significant challenge as older adults can present with multiple 
conditions for which multiple medications are often indicated. Potentially 
inappropriate prescribing (PIP) in older adults is common and is associated with 
negative health outcomes such as morbidity, adverse drug events, extended hospital 
stays and increased mortality. Therefore, the overarching aim of this thesis was to 
understand the potential role of the pharmacist in optimising prescribing for older 
people in primary care. 
Methods 
Multiple research methods were performed to address the thesis aim. A cross-
sectional study was carried out to highlight the prevalence of prescribing issues in 
older adults across three countries. The published literature was then systematically 
reviewed to evaluate studies of pharmacist-led interventions on PIP among 
community-dwelling older adults in primary care to identify the components of a 
successful intervention. Based on the findings from the systematic review, a 
qualitative study was carried out to reveal the determinants of GP prescribing 
behaviour for older adults in primary care and to elicit GPs’ views on the potential 
role for broad intervention strategies involving pharmacists and/or information 
technology systems in general practice. These findings then informed the 
pharmacist-led academic detailing intervention with GPs on the topic of urinary 
12 
 
incontinence in older people. This was a mixed methods feasibility study utilising 
qualitative focus groups with GPs and quantitative data from patient medical records 
in those ≥65 years with urinary incontinence in a region of Ireland. 
Results 
The cross-sectional study highlighted that the overall prevalence of PIP and potential 
prescribing omissions (PPOs) was 12.9% and 22.2% respectively in this cohort of 
European participants. The systematic review concluded that four out of the five 
studies included in the review were associated with an improvement in prescribing 
appropriateness. However it is unclear if these interventions result in clinically 
significant improvements in patient outcomes. The qualitative study highlighted the 
complexities of behavioural determinants of prescribing for older people in primary 
care and the need for additional supports for example, extra training in geriatric 
pharmacology and drug interactions to optimise prescribing for this growing cohort 
of patients. One approach that GP participants agreed could lead to a meaningful and 
sustained improvement in prescribing is interactive educational outreach or 
academic detailing. Therefore, an intervention was developed incorporating 
pharmacist-led academic detailing. In the feasibility study, the intervention was well 
received and highly valued by GPs. The measures of prescribing assessed before and 
after the intervention (LUTS-FORTA criteria; Drug Burden Index (DBI); Anticholinergic 
cognitive burden scale (ACB)); and the Screening Tool of Older Person’s Prescriptions-
Screening Tool to Alert Doctors to Right Treatment (STOPP/START) version 2 criteria) 
reported minimal or no change. However, as this was a feasibility study it was not 
designed or powered to demonstrate a change in these parameters. 
13 
 
 
Conclusion 
This study has made an important contribution to the topic of prescribing for older 
adults in primary care by highlighting that educational interventions such as 
academic detailing are welcomed in the context of general practice in Ireland. The 
success of this educational strategy is likely to depend on engaging with all key 
stakeholders e.g. academic detailers, prescribers, professional bodies and academic 
institutions to ensure that the content delivered is relevant and practical to 
prescribers.  
14 
 
Chapter 1. Introduction  
 
Population demographics are changing worldwide, with life expectancy and numbers 
of older persons increasing (1). In 1960, 8.6% of the Organisation for Economic Co-
operation and Development (OECD) population was aged ≥65 years (2, 3). Today, 
that figure is 15.4% and by 2050 it is expected to rise to 27.2% (2, 3). In Ireland older 
individuals aged ≥ 65 years constitute approximately 12% of the population and it is 
estimated that by 2045 this figure will almost double. The proportion of individuals 
≥85 years will almost triple during the same time period (4). 
The ageing process is characterised by physiological changes that can influence the 
function of organ systems and compromise homeostatic capacity (5). Changes in 
body composition, hepatic and renal function can alter the volume of distribution of 
lipid soluble drugs, reduce the clearance of lipid and water soluble drugs, 
respectively. Pharmacodynamic changes can in general, increase the sensitivity to 
drugs (5). Additionally, older people are more likely to present with multiple 
conditions for which multiple medicines are required, increasing the probability of 
drug-drug and drug-disease interactions (6-9). Another major challenge is providing 
optimal care for older adults with multiple chronic conditions or “multimorbidity” 
(10-13). It is defined as the co-occurrence of two or more chronic conditions in a 
person (14). Multimorbidity is associated with many adverse outcomes including 
death, disability, increased burden of healthcare resources, negative impact on 
quality of life and a higher incidence of adverse effects to pharmacological or non-
pharmacological interventions (10).   
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Therefore, providing optimal care for older adults creates many challenges for 
healthcare providers especially general practitioners (GPs) as they are the main 
prescribers of medication in primary care (11-13, 15).  
 
1.1 Potentially inappropriate prescribing (PIP) 
Medication related problems are common in older adults and are associated with 
increased morbidity, adverse drug events, adverse drug reactions, extended hospital 
stays and increased mortality (16-18). Potentially inappropriate prescribing (PIP) is a 
term used to describe a range of sub-optimal prescribing practices and can be 
classified as either:  
i. The prescribing of potentially inappropriate medicines (PIMs), the use of a 
medicine where no clear clinical indication exists or the use of a medicine in 
circumstances where the risks outweigh the benefits. 
ii. Potential prescribing omissions (PPOs), the under-prescribing of medicines 
for which there is a clear clinical indication (9). 
 
PIP introduces the risk of an adverse drug event (ADE) which has the potential to 
outweigh the drug’s clinical benefit, particularly when a safer or more effective 
alternative treatment option is available (19).  
 
A number of studies have reported the prevalence of PIP/PPOs in large populations 
of older adults. Cahir  et al. estimated the prevalence of PIP was 36% among adult’s 
≥70 years in a primary care population in Ireland (20). In a similar study, Bradley  et 
al. reported a prevalence of PIP of 29% among older adults in primary care in the UK 
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(21). In the United States and Canada epidemiological studies have documented PIP 
prevalence rates in community-dwelling older adults ranging from 14% to 37% (22-
24), while in Europe, PIP has been identified in 12-20% of older adults (25-27).   
 
As older people have substantial variation in their health status for example, health, 
disease and disability, this makes the generalisation of prescribing decisions more 
challenging for prescribers (18). Limited availability and access to appropriate 
evidence based information in older and frail patients (studies have not been carried 
out, not synthesised or not available in the public domain) can also present 
challenges to healthcare providers (18, 28, 29). Despite the high prevalence of 
multimorbidity in the elderly population, most clinical trials focus on the benefit of 
one drug in one condition, thus excluding multimorbid participants (30, 31). These 
limitations cast doubt on otherwise high-quality clinical evidence, which in turn 
weakens prescribers’ confidence in trial results (13). Therefore, interventions that 
optimise the quality of prescribing for this cohort of patients are necessary.  
 
1.2. Methods to assess PIP 
Assessing the appropriateness of prescribing in older people involves both implicit 
and explicit measures (20). Implicit measures involve a prescriber’s judgment of 
appropriateness based on patient characteristics and published work (32). Explicit 
measures are criterion based and are derived from published literature, 
multidisciplinary expert panels and consensus validation methods (33). 
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The Medication Appropriateness Index (MAI) is an example of a validated implicit 
tool (34). It consists of ten criteria that relate to a number of different prescribing 
domains for example, indication, effectiveness, dose, duration, correct directions, 
practical directions, drug-drug interactions, drug-disease interactions, duplication 
and cost. The tool generates a weighted score (ranging from 0-18) per drug that 
serves as a measure of medication appropriateness. A higher score indicates an 
increased level of inappropriateness (34).  The Assessment of Underutilization (AOU) 
is another implicit tool, however it only identifies prescribing omissions (35).  
 
The first explicit tool for identifying PIP was the Beers criteria, developed in the 
United States in 1991 (19). The criteria were revised and updated in 1997, 2003, 2012 
and 2015 (36). The Beers 2015 criteria are divided into five categories: 
i. Drugs to be avoided in older people independent of diagnoses. 
ii. Drugs to be avoided in older people with certain diseases and syndromes. 
iii. Drugs to be used with caution in older people. 
iv. Drugs to be avoided or have their dose adjusted, based on the individual’s 
kidney function. 
v. Select drug-drug interactions documented to be associated with harm in 
older adults.  
 
However, the Beers criteria contain several medicines that are either not prescribed 
or not available in most European drug formularies, thus its application in an EU 
setting is limited (37). 
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In recent years, the STOPP/START (Screening Tool of Older Persons Prescriptions, 
Screening Tool to Alert doctors to Right Treatment) criteria were developed and 
validated as an explicit measure of PIP and potential prescribing omissions (PPOs) for 
use in older adults (≥ 65 years) in European countries (38). The original STOPP set 
consisted of 65 criteria of PIP, including drug-drug and drug-disease interactions 
(potentially leading to side effects such as cognitive decline and falls in older people), 
as well as duplicate drug class prescriptions. The original START set consisted of 22 
criteria that identify PPOs (38, 39). All criteria are organised according to 
physiological systems for ease of use (38). In 2014, due to an expanding therapeutics 
evidence base the STOPP/START criteria were revised and updated. A number of new 
evidence-based criteria were added and any obsolete or out of date criteria were 
removed. The revised set, STOPP/START version 2 (STOPP/START V2), consists of 80 
STOPP and 34 START criteria. Several new STOPP categories created in version 2 
include antiplatelet/anticoagulant drugs, drugs affecting, or affected by, renal 
function and drugs that increase anticholinergic burden. New START categories 
include urogenital system drugs, analgesics and vaccines (40). 
 
Other explicit tools that have been developed worldwide include: the Australian 
Prescribing Indicators Tool which contains 45 explicit and 3 implicit prescribing 
indicators (41).  The French Consensus Panel List contains 34 inappropriate practices 
in prescribing with recommendations for alternative therapies (42).  The Improved 
Prescribing in the Elderly Tool (IPET) consists of 14 inappropriate practices in 
prescribing (43). The Norwegian General Practice Criteria (NORGEP) contains 36 
criteria for pharmacologically inappropriate prescribing in general practice (44). The 
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PRISCUS list contains 83 drugs in a total of 18 drug classes as potentially inappropriate 
(45). The Thailand criteria consists of 77 practice statements or criteria for high-risk 
medication use (46). McLeod et al. developed a consensus-based list of 38 
inappropriate high-risk practices in prescribing grouped into 4 categories with 
recommendations for alternative therapies (47). Zhan’s criteria contains a 
classification of 33 drugs (48). The Zhan and McLeod criteria target older people ≥ 65 
years, the IPET and NORGEP criteria focus on those ≥ 70 years, while the intended 
population for the French Consensus Panel list are those ≥ 75 years (42-44, 47, 48). 
There is no age stated for the Thailand criteria (46).  
 
1.2.1. Other methods to optimise prescribing appropriateness  
This section highlights a number of other criteria that focus on particular classes of 
medicines. 
 
LUTS-FORTA criteria 
Drugs to treat lower urinary tract symptoms (LUTS) regularly used in older people 
aged ≥65 years are classified on their appropriateness based on efficacy, safety and 
tolerability using the Fit fOR The Aged (FORTA) criteria. This validated criteria 
classifies drugs for the treatment of LUTS into four categories, A (absolutely: 
indispensable drug), B (beneficial: drugs with proven efficacy), C (careful: drugs with 
questionable efficacy/safety profiles) and D (don’t: avoid in older people). Using a 
systematic approach including a literature search and a subsequent two-step Delphi 
process, an interdisciplinary international panel rated the appropriateness of the 16 
most frequently prescribed drugs for the long term treatment of LUTS (49) . 
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The Drug Burden Index (DBI) 
The DBI was developed to measure the cumulative exposure to anticholinergic and 
sedative medicines in older people and its impact on physical and cognitive function 
(50). The calculation of the DBI is based on a pharmacological equation that 
incorporates drug dose and the principles of dose response (51). 
DBI = Σ D / δ + D 
D is equal to the daily dose taken and δ is the minimum dose recommended by a 
relevant formulary (50). For each drug the DBI ranges from 0-1, with 0 being no 
burden, 0.5 being exposure to the minimum daily dose and upwards to 1 as the dose 
is increased exponentially (52). The sum of these individual drugs equals to the total 
drug burden. 
 
Anticholinergic cognitive burden scale (ACB) 
The cumulative effect of taking multiple medicines with anticholinergic properties is 
defined as the anticholinergic burden (53). Previous studies have demonstrated that 
the use of medicines with anticholinergic activity among older adults is associated 
with physical and cognitive decline (54, 55). The ACB is based on a systematic 
literature review of medicines with known anticholinergic activity. The scale assesses 
individual drugs that have none, possible or definite anticholinergic properties with 
a score ranging from 0 to 3 (56). 
 
Several criteria e.g. STOPP/START, Beers, MAI have been developed to assess the 
prescribing appropriateness in older people. Application of such criteria may reduce 
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unnecessary use of medicines, adverse drug events, healthcare utilisation and 
economic burden (57).  When selecting criteria for research purposes, it is important 
to consider the target population and clinical information available. Different tools 
can be used to optimise prescribing in older people, however, they are only intended 
to inform clinical judgment and not to replace it (58).  
 
 
1.3 Interventions to optimise prescribing appropriateness 
Interventions to optimise prescribing appropriateness in older adults have shown 
mixed results (59, 60). A number of strategies to address PIP are detailed in the 
following section. 
 
1.3.1 Medication reviews 
The overall aim of a medication review is to improve the quality, safety and 
appropriate use of prescribed medicines. Medication review is an overarching term 
which includes a number of interventions that may be carried out by the prescriber 
themselves (e.g. self-review by GPs, pharmacists or nurses) or by other healthcare 
professionals providing advice to prescribers (e.g. independent review carried out by 
pharmacists) (61). There is good evidence that medication reviews can improve 
prescribing outcomes including reduced polypharmacy, inappropriate prescribing 
and adverse drug effects (62, 63).  
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1.3.2 Computerised decision-support systems  
Computerised decision support systems (CDSS) are widely used tools that optimise 
quality of care and patient outcomes (64). They are defined by Musen  et al. as “any 
computer program designed to help healthcare professionals to make clinical 
decisions” (65). In practice these systems may involve an alert system appearing at 
the end of a consultation or at the time of prescribing (9, 38, 66). 
These software systems have the potential to optimise prescribing appropriateness. 
A number of research projects are currently underway to assess prescribing 
appropriateness using CDSS. For example, a new Software ENgine for the Assessment 
& Optimisation of drug and non-drug Therapy in Older peRsons (SENATOR) trial aims 
to optimise pharmacological and non-pharmacological therapy, and reduce the risk 
of adverse drug reactions (ADRs) in multimorbid hospitalised older adults. This 
randomised control trial (RCT) involves recruiting patients from six European hospital 
sites. The STOPP/START V2 criteria will be incorporated into the software engine and 
will form the basis of recommendations on optimal pharmacological therapy 
(http://www.senator-project.eu/). The OPERAM study (OPtimising thERapy to 
prevent Avoidable hospital admissions in the Multimorbid elderly) aims to reduce the 
rates of over and under prescribing of medications among older European adults with 
multimorbidity. This large multicentre cluster randomised clinical trial will use a 
sophisticated software tool to determine if the intervention can improve clinical and 
economic outcomes for patients (67).  
 
 
 
23 
 
1.3.3 Academic detailing  
Academic detailing (AD) or educational outreach is a form of continuing medical 
education (CME) in which a trained healthcare professional such as a pharmacist, 
nurse or doctor visits a prescriber in their practice environment to provide evidence-
based information on a selected topic (68). These educational strategies which utilise 
interactive and tailored approaches with direct feedback have been shown to be 
effective at improving prescribing appropriateness (69). Several studies have also 
highlighted that GPs rate the educational value of AD highly (70, 71).  
 
1.4 The role of the pharmacist in primary care in Ireland 
Pharmacists play a vital role in the primary healthcare system. In Ireland, they are the 
most accessible healthcare professional, with approximately 2 million people visiting 
a pharmacy on a monthly basis, while 20 million prescriptions are filled in pharmacies 
annually (72). Therefore, pharmacists are ideally placed to support patients in 
maintaining and improving their health. Over the years, the role of the pharmacist in 
Ireland has changed significantly, with more pharmacists providing healthcare 
services such as administration of the flu vaccine, provision of emergency 
contraception, smoking cessation initiatives, cholesterol, diabetes and INR testing as 
well as dispensing medicines. These services can deliver significant benefits to both 
patients and the State by relieving the pressure from other areas of the healthcare 
system such as GPs and hospitals, allowing them to focus on more complex patients 
who require medical intervention (72).  
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1.5. Aim 
The overall aim of this thesis is to understand the potential role of the pharmacist in 
optimising prescribing for older people in primary care.  
 
1.6. Objectives 
The specific objectives of the thesis are: 
1. To estimate and compare the prevalence and type of PIP and PPOs amongst 
community-dwelling older adults (≥65 years) in three European populations. 
This sets the scene for the thesis by highlighting and comparing the 
prescribing issues for older adults across three populations. 
2. To systematically review and summarise the literature on pharmacist-led 
interventions that optimise prescribing appropriateness among community-
dwelling older adults receiving primary care to identify the components of a 
successful intervention.   
3. To explore GPs’ experiences of prescribing for patients ≥65 years and their 
views on the potential role for interventions involving pharmacists and/or 
information technology systems in general practice. 
4. To evaluate the feasibility and satisfaction of a pharmacist-led academic 
detailing intervention with GPs in primary care. 
 
1.7. Thesis Outline 
This thesis contains seven chapters, four of which are studies that address the aims 
and objectives (Figure 1.1).  
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Chapter 2 gives an overview of the research methods used in this thesis. This chapter 
reviews and justifies the research methods which underpinned this doctoral 
research. 
 
In Chapter 3, the prevalence and type of PIP and PPOs amongst community-dwelling 
older adults are compared across three European populations to highlight the 
complex nature of prescribing in this cohort of patients. A secondary analysis of the 
Thyroid Hormone Replacement for Subclinical Hypo-Thyroidism Trial (TRUST) dataset 
was carried out. A subset of 48/80 PIP and 22/34 PPOs indicators from the 
STOPP/START V2 criteria were applied to prescribed medication data for 532 out of 
737 trial participants in Ireland, Switzerland and the Netherlands. 
 
Chapter 4 systematically reviews the literature of pharmacist-led interventions that 
optimise prescribing appropriateness in community-dwelling older adults to identify 
components of a successful intervention. An electronic search of the literature was 
conducted using 11 databases. Studies were included if they were randomised 
controlled trials (RCTs) or quasi-randomised studies involving a pharmacist-led 
intervention compared to usual/routine care which aimed to reduce potentially 
inappropriate prescribing (PIP) in older adults in primary care. 
 
Chapter 5 describes qualitative research on GPs’ perspectives on prescribing for 
older people in primary care. Semi-structured qualitative interviews were carried out 
with a purposive sample of 16 GPs in County Cork, Ireland.  Emerging themes were 
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mapped to the Theoretical Domains Framework (TDF), a tool used to apply behaviour 
change theories. 
 
Chapter 6 is a feasibility study of a pharmacist-led intervention, which was conducted 
with GPs. This is a mixed methods feasibility study utilising data from qualitative 
focus groups with GPs and patient medical records in those ≥65 years with urinary 
incontinence in a region of Ireland. Qualitative focus groups were carried out with 14 
GPs who participated in the AD intervention on urinary incontinence in older people. 
The focus groups were transcribed verbatim and analysed using thematic analysis. 
The medical records for all patients (154) aged ≥65 years who were attending a 
participating GP with a diagnosis of urinary incontinence were retrieved and analysed 
using a before-after approach. The measures of prescribing assessed before and after 
the AD intervention were: LUTS-FORTA criteria; Drug Burden Index; Anticholinergic 
cognitive burden scale; and the Screening tool of older person’s prescriptions- 
screening tool to alert doctors to right treatment (STOPP/START) version 2 criteria. 
 
Chapter 7 provides an overall discussion of the research, including strengths and 
limitations and makes suggestions for future research and policy implications.  
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Figure 1.1 Thesis outline
Aim: To understand the potential role of the pharmacist in optimising prescribing for older people in primary care 
Objective 1 
To estimate and compare 
the prevalence and type 
of PIP and PPOs amongst 
community dwelling older 
adults (≥65 years) in three 
European countries. 
Objective 2 
To evaluate studies of 
pharmacist-led interventions on 
potentially inappropriate 
prescribing among community-
dwelling older adults receiving 
primary care to identify the 
components of a successful 
intervention. 
Objective 3 
Firstly to reveal the determinants of GP 
prescribing behaviour for older adults in 
primary care and secondly to elicit GPs’ 
views on the potential role for broad 
intervention strategies involving 
pharmacists and/or information 
technology systems in general practice. 
Objective 4 
To evaluate the feasibility and 
satisfaction of a pharmacist-led 
academic detailing intervention 
with GPs in primary care. 
Chapter 3 
Prevalence of potentially 
inappropriate prescribing 
in a subpopulation of 
older European clinical 
trial participants. 
Under peer review in BMJ 
Open 
 
 
 
 
 
Chapter 4 
The effect of pharmacist-led 
interventions in optimising 
prescribing in older adults in 
primary care: a systematic review. 
 
Published in SAGE Open Medicine 
Chapter 5 
GPs’ perspectives on prescribing for 
older people in primary care: a 
qualitative study. 
 
Published in the British Journal of 
Clinical Pharmacology 
 
 
Chapter 6 
To evaluate the feasibility and 
satisfaction of a pharmacist-led 
academic detailing intervention 
with GPs in primary care: a mixed 
methods study. 
To be submitted to the British 
Journal of Urology                      
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1.8. Author’s contribution to the included studies 
 
I was the lead author of the research papers in Chapters 3 to 6. This involved the 
acquisition, analysis and interpretation of data for the study, the drafting and revising 
of each manuscript. 
Additional expertise was gained from the following individuals: 
 Dr Anthony Fitzgerald, School of Mathematical Sciences, UCC. 
o Expertise on regression analysis for the cross-sectional study   
(Chapter 3). 
 
 Professor Patricia Kearney, Department of Epidemiology & Public Health, 
UCC.  
o Expertise on the study design and statistical analysis, for the cross-
sectional study (Chapter 3). 
 
 Professor Stephen Byrne, School of Pharmacy, UCC. 
o Expertise on study design and inclusion/exclusion criteria required for 
the systematic review (Chapter 4). 
 
 Dr Paul Beirne, Department of Epidemiology and Public Health, UCC. 
o Expertise on the appropriate risk of bias tool for the systematic review 
(Chapter 4). 
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 Dr Rose Galvin, Department of Clinical Therapies, Health Research Institute, 
University of Limerick. 
o Expertise on evaluating the risk of bias for the included studies for the 
systematic review (Chapter 4).  
 
 Mr Ben Meehan, QDATRAINING: NVivo Training, Consultancy & Support. 
o Expertise on the use of NVivo software for the qualitative study 
(Chapter 5). 
 
 Dr Carol Sinnott, Department of Public Health and Primary Care, Cambridge 
Institute of Public Health, Cambridge, UK. 
o Expertise on the study design, sampling approach and data analysis 
for the qualitative study (Chapter 5). 
 
 Dr Michael Fisher, Harvard Medical School, Boston, Massachusetts, USA. 
o Expertise on formulating the academic detailing intervention for the 
mixed methods study (Chapter 6). 
 
 Professor Jerry Avorn, Harvard Medical School, Boston, Massachusetts, USA. 
o Expertise on formulating the academic detailing intervention and 
permission for use of the urinary incontinence educational materials 
for the mixed methods study (Chapter 6).  
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 Miss Eimir Hurley, Centre for Health Policy and Management, Trinity College 
Dublin. 
o Expertise on the design, implementation and evaluation of the 
academic detailing intervention, and facilitation of three focus groups 
for the mixed methods study (Chapter 6).  
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Poster 
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Thursday 12th 
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Wednesday 22nd – 
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Chapter 2. Proposed stepped wedge trial design in primary 
care 
 
This brief chapter describes an alternative intervention that was proposed for this 
thesis, however after some considerable discussion it was decided that it would not 
be feasible to carry out. 
It consisted of a structured pharmacist review of medication (SPRM) with CDSS using 
STOPP/START V2 with feedback to GPs. This intervention was proposed for Mallow 
Primary Health Centre (MPHC), Mallow, County Cork. There are three GP practices 
that work independently of each other in MPHC with a total of 13 GPs (surgery 1: 6 
GPs, surgery 2: 5 GPs, surgery 3: 2 GPs). The proposed intervention consisted of two 
components:  
Intervention one: Structured pharmacist review of medication (SPRM) with CDSS 
using STOPP/START V2 with feedback to GPs. 
Intervention two: Use of a CDSS by the GPs using STOPP/START V2. 
The proposed method for carrying out this study was a stepped wedge randomised 
trial design. This involves sequential roll-out of an intervention to participants (either 
as individuals or clusters of individuals) over a number of time periods. By the end of 
the study, all participants receive the intervention, although the order in which 
participants receive the intervention is determined at random. Stepped wedge 
designs incorporate data collection at each point where a new group (step) receives 
the intervention. Data analysis to determine the overall effectiveness of the 
intervention subsequently involves comparison of the data points in the control 
section of the wedge with those in the intervention section (73). 
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Figure 2.1 shows the proposed stepped wedge trial design with the interventions 
rolled out over three time periods (T0, T6, T12 months). Firstly, a prevalence study of 
PIP & PPO using STOPP/START V2 was proposed to be carried at GP level (13 in total) 
in MPHC. Each surgery was due to be randomly assigned to an intervention (SPRM 
with CDSS using STOPP/START V2 with feedback to GPs, CDSS using STOPP/START V2 
by GP or control).  The aim of SPRM was to focus on medication optimisation which 
had the potential to identify and reduce ADRs. This was due be carried out by a 
research pharmacist (D.O.R.).  MAI scores and prescribing patterns were due to be 
measured at baseline and at two subsequent six month intervals. The calculated MAI 
score in the control sections would then be compared with the intervention sections 
to assess prescribing appropriateness. 
However, after discussing the proposed intervention with the IT software developer 
in MPHC it was suggested that this would not be feasible to carry out. This was 
primarily due to the cost of developing the CDSS software and compatibility issues 
with the GP software in the health centre.  In MPHC, when the drug files are exported 
they are based on a comma delimited file, for example Amoxicillin 500mg tds is 
described as a “single word” i.e. “Amoxicillin500mgtds”. Also, these drug files are not 
linked to Anatomical Therapeutic Chemical (ATC) Classification System codes and are 
therefore not compatible with other software engines such as Software ENgine for 
the Assessment & optimization of drug and non-drug Therapy in Older peRsons 
(SENATOR) that are based on these codes. It was estimated that the cost of 
developing the software application would be between €10,000 and €25,000, 
however this was beyond the study budget. Therefore, developing an efficient 
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software engine to optimise drug therapy was going to be a significant challenge and 
as a result it was decided that a different intervention would have to be considered 
for the thesis. 
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   Intervention 1:  SPRM + CDSS + STOPP/START V2 
   Intervention 2:  CDSS + STOPP/START V2 
   Control and prevalence study  
Figure 2.1 Stepped wedge design 
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Abstract 
Objectives 
To estimate and compare the prevalence and type of potentially inappropriate 
prescribing (PIP) and potential prescribing omissions (PPOs) amongst community-
dwelling older adults (≥65 years) enrolled to a clinical trial in three European 
countries. 
Design  
A secondary analysis of the Thyroid Hormone Replacement for Subclinical 
Hypothyroidism Trial (TRUST) dataset. 
Participants 
A subset of 48/80 PIP and 22/34 PPOs indicators from the STOPP/START V2 criteria 
were applied to prescribed medication data for 532/737 trial participants in Ireland, 
Switzerland and the Netherlands.  
Results  
The overall prevalence of PIP was lower in the Irish participants (8.7%), compared to 
the Swiss (16.7%) and Dutch (12.5%) participants (p=0.15) and was not statistically 
significant. The overall prevalence of PPOs was approximately one-quarter in the 
Swiss (25.3%) and Dutch (24%) participants and lower in the Irish (14%) participants 
(p=0.04) and the difference was statistically significant. The hypnotic Z-drugs were 
the most frequent PIP in Irish participants, (3.5%, n=4), while it was NSAID and oral 
anticoagulant combination, sulphonylureas with a long duration of action, and 
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benzodiazepines (all 4.3%, n=7) in Swiss, and benzodiazepines (7.1%, n=18) in Dutch 
participants. The most frequent PPOs in Irish participants were vitamin D and calcium 
in osteoporosis (3.5%, n=4). In the Swiss and Dutch participants, they were bone anti-
resorptive/anabolic therapy in osteoporosis (9.9%, n=16; 8.6%, n=22) respectively. 
The odds of any PIP after adjusting for age, sex, multimorbidity and polypharmacy 
were ([aOR]) 3.04 (95% CI 1.33-6.95, p<0.01) for Swiss participants and aOR 1.74 
(95% CI 0.79-3.85, p=0.17) for Dutch participants compared to Irish participants. The 
odds of any PPOs were aOR 2.48 (95% CI 1.27-4.85, p<0.01) for Swiss participants and 
aOR 2.10 (95% CI 1.11-3.96, p=0.02) for Dutch participants compared to Irish 
participants. 
Conclusions  
This study has estimated and compared the prevalence and type of PIP and PPOs 
among this cohort of community dwelling older people. It demonstrated a significant 
difference in the prevalence of PPOs between the three populations. Further 
research is urgently needed into the impact of system level factors as this has 
important implications for patient safety, healthcare provision and economic costs.  
Keywords: Potentially inappropriate prescribing, Potential prescribing omissions, 
STOPP/START V2 criteria, European older adults. 
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Strengths and limitations of this study  
 
 This is the first study to estimate and compare the prevalence and type of PIP 
and PPOs using a subset of the STOPP/START V2 criteria in community-
dwelling older adults enrolled to a clinical trial across three different 
European countries. 
 The TRUST database contains comprehensive information on patient 
demographics, co-morbidities and medication which facilitated the 
assessment and measurement of prescribing commission and omission for 
participants included in the clinical trial. 
 The sample size (n=532) and sampling scheme may limit insights about 
prescribing nationally in the three countries. 
 It was only possible to apply a subset of the criteria to the database due to a 
lack of information on drug strength, dose and duration of prescriptions and 
this may explain the low prevalence of PIP and PPOs in the study. 
 Some countries may have specific guidelines for the optimal treatment of 
conditions, therefore these guidelines could differ from the 
recommendations in the STOPP/START criteria and could explain why some 
PIP and PPOs were identified in one population and not in others. 
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Introduction 
Older people often have multiple comorbidities and as a consequence are frequently 
prescribed multiple drugs. This increases their risk of adverse drug events (ADEs), 
extended hospital stays and mortality (74). Potentially inappropriate prescribing (PIP) 
describes any drug that has the potential to cause an adverse event which can 
outweigh its clinical benefit when compared to alternative treatment options (19). 
Appropriateness of prescribing in older people can be assessed using either implicit 
(judgement-based) or explicit (criterion-based) screening tools (18). Implicit tools 
require healthcare professionals to assess the appropriateness of prescribing based 
on clinical guidelines and each patient situation (18). Explicit tools are usually 
developed from published literature, expert opinion and consensus techniques (75).  
In recent years, the STOPP/START (Screening Tool of Older Persons Prescriptions, 
Screening Tool to Alert doctors to Right Treatment) criteria were developed and 
validated as an explicit measure of PIP and potential prescribing omissions (PPOs) for 
use in older adults (≥ 65 years) in European countries (76). The STOPP set consists of 
65 criteria for PIP, including drug-drug and drug-disease interactions (potentially 
leading to side effects such as cognitive decline and falls in older people), as well as 
duplicate drug class prescriptions. The START set consists of 22 criteria that identify 
PPOs (39, 76). All criteria are organised according to physiological systems for ease 
of use (77). In 2014, the STOPP/START criteria were revised and adapted to new 
evidence-based guidelines. Twelve STOPP version 1 criteria were removed from 
version 2 because of weak or equivocal supporting evidence, while 27 new criteria 
were introduced in STOPP version 2. Three START version 1 criteria were removed 
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from version 2, while 15 new criteria were introduced. The revised set, STOPP/START 
version 2 (STOPP/START V2), consists of 80 STOPP and 34 START criteria. Several new 
STOPP categories created in version 2 include antiplatelet/anticoagulant drugs, drugs 
affecting, or affected by, renal function and drugs that increase anticholinergic 
burden. New START categories include urogenital system drugs, analgesics and 
vaccines (40). The effectiveness of the STOPP/START criteria in improving prescribing 
quality and clinical and economic outcomes has been shown in a recent systematic 
review (78).  
A number of studies have reported the prevalence of PIP/PPOs in large populations 
of older adults using subsets of the STOPP/START V1 criteria. Cahir et al. estimated 
the prevalence of PIP was 36% among adults ≥70 years in a primary care population 
in Ireland (20). In a similar study, Bradley et al. reported a prevalence of PIP of 29% 
among older adults in primary care in the UK (21). However, there is a lack of research 
exploring the prevalence of PIP and PPOs in community-dwelling older adults using 
the updated criteria. Therefore, the aim of this study is to estimate and compare the 
prevalence and type of PIP and PPOs among a sample of community-dwelling older 
adults enrolled to a clinical trial across three different European countries using a 
subset of the STOPP/START V2 criteria. 
44 
 
Methods 
Study population  
This current study was a secondary analysis of the Thyroid Hormone Replacement 
for Subclinical Hypo-Thyroidism Trial (TRUST) dataset. The full study protocol for the 
TRUST trial has been previously published and a summary is provided here (79). The 
trial was conducted in four countries (Ireland, Scotland, Switzerland and the 
Netherlands). Community-dwelling participants aged ≥65 years with untreated 
subclinical hypothyroidism (SCH) were identified from clinical laboratory databases 
or by searching General Practitioners’ (GP) databases/notes and were randomly 
assigned to levothyroxine or placebo. SCH was defined as persistently elevated 
thyroid stimulating hormone (TSH) levels (4.6-19.9 mU/L) with free thyroxine (fT4) 
within the local laboratory reference range (79, 80).  
Medication information from the TRUST dataset was available for three of the four 
countries (Ireland, Switzerland [one site, Bern] and the Netherlands). On enrolment 
to the TRUST study in Ireland and the Netherlands, participants self-reported their 
prescription medicines and medical history to the study nurses. In Ireland, this 
involved participants bringing their medicines or prescription and a list of their 
medical conditions to the study visit. In the Netherlands, the study visit was carried 
out in the participant’s home. In Switzerland, the study nurses received a list of the 
medical history and prescription medicines from the participant’s GP. When it was 
not possible to obtain either list, the participants self-reported their medical history 
and prescription medicines. If ambiguity occurred regarding the reporting of 
prescription medicines or medical history in any of the study sites, the participant’s 
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GP or local pharmacy were contacted. The study nurses recorded all the participants’ 
prescribed medicines and entered them into an online electronic case report form 
(eCRF). Detailed information on participant demographics (date of birth, sex, race, 
smoking history, alcohol consumption), social circumstances (living arrangements, 
home support services, district nurse/public health nurse, informal caregiver), body 
measurements (systolic and diastolic blood pressure, heart rate, weight, height, 
waist circumference) and medical history were also collected. The data for this 
current study was obtained following access to the secure eCRF on the TRUST web 
portal (79).  
Application of the STOPP/START criteria 
There have been significant changes to the updated criteria. Firstly there are more 
criteria in V2 (80 STOPP and 34 START compared 65 STOPP and 22 START in V1). 
Secondly, new drug groups have been included in the updated criteria for example, 
sulphonylureas with a long duration of action. Thirdly, a number of criteria from V1 
were removed from V2 due to a lack of evidence from the published literature. The 
extra criteria included in V2 arose from new clinical trial information, new systematic 
information and expert panel suggestions for new criteria. This highlights the need 
to update and revise the criteria on a regular basis as some criteria can become 
outdated or obsolete. Also, new drugs have entered the market since the V1 criteria 
were validated in 2008. 
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A subset of the STOPP/START V2 criteria were applied, as information required for 
some criteria (i.e. drug strength, dose and duration of prescriptions) was not 
available in the TRUST dataset. There was consensus among the study pharmacists 
(D.O.R., K.W. and S.B.) on the number and type of criteria selected, based on the 
ability to confidently apply the criteria to the data available. Therefore 48 PIP 
indicators and 22 PPOs indicators were applied (See Appendix I). Prescription drugs 
identified from the database were used as proxies to indicate a diagnosis of certain 
clinical conditions such as Parkinson’s disease, glaucoma and gout. For example, if a 
participant was prescribed colchicine this information was used as a proxy for a 
diagnosis for gout. This methodology has been used in previous studies (57). A coding 
scheme was then developed between D.O.R. and K.W. PIP and PPOs prevalence were 
estimated according to STOPP/START V2 and recorded in Microsoft Office Excel ® 
(2013). It was agreed a priori by the authors that D.O.R. (research pharmacist) would 
manually apply the criteria to all the Irish, Swiss and Dutch data. For validation 
purposes, the criteria were applied independently by a second member of the 
research team. K.W. (research pharmacist) applied the criteria to a random 10% 
sample of the Irish and Dutch data. C.E.A. (research medical doctor) applied the 
criteria to a random 10% sample of the Swiss data. There are two studies (OPERAM, 
SENATOR) currently assessing the automatisation of the STOPP/START criteria to 
identify PIP and PPOs in older people. The results from both studies should inform 
on the best method of automatizing screening tools to identify PIP and PPOs in this 
group of people. Therefore, the method used in this study for assessing the 
STOPP/START criteria should be considered as valid. 
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Outcomes 
The main outcome of interest in this current study was the overall prevalence of any 
PIP or PPOs among participants from the TRUST trial in Ireland, Switzerland and the 
Netherlands according to a subset of the STOPP/START V2 criteria. Secondary 
outcome measures were: (1) the prevalence of PIP and PPOs for each individual 
STOPP/START V2 criterion (2) the most common PIP and PPOs in each country and 
(3) the association between the explanatory variables: country, age, sex, 
multimorbidity and polypharmacy and dependent variables: PIP and PPOs. 
Statistical analysis  
Data analyses were performed using STATA® version 13 (StataCorp, College Station, 
Tx, USA). Statistical significance was considered p<0.05. Characteristics of included 
participants were stratified by country. Continuous variables were presented as 
mean with standard deviation (SD) and range, or median with interquartile range 
(IQR), as appropriate, and categorical variables as frequency (percentage). The 
overall prevalence of PIP/PPOs was defined as the proportion of participants having 
at least one PIP or PPO according to the STOPP/START V2 criteria among all 
participants included in this analysis and was further stratified by country. The 
prevalence estimates were compared using the χ2 test. Participants were further 
classified by sex and age group (65–74 years, ≥75 years). Other explanatory variables 
included polypharmacy, defined as the concurrent use of five or more medications 
and multimorbidity (co-occurrence of three or more chronic conditions) (81). The 
association between age, sex, multimorbidity, polypharmacy and country with any 
PIP/PPOs (versus none) was assessed using multivariable logistic regression and 
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presented as adjusted odds ratios (aOR) with 95% confidence intervals (CI) and p-
values. Multicollinearity between the independent variables polypharmacy and 
multimorbidity was assessed by calculating the variance inflation factor (VIF).  
Sensitivity analysis excluding criteria triggered by combination of more than one drug 
was also performed. 
Standardised reporting guidelines  
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) 
standardised reporting guidelines for cross-sectional studies have been followed to 
ensure the uniform conduct and reporting of the research (See Appendix I) (82).  
Ethical approval 
Ethical approval was received from the relevant ethics committees at each TRUST 
site (See Appendix IX).  
Results  
Population characteristics 
The population characteristics of the 532 out of 737 included TRUST participants are 
detailed in Table 3.1. The mean age (± SD) of participants was 74.6 (5.9) in Ireland, 
76.4 (5.9) in Switzerland and 76.1 (6.8) years in the Netherlands. The proportion of 
females varied across countries from 42.6% in Ireland and 46.3% in Switzerland to 
65% in the Netherlands (p<0.01). Hypertension (which was defined from participants’ 
medical history) was the most common morbidity reported in each country (Ireland 
65.2%, Switzerland 51.2%, the Netherlands 44.7%). The median number of drugs 
(IQR) prescribed to participants in each country was 4 (2, 6).  
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Table 3.1 Baseline characteristics 
Population characteristics 
(n=532) 
Ireland Switzerland Netherlands P-values 
Number of patients, n  
(% of total population in study)  
115 (21.6) 162 (30.5) 255 (47.9)  
Mean age (years) (± SD), range 74.6 (5.9), 66-95 76.4 (5.9), 66-92 76.1 (6.8), 66-95 P= 0.054 
Female, n (%) 49 (42.6) 75 (46.3) 166 (65.1) P< 0.001 
Current smokers, n (%) 5 (4.3) 12 (7.4) 24 (9.4) P= 0.02 
Mean alcohol consumption (units per week) (± SD) 5.5 (9.4) 3.6 (4.9) 7.4 (10.3) P= 0.008 
*Living arrangements (co-habiting), n (%) 77 (66.9) 91 (56.2) 161 (63.1) P= 0.021 
Mean BMI (± SD) 28.3 (4.3) 27.5 (4.9) 27.8 (4.8) P= 0.318 
Most common morbidity, Hypertension, n (%) 75 (65.2) 83 (51.2) 114 (44.7) P= 0.001 
Median number of drugs prescribed per patient,  
interquartile range (IQR) 
4 (2,5) 4 (2,5) 4 (2,6) P= 0.828 
**Polypharmacy, n (%) 51 (44.3) 60 (37.0) 106 (41.6) P= 0.447 
Mean (± SD) EuroQol 5D: EQ Visual Analogue Scale score/100 82 (15.2) 82 (12.1) 76 (11.6) P<0.001 
Mean (± SD) Mini-Mental State Examination (MMSE/30) 28 (2.2) 28 (1.8) 29 (1.2) P< 0.001 
Mean (± SD) ***TRUST Barthel Index/22 22 (1.0) 22 (1.0) 22 (1.0) P= 0.010 
* Living arrangements: Whether participants were co-habiting or living alone.  ** Polypharmacy: defined as 5 or more regular medicines.  ***An extra question was added under the heading 
“Bladder”: “Does the participant have a urinary catheter?” 
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Overall prevalence of PIP and PPOs in each country 
The overall prevalence of PIP in the three populations was 12.9% (n=69). It was lower 
in the Irish participants 8.7% (n=10) compared to the Swiss 16.7% (n=27) and Dutch 
12.5% (n=32) participants (p=0.15). In Ireland, 7% (n=8) of participants had a single 
PIP compared to 13.6% (n=22) of participants in Switzerland and 11.8% (n=30) of 
participants in the Netherlands. In Ireland, 1.8% (n=2) of participants had two or 
more PIP compared to 3.1% (n=5) of participants in Switzerland and 0.8% (n=2) of 
participants in the Netherlands.  
The overall prevalence of PPOs in the three populations was 22.2% (n=118). It was 
approximately one-quarter in the Swiss 25.3% (n=41) and Dutch 24% (n=61) 
participants and lower in the Irish 14% (n=16) participants (p=0.04).  In Ireland, 12.0% 
(n=14) of participants presented with one PPO compared with 15.4% (n=25) of 
participants in Switzerland and 13.7% (n=35) of participants in the Netherlands. In 
Ireland, 1.7% (n=2) of participants presented with two or more PPOs compared with 
9.9% (n=16) of participants in Switzerland and 10.2% (n=26) of participants in the 
Netherlands.  
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The most common PIP in each country 
Figure 3.1 shows the most common PIP in each population. The hypnotic Z-drugs 
(zopiclone, zolpidem, zaleplon) were the most frequent PIP in Irish participants with 
3.5% (n=4), followed by the prescribing of a beta blocker in participants diagnosed 
with bradycardia (< 50/min), type II heart block or complete heart block with 1.7% 
(n=2). The most frequent PIP in the Swiss participants were: 1) the combination of a 
non-steroidal anti-inflammatory drug (NSAID) with oral anticoagulants, (4.3%, n=7); 
2) Sulphonylureas with a long duration of action (e.g. glibenclamide, chlorpropamide, 
glimepiride) in participants with type 2 diabetes mellitus, (4.3%, n=7); and 3) the 
prescribing of benzodiazepines, (4.3%, n=7). The most frequent PIP in the Dutch 
participants was the prescribing of benzodiazepines, (7.1%, n=18), followed by 
sulphonylureas with a long duration of action in participants with type 2 diabetes 
mellitus, (2.4%, n=6).  
 
 
 
 
 
 
 
 
52 
 
 
Figure 3.1 The most common types of PIP in each country.  
Abbreviations: T2DM, Type 2 diabetes mellitus; COX, Cyclo-oxygenase; NSAID,Non-steroidal anti-inflammatory drug; CVD, Cardiovascular disease; HF, Heart failure; PPI, Proton 
pump inhibitor; AF, Atrial fibrillation. 
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The most common PPOs in each country 
Figure 3.2 shows the most common PPOs in each population. The most frequent 
PPOs in Irish participants were vitamin D and calcium supplements in participants 
with known osteoporosis and/or previous fragility fracture(s), 3.5% (n=4). The second 
most frequent PPOs were regular inhaled β2 agonists or antimuscarinic 
bronchodilators for mild to moderate asthma or COPD, 2.6% (n=3). The most 
frequent PPOs in the Swiss participants were bone anti-resorptive or anabolic 
therapy (e.g. bisphosphonate, strontium ranelate, teriparatide, denosumab) in 
participants with documented osteoporosis, 9.9% (n=16). The second most frequent 
PPOs in the Swiss participants were antiplatelet therapy with a documented history 
of coronary, cerebral or peripheral vascular disease, 7.4% (n=12). The most frequent 
PPOs in the Dutch participants were bone anti-resorptive or anabolic therapy in 
participants with documented osteoporosis, 8.6% (n=22), followed by prescribing 
omissions of vitamin D and calcium supplement in participants with known 
osteoporosis and/or previous fragility fracture(s), 6.3% (n=16).  
Factors associated with PIP 
Table 3.2 shows the univariable and multivariable logistic regression analysis for the 
association between age, sex, comorbidities and polypharmacy with PIP. In the 
univariable and multivariable models, there was no statistically significant 
association between age or sex and PIP. However, the association between 
comorbidities or polypharmacy and PIP was statistically significant for both models.  
Further analysis demonstrated that the odds of any PIP after adjusting for age, sex, 
multimorbidity and polypharmacy were (adjusted odds ratio) (aOR) 3.04, [(95% CI) 
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1.33-6.95, p<0.01] for Swiss participants and aOR 1.74, [(95% CI) 0.79-3.85, p=0.17], 
for Dutch participants compared to Irish participants. 
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Figure 3.2 The most common types of PPOs in each country. 
 Abbreviations: ACE, Angiotensin converting enzyme; COPD, Chronic obstructive pulmonary disease; HF, Heart failure; CAD, Coronary artery disease; VD, Vascular disease;* Unless 
the patient’s status is end-of-life or age is  > 85 years
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Table 3.2  Results of the univariable and multivariable logistic regression analyses for the association between age, sex, 
multimorbidity and polypharmacy with potentially inappropriate prescribing (PIP).  
   Univariable model   Multivariable model*   
Explanatory variable Odds ratio 
(95% CI) 
p-value Odds ratio 
(95% CI) 
p-value 
Age (years) 1.02  (0.99-1.06) 0.22 0.99  (0.94-1.03) 0.54 
Female (vs. male) 1.18  (0.70-1.96) 0.54 1.47  (0.84-2.59) 0.18 
**Multimorbidity 3.24  (1.93-5.44) <0.01 2.08  (1.16-3.73) <0.01 
***Polypharmacy 5.52  (3.10-9.86) <0.01 4.81  (2.52-9.16) <0.01 
 *Adjusted for age, sex, multimorbidity, polypharmacy and country. **Multimorbidity: defined as the co-occurrence of 3 or more chronic 
conditions. ***Polypharmacy: defined as 5 or more regular medicines.   
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Factors associated with PPOs 
Table 3.3 shows the univariable and multivariable logistic regression analysis for the 
association between age, sex, multimorbidity and polypharmacy with PPOs. In the 
univariable model the association between age or multimorbidity and PPOs was 
statistically significant. However, the association was not statistically significant for 
sex or polypharmacy. In the multivariable model the association between sex or 
multimorbidity or age and PPOs was statistically significant. However, the association 
was not statistically significant for polypharmacy. 
The odds of any PPOs after adjusting for age, sex, multimorbidity and polypharmacy 
were aOR 2.48, [(95% CI) 1.27-4.85, p<0.01] for Swiss participants and aOR 2.10, 
[(95% CI) 1.11-3.96, p=0.02] for Dutch participants compared to Irish participants. 
The VIF for multimorbidity and polypharmacy were 1.82 and 2.13 respectively. 
Sensitivity analysis excluding criteria triggered by combination of more than one drug 
had no effect on the study results. 
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Table 3.3 Results of the univariable and multivariable logistic regression analyses for the association between age, sex, 
multimorbidity and polypharmacy with potential prescribing omissions (PPOs). 
 Univariable model  Multivariable model*  
Explanatory variable Odds ratio 
(95% CI) 
p-value Odds ratio 
(95% CI) 
p-value 
Age (years)  1.04 (1.01-1.08) <0.01  1.04 (1.00-1.07) 0.05 
Female (vs. male)  1.41 (0.93-2.14) 0.11  1.63 (1.04-2.57) 0.04 
**Multimorbidity 3.04 (1.99-4.65)  <0.01  4.01 (2.43-6.63) <0.01 
***Polypharmacy  1.30 (0.86-1.96) 0.21  0.69 (0.42-1.14) 0.144   
*Adjusted for age, sex, multimorbidity, polypharmacy and country. **Multimorbidity: defined as the co-occurrence of 3 or more chronic 
conditions. ***Polypharmacy: defined as 5 or more regular medicines.   
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Discussion 
Statement of principal findings 
In this study across three European populations in adults aged 65 years or older, the 
overall prevalence of PIP was 12.9% (n=69) and was similar in the Irish, Swiss and 
Dutch participants. The overall prevalence of PPOs in the three populations was 
22.2% (n=118) and was higher in the Swiss and Dutch than in the Irish participants.  
Participants at the Swiss and Dutch sites were at increased odds of any PIP and PPOs 
after adjusting for age, sex, comorbidities and polypharmacy compared to 
participants at the Irish site.  
Results in the context of the current literature 
A systematic review of thirteen research studies described the application of the 
STOPP/START V1 criteria in different healthcare settings. The prevalence of PIP and 
PPOs ranged from 21% to 79% and 23% to 74%, respectively (83). Studies reporting 
the prevalence of PIP and PPOs using the expanded STOPP/START V2 criteria in large 
populations of older people are limited. One study of 225 community-dwelling adults 
aged ≥65 years in Spain found an overall prevalence of PIP and PPOs of 40.4% and 
21.8%, respectively (84). In a study conducted in Turkey, 667 participants aged ≥65 
years were admitted to an outpatient clinic of a university hospital. The prevalence 
of PIP reported was 39.1% (85). A study conducted among 319 older patients 
discharged from a hospital in Albania identified that 63% received at least one PIP 
(86). In another study carried out in Ethiopia, the prevalence of inappropriate 
prescribing of antithrombotic therapy among 156 hospitalised elderly patients was 
assessed. The prevalence of PIP and PPOs were 51.4% and 48.6% respectively (87). 
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The overall prevalence of PIP and PPOs in this current study was lower compared to 
these studies. However, this may have been due to differences in number and type 
of criteria applied to the data. 
In this study, the prescribing of benzodiazepines was identified as a common PIP 
among Dutch (7.1%, n=18) and Swiss participants (4.32%, n=7). However, in Ireland, 
it was reported at less than 1% (n=1). These findings are in keeping with a recent 
panel survey in Ireland using patient-level dispensing data, which highlighted that 
benzodiazepines were one of the few medicines without a yearly increase in 
prescribing between 1997 and 2012 (88). In 2009 a nationwide program was 
introduced in the Netherlands which aimed to reduce the prescribing rates of 
benzodiazepines. Dutch GPs are required to state the indication for all 
benzodiazepines prescribed to allow patients apply for reimbursement of the 
medicine costs (89). In Switzerland, no similar program exists. In Ireland, GPs receive 
a printout of their benzodiazepine prescribing from the General Medical Scheme 
(GMS). The GMS is a national tax-funded health insurance program that provides 
access to medical and surgical services for low income individuals/families and older 
people (89). This feedback highlights the prescribing practice of the GPs compared to 
their peers and allows them to carry out a clinical audit in this topic area. The audit 
also provides GPs with the necessary tools to identify best practice and this may have 
impacted on the low prescribing of benzodiazepines in this study, when compared 
with the two other countries. This low prevalence could also be due to a difference 
in the sampling approach in Ireland or it may have occurred by chance. 
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Frequent PPOs across all three populations in this study included vitamin D and 
calcium supplements in participants with known osteoporosis and/or fractures. 
These findings are similar to a previous study that used STOPP/START V1 criteria in a 
primary care setting in Ireland (37). Prescribing of proton pump inhibitors (PPIs) at 
full therapeutic dose for more than eight weeks is one of the most common STOPP 
criteria reported in studies but was not reported in this study as information relating 
to drug duration was not available (21, 88).  
The screening process and identification of potential participants for this clinical trial 
differed between countries and may explain some of the differences in the 
prevalence of PIP and PPOs. In Ireland, clinical trial nurses visited individual GP 
surgeries and with GP approval performed a search of the GPs’ databases/notes to 
identify potentially eligible participants. The GP then confirmed whether the 
participant was eligible to participate in a screening visit. In Switzerland and the 
Netherlands, potential participants were identified directly from clinical laboratory 
databases. A list of potential participants was sent to their GPs to confirm their 
eligibility in the trial. This screening process was carried out twice by the GPs and 
those who were deemed eligible were invited to participate (79). This process may 
have introduced selection bias at GP level as only GPs interested in participating in a 
clinical trial facilitated recruitment and also at the patient level as GPs may have 
excluded more complex patients. Furthermore, in Ireland and the Netherlands, GPs 
are gatekeepers of referral to specialist services (90, 91). Whereas in Switzerland, 
participants can visit medical specialists directly if necessary (91). A systematic 
review and meta-ethnographic synthesis of GPs’ experiences on the clinical 
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management of multimorbidity identified “Disorganisation and fragmentation of 
healthcare” as a key difficulty. The authors highlighted that GPs have a more holistic 
view of the patient in contrast to specialists who manage disease specific conditions 
(92). As Swiss patients can visit medical specialists directly if necessary they may 
receive more non-essential medicines. The prescribing process is further complicated 
if patients attend several specialists. Also, if there is a lack of collaborative decision 
making between the patients’ GP and medical specialists this could result in a higher 
prevalence of PIP/PPOs among Swiss participants. Therefore, enhancing 
collaborative decision-making between GPs and specialists may help to optimise the 
prescribing of older patients. Finally, some countries may have specific guidelines for 
the optimal treatment of conditions. These guidelines could differ from the 
recommendations in the STOPP/START criteria and could explain why some PIP and 
PPOs were identified in one population and not in others. 
Clinical and policy implications 
The study findings indicate that the overall prevalence of PIP using a subset of the 
STOPP/START V2 criteria across three European populations was 12.9%. As PIP is 
associated with adverse health outcomes, healthcare providers should aim to reduce 
their prevalence (93, 94). A recent systematic review of 12  randomised controlled 
trials concluded that various interventions including pharmacist interventions, 
clinical decision support systems and multifaceted approaches can reduce 
inappropriate prescribing (60). However, it was unclear whether these interventions 
led to clinically significant improvements in patient outcomes due to the variability 
in methodological quality of the included studies and the heterogeneity of the 
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interventions and outcomes measured (60). Further large randomised controlled 
trials that are methodologically robust, adhere to the appropriate reporting 
guidelines, and have a long duration of follow-up are needed to address the 
efficiency of such interventions to reduce the prevalence of PIP/PPOs and improve 
patient outcomes. Despite the high prevalence of multimorbidity in the elderly 
population, most clinical trials focus on the benefit of one drug in one condition, thus 
excluding multimorbid participants (30, 31). These limitations cast doubt on 
otherwise high-quality clinical evidence, which in turn weakens prescribers’ 
confidence in trial results (13). A number of prescribed drugs can be used as a proxy 
measure of multimorbidity in primary care (95, 96). Therefore, recruiting participants 
with higher levels of polypharmacy is one approach to help build an evidence base 
that is relevant to the majority of older people with multiple chronic conditions (97). 
For example, the OPERAM study (Optimising thERapy to prevent Avoidable hospital 
admissions in the Multimorbid elderly) aims to reduce the rates of over- and 
underprescribing of medications among older European adults with multimorbidity. 
This large multicentre randomised clinical trial will use a sophisticated software tool 
to determine if the intervention can improve clinical and economic outcomes. The 
TRUST trial succeeded in recruiting participants with multimorbidity and 
polypharmacy by using a broad inclusion criteria and recruiting from primary care 
(80).  
The potential role for medication reviews incorporating explicit screening tools of PIP 
for participants recruited to clinical trials requires further investigation. This may 
provide trialists with important information on the complex nature of prescribing 
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medication regimens in such participants, and how new interventions are expected 
to perform alongside these regimens. In addition, the cost of conducting these 
interventions in clinical trial participants should also be explored. Finally, screening 
tools such as the STOPP/START criteria have proven to be very beneficial not only in 
identifying the prevalence of PIP/PPOs in studies but also in intervention studies to 
improve medication appropriateness and reduce the risk of ADRs in older people 
(98). The updated version with the additional criteria will help to identify a larger 
number of PIP and PPO instances and therefore has a greater potential to reduce 
ADRs and improve other relevant patient outcomes. 
Strengths and limitations of the study 
To the best of our knowledge, this is the first study to estimate and compare the 
prevalence and type of PIP and PPOs using a subset of the STOPP/START V2 criteria 
in community-dwelling older adults across three different European populations. It 
also offered an opportunity to compare the characteristics of trial participants 
recruited by sites in different countries and to compare prescribing behaviours 
internationally. International comparisons can support or refute arguments for 
change in healthcare, serve as an additional lens on the state of the quality of care 
provided nationally, and can help build the evidence base necessary to identify 
problems and understand changes in the quality of care between countries. The 
TRUST database contains comprehensive information on patient demographics, co-
morbidities and medication. This facilitated the assessment and measurement of 
prescribing commission and omission for participants randomised to the clinical trial. 
A number of different approaches for optimising prescribing appropriateness have 
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been published. For example, comprehensive geriatric assessment (CGA) is a time 
consuming and resource intensive strategy to deploy and is more commonly used for 
intervention rather than prevalence studies (9). Therefore, STOPP/START was 
considered the most appropriate and feasible tool for this study. The STOPP/START 
V2 criteria were applied by a pharmacist (D.O.R.) who is familiar with using this 
screening tool. To enhance the validity of the results, a sample of the data were 
independently reviewed by two health care professionals. It was agreed a priori to 
perform the multivariable analysis at the level of the patient rather than individual 
drug as the aim of the study was to estimate and compare the prevalence and type 
of PIP and PPOs in the study population.  
It is acknowledged that the sample size (n=532) is relatively small, however, the aim 
was to estimate and compare the prevalence and type of PIP and PPOs in a sample 
of patients from three different European countries. The study population was based 
on participants enrolled to a clinical trial and may be somewhat different from the 
general population. However, the main inclusion criteria for the TRUST trial are quite 
broad. Secondly, although the data is based on a population of patients with SCH, 
there is no evidence to suggest that this would influence their chance of having a PIP 
or PPO. Although different approaches to the collection of medication data were 
used in each country, the authors (and the TRUST consortium with regards to safety) 
believe that all methods are thorough enough to capture all medication. For 
example, studies have highlighted that self-report medications are most likely to be 
congruent with patient records as a measure of current medications (99). It was only 
possible to apply a subset of the STOPP/START V2 criteria, as information required 
66 
 
for some criteria (i.e. drug strength, dose and duration of prescriptions) was not 
available in the TRUST dataset. For example, the prescribing of PPIs at full therapeutic 
dose for more than eight weeks was not reported. This may have contributed to an 
underestimation of the real prevalence of PIP in the study. Also, some of the criteria 
could be more explicit. For example, the C1 STOPP criterion “long term aspirin at 
doses greater than 160mg per day” does not define “long term”. This requires further 
clarification in future versions of the criteria (100). Although prescription drugs were 
used as proxies to indicate diagnoses, the possibility that these drugs may have been 
used to treat other conditions cannot be excluded. Finally, the TRUST trial concerned 
patients with subclinical hypothyroidism (SCH). It is possible that women with SCH 
were more likely than men to have been treated by doctors and therefore not eligible 
for the trial, as doctors tend to associate thyroid disease more with women. Also, 
SCH symptoms can overlap with post-menopausal symptoms that women report (i.e. 
tiredness, low mood etc.) therefore pushing doctors to treat this condition. 
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Conclusions 
These study findings highlight that PIP and PPOs are prevalent among a sample of 
community-dwelling older people enrolled to a clinical trial in three European 
countries. The screening process and identification of potential participants for this 
clinical trial differed between the countries and may explain some variation in the 
populations recruited and prevalence of PIP and PPOs. This study is an important first 
step to justify the need for large comparative studies using routine data. This can 
then help to inform policy or the development of appropriate interventions on 
optimising prescribing practices in older adults at a national or international level. 
Further research is urgently needed into the impact of system level factors as this has 
important implications for patient safety, healthcare provision and economic costs.  
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Abstract 
Objective: 
To evaluate studies of pharmacist-led interventions on potentially inappropriate 
prescribing among community-dwelling older adults receiving primary care to 
identify the components of a successful intervention.   
Data Sources:  
An electronic search of the literature was conducted using the following databases 
from inception to December 2015: PubMed, EMBASE, CINAHL, MEDLINE (through 
OVID), TRIP, Centre for Reviews and Dissemination databases, Cochrane Database of 
Systematic Reviews, ISI Web of Science, Science Direct, ClinialTrials.gov, 
metaRegister of Controlled Trials (mRCT), ProQuest Dissertation and Theses 
Database, (Theses in Great Britain, Ireland and North America).  
Review Methods: 
Studies were included if they were randomised controlled trials (RCTs) or quasi-
randomised studies involving a pharmacist-led intervention compared to 
usual/routine care which aimed to reduce potentially inappropriate prescribing (PIP) 
in older adults in primary care. Methodological quality of the included studies was 
independently assessed.  
Results: 
A comprehensive literature search was conducted which identified 2,193 studies 
following removal of duplicates. Five studies met the inclusion criteria. Four studies 
involved a pharmacist conducting a medication review and providing feedback to 
71 
 
patients or their family physician. One RCT evaluated the effect of a computerised 
tool that alerted pharmacists when elderly patients were newly prescribed 
potentially inappropriate medications. Four studies were associated with an 
improvement in prescribing appropriateness.  
 
Conclusion: 
Overall, this review demonstrates that pharmacist-led interventions may improve 
prescribing appropriateness in community-dwelling older adults. However, the 
quality of evidence is low. The role of a pharmacist working as part of a 
multidisciplinary primary care team requires further investigation to optimise 
prescribing in this group of patients.  
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Introduction  
Medication related problems are common in older adults and are associated with 
increased morbidity, adverse drug events, extended hospital stays and increased 
mortality (16, 17, 101). Potentially inappropriate prescribing (PIP) can introduce the 
risk of an adverse drug event (ADE) which has the potential to outweigh the drug’s 
clinical benefit, particularly when a safer or more effective alternative treatment 
option is available (19). The term “potentially” is used, as the physician may have 
considered the potential negative consequences of prescribing the drug as well as 
alternative treatment options for that patient but chose to proceed with a given 
approach (102).  Recent evidence indicates that the prevalence of PIP in older adults 
in primary care is high, with nationally representative estimates in Ireland, Northern 
Ireland and the UK at 36%, 34% and 29% respectively using an explicit measure of 
inappropriate prescribing (103-105). Curtis et al. conducted a retrospective cohort 
study using a national sample of prescription drug claims for patients over 65 
enrolled with a pharmaceutical benefit manager in the United States. The study 
highlighted that more than one in five patients filled a prescription for one or more 
drugs of concern based on the Beers revised list of drugs to be avoided in elderly 
populations (106).  
A number of screening tools have been developed to assess the appropriateness of 
prescribing, which use an explicit (criterion-based) or implicit (judgement-based) 
approach (107). Explicit tools are usually developed from published literature, 
multidisciplinary expert panels and consensus validation methods. The potential 
drawbacks of using explicit criteria include a lack of transparency of the literature 
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used, reliability of the consensus techniques and conflicts of interest of the expert 
panels (33). Explicit criteria include the Beers and STOPP/START (Screening Tool of 
Older Persons Prescriptions, Screening Tool to Alert doctors to Right Treatment) 
criteria (19, 38). Beers criteria contain several medicines that are either not 
prescribed or not available in most European drug formularies, thus its application in 
an EU setting is limited (108). The STOPP criteria comprise a physiological systems 
based screening tool designed for use in Europe. It aims to identify potentially 
inappropriate medicines (PIMs) by listing explicit rules for avoidance of particular 
medicines in older people. In addition, potential prescribing omissions (PPOs) have 
been identified by an accompanying screening tool known as START (57). 
 In implicit approaches, healthcare professionals use information from the patient 
and published reviews to assess the appropriateness of medicines (18, 109). The 
Medication Appropriateness Index (MAI) is an example of a validated implicit tool 
(110). It consists of ten criteria that relate to a number of different prescribing 
domains for example, indication, effectiveness, dose, duration, correct directions, 
practical directions, drug-drug interactions, drug-disease interactions, duplication 
and cost. The tool generates a weighted score (ranging from 0-18) per drug that 
serves as a measure of medication appropriateness. A higher score indicates an 
increased level of inappropriateness (110). The application of implicit tools is time-
consuming, depends on the users knowledge and in addition the MAI does not 
address under prescribing (107).  
Across transitions of care, evidence indicates that pharmacists play a significant role 
in gate-keeping medication appropriateness, with respect to quality and safety of 
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prescribing (111). Research suggests that pharmacists can reduce PIP and adverse 
health outcomes in patients across a range of healthcare settings by utilising explicit 
and implicit screening tools systematically (112-115).  
To date, evidence has been collated on various pharmacist-led interventions to 
reduce PIP across healthcare settings. However, no review has summarised the 
totality of evidence regarding the impact of pharmacist-led interventions to reduce 
PIP in older adults specifically in primary care.  
Therefore, the aim of this review is to evaluate studies of pharmacist-led 
interventions on medication prescribing among community-dwelling older adults 
receiving primary care to identify the components of a successful intervention.   
 
Methods  
Standardised reporting guidelines  
This systematic review adhered to the PRISMA (Preferred Reporting Items for 
Systematic Reviews And Meta-Analysis) standardised reporting guidelines to ensure 
the standardised conduct and reporting of the research (116). (See Appendix II) 
Study identification  
An electronic search of the literature was conducted using the following databases 
from inception to December 2015: PubMed, EMBASE, CINAHL, MEDLINE (through 
OVID), TRIP, Centre for Reviews and Dissemination databases, Cochrane Database of 
Systematic Reviews, ISI Web of Science, Science Direct, ClinialTrials.gov, 
metaRegister of Controlled Trials (mRCT), ProQuest Dissertation and Theses 
75 
 
Database, (Theses in Great Britain, Ireland and North America). A combination of the 
following keywords and MeSH terms were used: “primary care” or “primary health 
care” or “outpatient care” AND “prescribing” or “prescription” AND “aged” or 
“middle aged” or “elderly” AND “pharmacist” or "pharmaceutical care". There were 
no date or language restrictions on the searches. A list of the search strategies for 
each database is provided in Appendix II.  The references of final search results were 
hand-searched along with hand-searching the references of some already published 
reviews and the authors own records (112, 117).  
Study selection  
Studies were included if they met the following inclusion criteria: Study design; All 
randomised (cluster) controlled trials (RCTs), quasi RCTs, controlled before and after 
studies and interrupted time series designs (ITS) were included. Population; 
Community-dwelling older adult’s ≥65 years. Studies based on nursing home 
populations were excluded. A recent Cochrane review published by Alldred et al. 
(2016) focused on interventions to optimise prescribing for older patients in care 
homes. Eight out of the twelve studies retrieved were pharmacist-led (114). 
Therefore, it was decided that this question had already been answered for patients 
in this particular setting.  Intervention; Pharmacist-led interventions were defined as 
any intervention where the pharmacist had the lead role in an intervention designed 
to reduce potentially inappropriate prescribing (PIP)/improve medication 
appropriateness in primary care. The comparison group were usual care or other 
active interventions not focused on medication appropriateness. Outcome; The 
primary outcome measure was the change in prescribing appropriateness using a 
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validated explicit or implicit screening tool for the detection of PIP i.e. Beers criteria, 
STOPP/START, MAI.  Secondary outcomes included any clinical or patient self-
reported outcomes (e.g. quality of life, patient satisfaction).    
Studies were excluded if they were: currently ongoing; if there was a lack of reply 
from the author for supplementary information and if they only carried out an 
economic analysis.  A list of the excluded studies reviewed with reasons for exclusion 
is provided in Appendix II.  
Study selection and data extraction 
Two reviewers (D.O.R. and K.W.) independently read the titles and/or abstracts of 
the identified papers and eliminated irrelevant studies. Studies considered to be 
eligible for inclusion were read in full and their suitability for inclusion was 
determined independently by two reviewers (D.O.R., K.W.). Disagreements were 
managed by consensus. However, if this was not successful, consensus was sought 
by a third reviewer (S.B.). 
Data were extracted using an extraction form created on Microsoft Excel, based on 
study design and setting, patient demographics and inclusion criteria, details of the 
intervention and comparison, length of follow-up and outcome measures used. 
Authors were contacted to provide supplementary information when insufficient 
data were provided in the study. The authors of five studies were contacted for 
further information having read their titles and abstracts. Three replied however 
none of these studies fulfilled the inclusion criteria. Despite emailing the authors of 
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the other two studies on two different occasions we received no reply. Therefore, 
these studies were not included.  
Assessment of risk of bias 
Two reviewers (D.O.R. and R.G.) independently assessed the risk of bias for ITS using 
the EPOC (Effective Practice and Organisation of Care) risk of bias criteria and for 
RCTs using the Cochrane Collaboration’s tool for assessing risk of bias (118, 119) . In 
any case of disagreement consensus was reached with a third reviewer (K.W.).  
 
Results  
 A total of 2,193 studies were identified following removal of duplicates and five 
additional studies were located from hand searching references. A PRISMA flowchart 
(Figure 4.1) describes the flow of studies in the review.  Fifty-eight full text studies 
were assessed for eligibility. At the end of the process five studies were eligible for 
inclusion in the systematic review. Of the five included studies, three were conducted 
in the United States, one in Europe and one in New Zealand (120-124).   
The characteristics of the five included studies are summarised in Table 4.1. 
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Figure 4.1 A PRISMA flowchart outlining the procurement of 5 included studies 
Records identified through database 
searching  
(n = 2,872) 
Records after duplicates removed  
(n = 2,193) 
Records screened  
(n = 2,193) 
Records excluded by Title 
and Abstract  
(n = 2,140) 
THI 
Full-text articles assessed 
for eligibility  
(n = 58) 
Full-text articles excluded, 
with reasons  
(n = 53) 
Clinical study currently 
ongoing: n=7 
Lack of reply from author for 
supplementary information: 
n=2 
Not a primary study: n=6 
Not an intervention study: 
n=4 
Not pharmacist led: n=2 
Not in primary care: n=3 
No control group: n=9 
Pharmacy based falls 
prevention program: n=1 
Economic analysis: n=1 
No validated screening tool: 
n=18 
 
 
Studies included in 
narrative synthesis  
(n = 5) 
5 records added from 
hand searching 
references 
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Table 4.1 Study design, characteristics and outcomes of the included studies 
 
Author 
and 
Year 
Country Setting Study 
design 
Aim of the 
study 
No of 
patients 
Mean age 
in years 
±S.D 
% 
Female 
Mean no of 
Rx meds 
per patient 
at baseline 
±S.D 
Mean 
Summated 
MAI score 
per patient 
at baseline 
±S.D 
Mean 
Summated 
MAI score 
per patient 
post 
intervention 
±S.D 
Secondary 
outcomes 
Bryant 
(2011) 
 
New 
Zealand 
 
General 
Practitioner 
(GP) 
practices in 
a primary 
health care 
 
Randomised 
controlled 
trial (RCT) 
 
The objective 
was to 
determine 
whether 
involvement of 
community 
pharmacists 
undertaking 
clinical 
medication 
reviews, 
working with 
general 
practitioners, 
improved 
medicine-
related 
therapeutic 
outcomes for 
patients. 
 
 
 
 
 
 
 
I: 269 
C: 229 
 
I: 75.9 
(Range 64-
92) 
C: 74.9 
(Range 60-
91) 
 
I: 
64.7% 
 
C: 
52.4% 
 
N/A 
 
 
 
I: 5.1 
 
C: 4.5 
 
I: 3.1 
 
C: 4.2 
 
Change in the 
number of 
medicines used: 
More meds were 
started in the control 
group than the 
intervention group 
(p<0.0001). More 
dosage reductions 
and medicine 
switches in the 
intervention group 
than the control 
group (p=0.037). 
Recommendations 
implemented: 46% 
of recommendations 
were implemented, 
16% partially 
implemented. 
Quality of life (SF-
36): Improvement in 
emotional role (13.4 
unit difference, 
p=0.024) and social 
functioning (7.7 unit 
difference, p=0.019) 
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for the control 
group.  
 
Hanlon  
(1996) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
USA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A general 
medicine 
clinic of a 
Veterans 
Affairs 
Medical 
Center 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Randomised 
controlled 
trial (RCT) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To evaluate the 
effect of 
sustained 
clinical 
pharmacist 
interventions 
involving elderly 
outpatients with 
polypharmacy 
and their 
primary 
physicians 
 
 
 
 
 
 
 
 
 
 
I: 105 
 
C: 103 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I: 69.7 ±3.5 
 
C: 69.9 ±4.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I: 1.9 
 
C: 0.0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I: 7.6 ± 2.8  
 
C: 8.2 ± 2.7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I: 17.7± 6.2 
 
C: 17.6± 
6.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I: 12.8± 7.2 
 
C: 16.7± 7.1 
(At 12 
months)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quality of life (SF-
36): No significant 
difference between 
groups (p=0.99) 
Adverse Drug Event 
(ADE) (%): No 
significant difference 
between groups 
(p=0.19). 
Medication 
compliance (%): No 
significant difference 
between groups 
(p=0.88) 
Medication 
Knowledge (%): No 
significant difference 
between groups 
(p=0.29). 
VA prescribed meds: 
No significant 
difference between 
groups (p=0.83). 
General health care 
satisfaction: No 
significant difference 
between groups 
(p=0.70) 
Pharmacy related 
health care 
satisfaction: No 
significant difference 
between groups 
(p=0.52). 
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Raebel 
(2007) 
USA Kaiser 
Permanaete 
Colorado 
(KPCO) 
Medical 
offices and 
pharmacies 
Randomised 
controlled 
trial (RCT) 
To determine 
whether a 
computerised 
tool that alerted 
pharmacists 
when patients ≥ 
65 were newly 
prescribed 
potentially 
inappropriate 
medicines was 
effective in 
decreasing the 
proportion of 
patients 
dispensed these 
medications. 
I: 
29,840 
C: 
29,840 
Median 
age 
(5th, 95th 
percentiles) 
I: 74 
(66,88) 
C: 74 
(66,88) 
I: 57% 
C:57% 
Median (5th, 
95th 
percentiles) 
I: 7 (1, 17) 
C: 7 (2, 16) 
N/A 
 
N/A 1.8% of intervention 
versus 2.2% of 
control had newly 
dispensed PIP 
(p=0.002). RRR = 
16%, ARR = 0.3%. 
Dispensing rates 
differed between 
groups for 
amitriptyline 
(p<0.001; 37% RRR) 
and diazepam 
(p=0.02; 21% RRR). 
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Richmond 
(2010) 
England All general 
practices in 
five Primary 
Care Trusts 
(PCTs) 
Interrupted 
time series 
(ITS) and 
repeated 
measures 
studies 
To estimate the 
effectiveness of 
pharmaceutical 
care for older 
people, shared 
between GPs and 
community 
pharmacists in the 
UK, relative to 
usual care. 
Usual care: 
Patients within 
each of the five 
primary care 
trusts (PCTs) on a 
waiting list before 
they received 
pharmaceutical 
care 
 
551 were 
followed 
through 
pharmaceutical 
care 
80.4 
± 4.1 
43.2 8.1± 
3.1 
 
 
23.6 ± 19.5 N/A Quality of life  (SF-
36):   
Mental score: No 
=742, mean = 
47.8, SD = 12.2 
Physical score: No 
= 742, mean = 
33.0, SD = 10.4. 
Nos of items on 
repeat 
prescription: No = 
760,  mean = 7.29, 
SD = 2.23 
Serious adverse 
events:  
Pharmaceutical 
care model was 
not associated 
with any of the 
reported serious 
adverse events.  
Taylor 
(2003) 
USA Three 
community-
based family 
medicine 
clinics 
Randomised 
controlled 
trial (RCT) 
The program’s 
primary purpose 
was to determine 
the effect of 
pharmaceutical 
care on the 
prevention, 
detection, and 
resolution of 
drug-related 
problems in high-
I: 33 
 
C: 36 
I: 
64.4± 
13.7 
C: 
66.7 
± 
12.3 
I: 
63.6 
 
C: 
72.2 
I: 
6.3 
± 
2.2 
C: 
5.7 
± 
1.7 
% of 
Inappropriate 
prescriptions  
according to 
each domain of 
the MAI at 
baseline for 
the 
intervention 
and control 
group. 
% of 
Inappropriate 
prescriptions  
according to 
each domain of 
the MAI at 12 
months for the 
intervention 
and control 
group. 
 
Quality of life (SF-
36);  No significant 
difference 
between groups 
Hospitalizations 
and Emergency 
Department (ED) 
admissions: Fewer 
hospitalisations (2 
v 11, p=0.003) and 
ED visits (4 v 6, 
p=0.044) in the 
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risk patients in a 
rural community. 
 The % of 
inappropriate 
prescriptions 
decreased in all 
10 domains in 
the 
intervention 
group and 
increased in 5 
domains in the 
control group. 
The domains in 
which 
prescribing was 
most frequently 
inappropriate 
were: dosage, 
correctness of 
directions, 
practicality of 
directions and 
expense. 
intervention group 
compared to the 
control group. 
Compared to the 
control group, the 
intervention group 
were more likely 
to have controlled 
blood pressure      
(p=0.001), HBA1C 
(p=0.001), LDL 
cholesterol 
(p=0.001), INRs 
(p=0.048) 
Medication 
compliance: This 
score improved in 
the intervention 
group but not in 
the control group 
(p=0.115) 
Medication 
knowledge: This 
score improved in 
the intervention 
group but 
decreased in the 
control group 
(p=0.000) 
ADE, Adverse drug event; ARR, Absolute risk reduction; C, Control; GP, General Practitioner; I, Intervention; INR, International normalised ratio; ITS, Interrupted 
times series; LDL, Low density lipoprotein; MAI, Medication Appropriateness Index; Meds, Medications; N/A, Not applicable; No, numbers; PCT,Primary Care Trust; 
RCT, Randomised Controlled Trial; RRR, Relative risk reductions;  Rx, Prescription; SD, Standard Deviation; UK, United Kingdom; VA, Veterans Affairs.
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Characteristics of included studies 
Four of the studies involved a pharmacist carrying out a medication review and 
providing feedback to patients or their family physician (120-123). One study 
evaluated the effect of a computerised tool that alerted pharmacists at the point of 
dispensing when older patients were newly prescribed potentially inappropriate 
medications (124). 
 Bryant et al. involved pharmacists carrying out clinical medication reviews and 
providing feedback to the patient’s physicians, while the control group received usual 
care which was not defined. Two hundred and sixty-nine patients were enrolled in 
the intervention group. The MAI score improved more in the intervention group than 
in the control group (mean change in MAI score -2.0 in the intervention group; -0.3 
in the control group, p<0.001). There were more medicines started in the control 
group than the intervention group (p<0.0001), while there were more dosage 
reductions and medicine switches in the intervention group than in the control group 
(p=0.037) (120).  
Hanlon et al. evaluated the effect of a pharmacist-led review of patient’s medical 
charts, followed by a clinical recommendation to the family physician in 105 cases. 
The researchers also provided compliance strategies to the patients. Patients in the 
control group had their medications reviewed by a clinical nurse, however the clinical 
pharmacist had no interaction with the patients or their clinicians during the study 
period. The MAI score improved more in the intervention group than in the control 
group (mean change in MAI score -4.9 in the intervention group; -0.9 in the control 
group, p<0.001). There was no significant difference between groups regarding 
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adverse drug events (ADEs), p=0.19 or veterans affairs (VA) medicines prescribed 
p=0.83 (121). 
Taylor et al. examined the effect of a pharmacist intervention that provided 
medication education to patients and therapeutic recommendations to their family 
physicians following a medication review in 33 older adults. A pharmacist evaluated 
the pharmacotherapy of each patient in the control group however no 
recommendations were reported to the patient or their physician. The percentage of 
inappropriate prescriptions decreased in all 10 MAI domains in the intervention 
group and increased in five domains in the control group. Clinical outcomes such as 
hypertension, diabetes mellitus, dyslipidaemia, anticoagulation, hospitalisations and 
emergency department (ED) admissions were reported. Compared to the control 
group, the intervention group were more likely to have controlled blood pressure 
(p=0.001), HBA1c (p=0.001), low density lipoprotein (LDL) cholesterol (p=0.001) and 
international normalised ratio (INRs) (p=0.048). There were fewer hospitalisations (2 
vs 11, p=0.003) and ED visits (4 vs 6, p=0.044) in the intervention group compared to 
the control group (122). 
Richmond et al. developed pharmaceutical care plans among pharmacists and family 
physicians. The pharmaceutical care model involved pharmacists carrying out 
medication reviews and collaborating with physicians, patients and carers to identify 
issues with compliance and adverse drug reactions. It was hypothesised that the 
review process would also serve to encourage the prescribing of generic medicines 
and reduce health costs. Following this, pharmacists conducted monthly medication 
reviews with feedback to the physicians. The usual care group consisted of patients 
86 
 
within each of the five primary care trusts (PCTs) on a waiting list to receive 
pharmaceutical care. A total of 551 participants completed the study. Results 
demonstrated that the pharmaceutical care model did not affect the appropriateness 
of prescribing (mean change in UK-MAI score from baseline to the end of the 
intervention was -0.26, p>0.05). Also, the pharmaceutical care model was not 
associated with any of the reported serious adverse events (123).  
Finally, Raebel et al. estimated the effect of a computerized tool that alerted 
pharmacists at the point of dispensing when older patients were newly prescribed 
potentially inappropriate medicines (PIMs). Pharmacists and physicians collaborated 
to develop a targeted medication list for the intervention group based on the Beers, 
Zhan and Kaiser Permanente Care Management Institute lists of medications to be 
avoided in older people (125-127). The intervention group consisted of 29,840 
patients. When a patient randomised to the intervention group was prescribed a new 
potentially inappropriate medication, the pharmacist was notified via a medication 
alert generated from an electronic database. Pharmacists were required to complete 
a note on a standard intervention template before printing a label to dispense the 
prescription. Pharmacists were then instructed to telephone the prescribing 
physician to suggest alternatives. Patients in the control group received medication 
prescribing and dispensing according to usual clinical practice. When medications 
were dispensed, monitoring and patient management proceeded according to the 
prescriber’s usual procedures. Over the course of the study, 1.8% of intervention 
group patients versus 2.2% of control group patients had a newly prescribed PIM 
(p=0.002). The relative risk reduction (RRR) and absolute risk reduction (ARR) were 
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16% and 0.3% respectively.  The dispensing rates for amitriptyline (p<0.001, RRR 
37%) and diazepam (p=0.02, RRR 21%) also differed significantly between groups 
(124).  
The appropriateness of sample sizes was addressed by Hanlon et al. and Richmond 
et al. (121, 123). Taylor et al. and Raebel et al. did not carry out a sample size 
calculation (122, 124). Finally Bryant  et al. calculated the sample size based on the 
quality of life tool, the SF-36, however it is unclear how many physicians were 
enrolled in each arm of the study (120). 
Characteristics of the pharmacist’s interventions 
The characteristics of the criteria applied, healthcare professionals involved in each 
study and details of the pharmacist interventions are summarised in Table 4.2. The 
MAI criteria were used in four of the studies (109, 120-123). In the Raebel et al. study 
the Beers criteria and Zhan criteria were used (124-127). According to Richmond et 
al. and Raebel et al., pharmacists did not have access to medical notes (123, 124). A 
medication review was conducted in four studies (120-123). Two studies, Hanlon et 
al. and Taylor et al. involved pharmacists providing patients with written educational 
materials as part of the intervention (121, 122). Pharmacists in four of the studies 
provided feedback to the physicians orally or in the written format (120-122, 124). 
Two of the studies provided feedback via both methods of communication (121, 
122).  It is not clear from the Richmond et al. study how feedback was communicated 
to physicians. Finally one study involved an educational meeting with physicians 
(123).
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Table 4.2 Characteristics of the pharmacist’s interventions 
  
Author, 
year, 
country 
Criteria 
applied 
List of 
healthcare 
professionals 
involved 
Number of 
healthcare 
professionals 
involved 
Access to 
lab data 
Access to 
medical 
notes 
Medication 
review carried 
out 
Patient 
counselling 
undertaken 
Patients given 
educational 
material 
Written 
communication 
with physicians 
Oral 
communication 
with physicians  
Educational meeting 
with physicians  
Bryant 
(2011), 
New 
Zealand 
MAI Pharmacists, 
Physicians 
Two No   Yes Yes Yes No Unclear Yes No 
Hanlon 
(1996), 
USA 
MAI Pharmacists, 
Physicians, 
Nurses 
Three Yes Yes Yes Yes Yes Yes Yes No 
Raebel 
(2007), 
USA 
Beers, 
Zhan, 
aKPCMI 
Pharmacists, 
Physicians 
Two  No No No No No No Yes No 
Richmond 
(2010), 
England 
MAI Pharmacists, 
Physicians 
Two No No Yes Unclear No Unclear Unclear Yes 
Taylor,  
(2003), 
USA 
 
MAI Pharmacists, 
Physicians, 
Nurses 
Three No Yes Yes Yes Yes Yes Yes Yes 
 a KPCMI: Kaiser Permanente Care Management Institute.  
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Results of the risk of bias assessment  
The results of the risk of bias are presented in Tables 4.3 and 4.4. Common sources 
of bias included inadequate sample size, performance bias and spectrum bias.  
Overall, the authors considered four of the five studies to be at high risk of bias.  
Synthesis method 
Due to the heterogeneity of the interventions and outcome measures reported a 
narrative synthesis was carried out. 
 
 
 
 
 
 
 
 
 
90 
 
Table 4.3 Methodological quality of RCT studies included in the review as carried out by the Cochrane Collaboration’s tool (118) 
Authors Selection bias Performance 
bias 
Detection bias Attrition 
bias 
Reporting 
bias 
Other 
bias 
Risk of 
bias 
Random 
sequence 
generation 
Allocation 
concealment 
Blinding of 
participants & 
personnel 
Blinding of 
outcome 
assessment 
Incomplete 
outcome 
data 
Selective 
outcome 
reporting 
Other 
source 
of bias 
Overall 
risk of bias 
Bryant 2011 High risk High risk Unclear Low risk High risk Low risk Unclear  High 
Hanlon 1996 Low risk Unclear High risk Low risk Low risk Low risk High risk  High 
Raebel 2007 Low risk Unclear Low risk  Unclear Low risk Low risk  Unclear Unclear 
Taylor 2003 Unclear Unclear Unclear Unclear Low risk Low risk High risk High 
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Table 4.4 Methodological quality of ITS study included in the review as carried out by the EPOC checklist (119) 
Author Was the 
intervention 
independent of 
other changes? 
Was the 
shape of the 
intervention 
effect pre-
specified? 
Was the 
intervention 
unlikely to 
affect data 
collection? 
Was knowledge of 
the allocated 
interventions 
adequately 
prevented during 
the study? 
Were incomplete 
outcome data 
adequately 
addressed? 
Was the study free 
from selective 
outcome 
reporting? 
Was the study 
free from other 
risks of bias? 
Overall 
risk of 
bias 
Richmond 
2010 
Low risk Low risk High risk Low risk Unclear risk High risk High risk High 
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Discussion 
Statement of principal findings 
This systematic review examined the impact of pharmacist-led interventions on 
appropriateness of prescribing in older adults in primary care. Interventions across 
the five studies consisted of structured medication reviews or computer alerts.  Three 
of the five studies reported an improvement in the MAI score in the intervention 
group compared to the control group (120-122). Raebel et al. reported a reduction 
in newly dispensed PIMs (124). Richmond et al. reported that pharmaceutical care 
undertaken by community pharmacists did not significantly change the 
appropriateness of prescribing in older patients. One of the limitations from this 
study was that pharmacists were unable to gather detailed clinical records for 
patients. This may have led to an underestimation of the true MAI score (123). In 
three of the studies pharmacists had access to the patients’ medical notes (120-122). 
This may have impacted on the nature and scope of the medication review by 
pharmacists. Another limitation was that pharmacists reported difficulties in 
accessing patients and physicians in order to prepare and discuss the pharmaceutical 
care plan. This was despite the fact that joint collaborative training on 
pharmaceutical care was provided to pharmacists and physicians (123). The two 
studies that involved pharmacists providing patients with written education 
materials may have further improved their understanding of and compliance with 
medicines (121, 122). In the study by Bryant et al. the medication review was 
conducted in the pharmacy or at the patient’s home. Although the MAI score 
improved more in the intervention group than in the control group approximately 
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40% of the pharmacist recommendations were not implemented by the physicians. 
It is not known whether the non-implementation was due to the physician-
pharmacist relationship or whether there were other barriers involved (120).  
According to Raebel et al., the absolute difference in dispensing numbers between 
intervention and control groups was minimal.  This was despite the fact that 
pharmacists and physicians collaborated to develop a list of medicines for the 
intervention, specific intervention guidelines and patient counselling scripts. The 
study highlights the difficulty in modifying prescribing behaviour even though the 
intervention was fully advocated by the physicians (124).  Finally, in the study by 
Hanlon et al. the target population was elderly male veterans. This may impact on 
the generalisability of the study findings (121). 
Clinical significance of MAI change 
In the studies carried out by Hanlon et al. and Taylor et al. the authors conclude that 
the clinical significance of the change in MAI remains unclear and highlight this as a 
potential limitation (121, 122). Bryant  et al. suggest further research be carried out 
to determine the relationship between the MAI and hospitalisations rates (120). 
Finally in the Richmond  et al. study the pharmaceutical care model carried out by 
pharmacists did not significantly change the appropriateness of prescribing or quality 
of life in older people (123).  
A narrative review identified seven studies that evaluated the predictive validity of 
the MAI in relation to various health outcomes (109). Three studies involved Veterans 
Affairs (VA) outpatients or VA medical centres across the USA (128-130). In these 
studies, higher MAI scores were significantly associated with unscheduled 
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ambulatory or emergency department (ED) visits and inadequate blood pressure 
control, adverse drug events using modified MAI scores and adverse drug reactions 
by drug-disease interaction criteria (128-130). 
 
Results in the context of the current literature 
A systematic review by Kaur et al. evaluated various interventions and strategies to 
reduce inappropriate prescribing in older people in primary and secondary care 
settings. The review highlighted that pharmacist interventions were successful in 
reducing inappropriate prescribing. Other interventions that demonstrated   positive 
effects on prescribing included, computerised support systems, geriatrician’s 
services and multidisciplinary team work. However, there were mixed responses for 
educational interventions aimed at improving inappropriate prescribing due to the 
variability in assessment methodologies. The effect of regulatory policies as an 
intervention was also variable (131). A further narrative review appraised 
prospective and intervention studies that focused on the use of potentially 
inappropriate medicines (PIM’s) in community-dwelling older adults. Intervention 
studies that were included aimed to change the prescribing patterns of physicians. 
The majority of included studies focused on the prevalence of PIM’s. Several others 
analysed the relationship between PIM’s and falls, cognitive function, sleep and 
quality of life. This narrative review recommends more collaborative 
multidisciplinary team approaches that include pharmacists to reduce the use of 
PIM’s. It also suggests that mixed-methods research could enhance the quality of 
interventions to address PIM use (117). A Cochrane review examined 12 intervention 
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studies including pharmacist-led studies aimed at improving appropriate 
polypharmacy for older people across healthcare settings (112). In hospital settings, 
pharmacists provided pharmaceutical care in outpatient clinics and inpatient 
departments. In primary care, pharmacist interventions included medication reviews 
with feedback to physicians and medicine education to patients. Finally, in nursing 
homes, pharmacists worked with other healthcare professionals on case conferences 
and provided education to staff members. A drug management service was also 
provided. The post-intervention results demonstrated a mean difference of -3.88 
(95% CI -5.40 to -2.35) in the change in MAI score in favour of the intervention group 
compared with the control group across the five studies. This updated review 
published in 2014 was based on a previous Cochrane review carried out by the same 
authors. It included two additional studies from the previous review (112) .  
A review by Castelino et al. evaluated 12 interventions involving pharmacists that 
focused on reducing inappropriate prescribing in older adults across different 
healthcare settings. The selected studies highlighted pharmacists working 
independently or as part of multidisciplinary healthcare teams. The services provided 
by pharmacists commonly involved some form of medication review, highlighting the 
important role that pharmacists play in optimising medication use for this group of 
patients (113).  
The current systematic review has highlighted that pharmacist-led interventions 
involving access to medical notes and medication reviews conducted in physician 
practices with feedback to physicians may improve prescribing appropriateness in 
community-dwelling older adults. The findings are broadly in-keeping with other 
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reviews including a recent systematic review with meta-analysis conducted to 
determine the effectiveness of pharmacist interventions to reduce PIP in older adults 
admitted to hospital. The review concluded that pharmacists carrying out medication 
reviews as part of multidisciplinary patient care teams may improve the quality of 
prescribing in older hospitalised patients (112, 115, 117, 131). 
In addition, the findings are consistent with the evidence highlighted that the quality 
of prescribing for older people in primary care could benefit from pharmacist-
physician collaboration.  
Clinical implications and areas for further research  
This review has implications for clinical practice and future research, in particular 
with respect to the emerging role that pharmacists play in moderating medication 
appropriateness in primary care. 
 There is a growing need for improved collaboration between physicians and 
pharmacists in order to optimise prescribing practices in primary care. Collaborative 
multidisciplinary models can improve the care of older adults with chronic 
multimorbidities (132). The PINCER trial is an example of such a model. It highlighted 
the benefit of a pharmacist-led intervention in general practices in the UK. The 
practices were cluster randomised to a pharmacist-led information technology 
intervention group or a control group. This trial demonstrated that the PINCER 
intervention was effective at reducing medication errors in general practice (133). 
Schmader et al. demonstrated that compared with usual care, inpatient and 
outpatient geriatric evaluation and management programs involving pharmacists 
97 
 
reduced suboptimal prescribing in frail elderly patients. The outpatient geriatric 
teams also reduced serious adverse drug reactions (110).   
The diverse range of outcome measures used in studies of prescribing 
appropriateness has made it difficult to make firm conclusions in this field. Ideally, 
prescribing outcome measures should be linked to important clinical outcomes such 
as morbidity or mortality. A pan-European study is currently underway and may add 
clarity to this issue: The OPERAM study (Optimising thERapy to prevent Avoidable 
hospital admissions in the Multimorbid elderly) aims to reduce the rates of over and 
under prescribing of medications among multimorbid older European adults. While 
PIP is one measure among others at measuring optimal prescribing there is an 
underreporting of medication errors in the literature. One major component of this 
large multi-centre randomised clinical trial will be the use of a sophisticated software 
tool to optimise medication therapy and to determine whether the applied 
intervention can improve clinical outcomes such as drug related admissions (DRAs), 
humanistic outcomes such as quality of life and reduce healthcare costs 
(https://operam2020.tp21.com). 
 Educational outreach interventions or “Academic detailing” provided by pharmacists 
(or other clinicians) to physicians in primary care is an area for further research. The 
term “Academic detailing” was coined by Jerry Avorn MD over thirty years ago (134). 
Clinical educators, who are usually pharmacists, nurses or physicians are trained to 
provide accurate, balanced, non-commercial and up to date synthesis of the best 
clinical evidence in an engaging format with healthcare physicians (134). Information 
highlighted to physicians often includes recommendations about alternative 
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treatment regimens or non-pharmacological interventions where appropriate. These 
recommendations are designed to complement the clinical judgement of a physician 
and not to replace it  (135). This evidence-based strategy has been shown to be an 
effective means of changing physician behaviour and improving patient care (136). 
For example, a pharmacist-led intervention comprising academic detailing 
demonstrated an improvement in statin prescribing in high-risk patients in primary 
care (137).  
There is a dearth of research examining the cost-benefit analysis of pharmacist-led 
interventions to improve prescribing patterns in healthcare. Cowper et al. conducted 
a cost analysis of a previously reported randomised control trial (121, 138). The total 
cost of the clinical pharmacist intervention was $120 per patient per year. This 
intervention was a cost-effective means at improving prescribing among elderly 
outpatients (138). In the PINCER trial, the cost per error avoided was estimated by 
incremental cost-effectiveness analysis. The pharmacist-led intervention had a 95% 
probability of being cost effective at various time points throughout the trial (133). 
The economic benefits of using validated screening tools in primary care are currently 
limited and require further research.  
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Strengths and weaknesses 
This is the first systematic review to focus specifically on the impact of pharmacist-
led interventions on prescribing appropriateness in older adults in primary care. An 
explicit and robust methodology was applied to identify and synthesise the study 
findings. However, the findings of the review need to be interpreted in the context 
of the study limitations. Firstly, the methodological quality of the studies was poor 
overall, limiting the generalisability of the findings. Secondly, despite applying a 
comprehensive search strategy, only five studies were eligible for inclusion in the 
review. Thirdly, if the following terms i.e. inappropriate prescribing, potentially 
inappropriate prescribing, suboptimal prescribing were applied across all databases 
it may have narrowed down the searches. Subsequently, the lack of standardised 
reporting across studies limited the statistical pooling of data. Moreover, three 
studies reported an improvement in the MAI score for the intervention group 
compared to the control group, however the effect sizes are small which highlights 
the need for further research to assess the impact of pharmacist-led interventions in 
primary care.  Furthermore, the clinical impact of reducing surrogate markers such 
as the MAI remains unknown and requires further investigation. However, one of the 
aims of the OPERAM study is to link prescribing outcome measures with clinical 
outcomes such as hospital admissions.  Finally, large cluster-randomised control trials 
that are methodologically robust and have a long duration of follow up are needed 
to address patient focused outcomes. In addition, reviews on the appropriateness of 
prescribing are warranted among other vulnerable populations including paediatric 
patients, drug users, homeless people and prisoners. 
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Conclusion  
This review concludes that pharmacist-led interventions involving access to medical 
notes and medication reviews conducted in physician practices with feedback to 
physicians may improve prescribing appropriateness in community-dwelling older 
adults. Interventions where computer alerts help to inform pharmacists of 
potentially inappropriate medicines may also improve prescribing appropriateness.  
However, it is unclear if these interventions result in clinically significant 
improvements in patient outcomes. Further high-quality research should be 
conducted to explore the generalisability of these interventions. Finally, the role of a 
pharmacist working as part of a multidisciplinary primary care team requires further 
investigation to optimise prescribing in this group of patients. 
 
 
 
 
 
 
 
 
 
101 
 
Chapter 5. GPs’ perspectives on prescribing for older people 
in primary care: a qualitative study 
 
 
 David O Riordan 
 
 Stephen Byrne  
 
 Aoife Fleming 
 
 Patricia M Kearney 
 
 Rose Galvin 
 
 Carol Sinnott 
 
 
 
 
This paper was published in the British Journal of Clinical Pharmacology 
in January 2017 
 
102 
 
Abstract 
Aims 
The aim of this study was firstly to reveal the determinants of GP prescribing 
behaviour for older adults in primary care and secondly to elicit GPs’ views on the 
potential role for broad intervention strategies involving pharmacists and/or 
information technology systems in general practice.  
Methods 
Semi-structured qualitative interviews were carried out with a purposive sample of 
GPs.  Three multidisciplinary researchers independently coded the interview data 
using a framework approach. Emerging themes were mapped to the Theoretical 
Domains Framework (TDF), a tool used to apply behaviour change theories.  
Results  
 Sixteen GPs participated in the study. The following domains in the TDF were 
identified as being important determinants of GP prescribing behaviour: 
“Knowledge”, “Skills” “Reinforcement”, “Memory Attention and Decision Process”, 
“Environmental Context and Resources”, “Social influences”, “Social/Professional 
Role and Identity”. Participants reported that the challenges associated with 
prescribing for an increasingly older population will require them to become more 
knowledgeable in pharmacology and drug interactions and they called for extra 
training in these topics. GPs viewed strategies such as academic detailing sessions 
delivered by pharmacists or information technology systems as having a positive role 
to play in optimising prescribing. 
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Conclusion  
This study highlights the complexities of behavioural determinants of prescribing for 
older people in primary care and the need for additional supports to optimise 
prescribing for this growing cohort of patients. Interventions that incorporate, but 
are not limited to interprofessional collaboration with pharmacists and information 
technology systems, were identified by GPs as being potentially useful for improving 
prescribing behaviour, therefore require further exploration. 
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What is known about this subject? 
 Providing optimal medication management for older people is a challenge for 
GPs. 
 Prescribing for older people can result in medication-related problems and 
preventable drug-related morbidity. 
 As the main prescribers of medication in primary care, GPs can provide a 
deeper insight into the complexities of prescribing for these patients. 
 
What this study adds 
 Prescribing for the growing older population is viewed by GPs as a significant 
challenge in their clinical practice. 
 GPs are calling for additional support in order to help them manage and treat 
these patients. 
 Academic detailing, an approach that provides GPs with accurate, non-biased 
and evidence-based information, is viewed by GPs as a potentially useful way 
to help optimise their prescribing. Information technology systems are also 
identified by GPs as having a role to play in supporting safer prescribing.   
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Introduction  
Providing optimal care for older adults creates many challenges for healthcare 
providers especially general practitioners (GPs) (11-13, 15). Appropriate prescribing 
of medications is a significant challenge as older adults can present with multiple 
conditions for which multiple medications are often indicated (1, 6). Age related 
changes in pharmacokinetics and pharmacodynamics contribute to the challenge of 
appropriate prescribing (139). Inappropriate prescribing results in preventable drug-
related morbidity (PDRM) including adverse drug events (ADEs), hospital admissions 
and mortality (107, 140, 141). Potential PDRM events occur in 1.0% of  patients 
attending general practice, with the most common PDRM events relating to the use 
of non-steroidal anti-inflammatory (NSAID) medicines in patients with congestive 
heart failure or hypertension, lack of monitoring in patients prescribed angiotensin 
converting enzyme (ACE) inhibitors and the use of hypnotic-anxiolytic agents (142). 
As GPs are the main prescribers of medication in primary care, understanding the 
factors influencing GP behaviour in relation to prescribing is a first step in reducing 
PDRM and improving clinical outcomes (143). Previous research has shown that 
factors influencing GP prescribing decisions include medication effectiveness, 
associated risks, medication costs and patient characteristics or preferences (144). 
Other influences include factors which relate specifically to the individual GP such as 
post-graduate qualifications or training (145), the prescribing behaviour of hospital 
consultants (146), or advertising by the pharmaceutical industry (147). However, how 
best to intervene on these influences to improve GP prescribing is not known. It has 
been proposed that knowledge of the key determinants of health care professionals’ 
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(HCP) behaviour can be used to theoretically inform interventions that aim to change 
that behaviour (148). Additionally, qualitative research with HCPs can inform and 
optimise the delivery of subsequent interventions. 
 The Theoretical Domains Framework (TDF) is an overarching framework of theories 
that identifies the specific process underlying successful behaviour change (149). It 
consists of 14 domains and 84 component constructs (150). The TDF has been used 
to identify key theoretical domains that are perceived to influence HCPs behaviours 
(150). For example, Cullinan et al. used the TDF to identify key influences of 
potentially inappropriate prescribing (PIP) by hospital doctors such as insufficient 
training in prescribing for older people (151).      
The aim of this study was firstly to reveal the determinants of GP prescribing 
behaviour for older adults in primary care and secondly to elicit GPs’ views on the 
potential role for broad intervention strategies   that is, involving pharmacists and/or 
information technology systems in general practice. Participants were also 
encouraged to suggest any other types of intervention that they thought would be 
feasible and useful.    
Methods 
Design  
Semi-structured qualitative interviews were conducted with GPs in primary care to 
explore their experiences of prescribing for patients aged 65 and older and their 
views on the potential role for interventions involving pharmacists and/or 
information technology systems in general practice. This interview method was 
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chosen due to its flexible and interactive nature and its ability to achieve 
comprehensive coverage of the topic discussed (152). The descriptions of their 
experiences were analysed using qualitative methods and mapped to the TDF 
framework to reveal behavioural determinants.     
Sampling 
This study was conducted in County Cork, Ireland. A purposive sample of GPs in 
teaching practices associated with University College Cork (UCC) were initially invited 
to participate. The purposive sampling strategy was based on years of experience 
(≥10 or ≤10 years), practice location (% urban population of GP practice location) and 
practice size (single or group practice). There were no inclusion or exclusion criteria 
for participants other than a requirement to be in active clinical practice. D.O.R. 
contacted potential participants by telephone and a brief summary of the study was 
given. In some cases, snowball sampling was used when participants who were based 
in single rural practices and had already been interviewed were asked to identify 
other GPs who they thought might be interested in participating. The nominated GPs 
were then sampled according to the needs of the sampling frame. 
Two pilot interviews were conducted. Following review of the data and topic guides, 
the authors agreed to include the data generated from the pilot interviews as it was 
highly relevant to the study question.  
The method developed by Francis  et al. was used to determine data saturation (153). 
Firstly, the authors agreed a priori that the first 10 participants (initial analysis 
sample) represented adequate diversity on the pre-specified stratification factors 
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(years of experience, gender, practice location and practice size). Secondly, it was 
agreed a priori that after 10 interviews were conducted data saturation was reached 
once three consecutive interviews did not contribute further to thematic 
development (stopping criterion). The stopping criterion was tested after each 
successive interview e.g. 11, 12, 13.  At interview 13, a further 3 interviews were 
carried out to identify new themes. However, these additional interviews did not 
contribute to the further development of emerging themes.  Therefore, interview 16 
was defined as the point of data saturation.  
Data collection 
The interviews were carried out by one researcher (D.O.R.) at the GPs surgeries 
between March 2015 and August 2015.  
A topic guide was developed based on previous literature and was agreed on by all 
authors (154, 155). It was iteratively refined after each interview was transcribed and 
analysed to pursue emerging themes. Further refinements were reviewed by another 
author (CS) and examples are provided as supplementary material to show its 
continuous development as the interviews proceeded (See Appendix III). 
Demographic details were collected including practice location, GP gender, years’ 
experience as a GP and number of GPs, including GP registrars where relevant, 
working in the practice. In addition to questions on their experience of prescribing 
for older patients, participants were asked for their views on the potential role for 
interventions (i.e. involving pharmacists and/or information technology systems) in 
general practice.   
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 The interviews were audio-recorded, fully transcribed and saved in QSR 
Internationals NVivo Qualitative Data Analysis Software (V.10.22) to facilitate 
analysis (76). Field notes were written and used to facilitate preliminary 
familiarisation with emerging themes immediately after each interview. 
 
Analysis 
The framework approach, which consists of five stages, was used to analyse the data 
(152). The first phase involved reading and re-reading each transcript as well as 
listening to interview recordings to become familiar with the content. The second 
phase involved identifying a thematic framework. Due to the specifics of the research 
aim, a deductive approach was taken with agreement by the authors to use the 
Theoretical Domains Framework (TDF) a priori. The next phase was indexing: this 
involved open coding (carried out by D.O.R.) and development of a coding scheme. 
The fourth phase involved arranging data into domains of the TDF and generating 
charts. In some cases, the data was relevant to more than one domain and this 
resulted in “double coding” of the data. The last phase involved interpreting the data 
by finding associations between themes with the aim of providing explanations for 
them. To enhance the credibility of coding, three multidisciplinary researchers 
(D.O.R., C.S., and S.B.) independently coded a sample of the transcripts. 
 The consolidated criteria for reporting qualitative research (COREQ) statement was 
used to guide reporting of the findings (see Appendix III) (156).  
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Ethical approval for this study was granted by the Clinical Research Ethics Committee 
of the Cork University Teaching Hospitals (reference ECM 3 (mmm) 14/04/15 & 4 (k) 
07/10/14) (See Appendix IX). All participants provided written informed consent.   
 
Results  
Sixteen interviews were conducted in total. The interviews ranged from 9 minutes to 
31 minutes (mean interview length 19 minutes). The mean duration of participating 
GPs’ medical experience was 17 years. The number of GPs working in a practice 
ranged from 1 to 6. The characteristics of participants interviewed are provided in 
Table 5.1.  
The definition of all 14 TDF domains as described by Cane et al.  together with 
supporting quotes from participants are shown in Table 5.2  (150). 
Almost all of the TDF domains were seen to be relevant to the study data but the 
domains presented in detail here were prioritised because of the emphasis placed on 
them by participants, the frequency of occurrence of the domain across all the 
transcripts, and the consensus agreement of the authors.    
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Table 5.1 Characteristics of GP participants 
General 
Practitioner 
(GP) 
Gender  Years of 
medical 
experience 
% Urban 
population of GP 
practice location 
No. of GPs 
in the 
practice 
No. of GP 
registrars in 
the practice 
1 F 4 19.5 2 0 
2 F 20 25.7 4 1 
3 M 33 25.7 4 1 
4 F 20 25.7 1 0 
5 F 4 100 2 0 
6 M 25 25.7 4 1 
7 F 4 8.4 2 0 
8 M 20 100 2 0 
9 M 35 25.7 4 1 
10 F 19 25.7 1 0 
11 F 13 100 3 1 
12 F 4 25.7 4 1 
13 M 3 19.5 2 0 
14 M 30 100 3 1 
15 M 14 8.8 6 0 
16 M 27 25.7 4 1 
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Table 5.2 TDF domains, explanatory constructs and supporting quotes (150) 
Domain (definition) & Constructs  Domain 
reported in 
the study 
results 
Supporting quotes 
1. Knowledge  
(An awareness of the existence of something) 
 
Constructs  
 Knowledge (including knowledge of 
condition/scientific rationale) 
 Procedural knowledge 
 Knowledge of task environment 
 
 
 
 
“… It’s going to have a huge impact on general practice and GPs, I think we’ll 
need to try and continue to improve our skills in that area and I think care of the 
elderly…  will be a speciality … it’s going to present a lot of challenges in terms of 
knowing the pharmacology and interactions.” (GP11) 
 
“Three times a week for 5 minutes I meet a drug rep … so while we take it with a 
pinch of salt, because we know it’s biased …. we inevitably are influenced by drug 
reps …..” (GP15) 
2. Skills  
(An ability or proficiency acquired through practice) 
 
Constructs  
 Skills/Skills development 
 Competence 
 Ability 
 Interpersonal skills 
 Practice  
 Skill assessment 
 
 
 
 
 
“I personally think that we should have to every 6 or 12 months sit some kind of 
exam in prescribing …because prescribing is so desperately important and I think 
the only way I would actually change the way I practice is if there was some kind 
of revalidation.….” (GP15) 
 
“We find that in General Practice there are so many important areas we need to 
up skill in ... And this is a particularly important one (Educational training), and I 
think you’d probably find that most GPs would agree with that.” (GP5) 
3. Social/Professional Role and Identity 
(A coherent set of behaviours and displayed personal 
qualities of an individual in a social or work setting) 
 
Constructs  
 Professional identity/ Social identity 
 Professional role 
 Identity/ Group identity 
 Professional boundaries 
 Professional confidence 
 
 
 
 
 
“I think some of the hospital sector, don’t fully understand the nature of general 
practice …I saw a person with a renal problem and I was in their house ….   I rang 
the Urology (team) because they had a nephrostomy tube and they were asking 
me what his creatinine was…… they just had no idea that you don’t have a 
portable creatinine monitor by your side….” (GP8) 
 
“As a GP, you have a role as a co-ordinator of care, and you’d have the most up 
to date record of everything that’s going on.” (GP5) 
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 Leadership 
 Organisational commitment 
4. Beliefs about Capabilities  
(Acceptance of the truth, reality, or validity about an ability, 
talent or facility that a person can put to constructive use) 
 
Constructs 
 Self-confidence  
 Perceived competence  
 Self-efficacy 
 Perceived behavioural control 
 Beliefs 
 Self-esteem 
 Empowerment 
 Professional confidence 
 
 
 
 
 
X  
 
 
“I am slow to start new medications for 6 to 12 months I leave it out on the 
market and I think sometimes other professionals … may not think of that in a 
positive way but that’s the way I am.” (GP16) 
 
 
“Sometimes there’s this feeling going around unless you are using the new 
medications you are sometimes behind the times or a bit old fashioned … but 
sometimes it might be that there’s much better evidence for the older medication 
or you know it’s been studied a lot more and there might be very little evidence 
for the new one and the new one might be 5-6 times the cost if not more.” (GP8) 
 
 
5. Optimism  
(The confidence that things will happen for the best or that 
desired goals will be attained)  
 
Constructs  
 Optimism 
 Pessimism 
 Unrealistic optimism  
 Identity 
 
 
 
 
 
 
X 
 
“We need enhanced roles of the … pharmacists, the practice nurses, advanced 
nurse practitioners, more community nurse workers as well as public health 
nurses you know such as dementia care nurses and things like that. I think all 
those things will sort of help give a better standard. I think it will happen bit by 
bit.” (GP8) 
 
“There needs to be a common goal that the patient is a priority and it is very 
significantly absent from management and health services. Ok, they do not look 
at the patient goal because the managers regard the management as being 
totally isolated from health responsibility. With any luck, we’ll bring that 
around.” (GP3) 
 
6. Beliefs about Consequences 
(Acceptance of the truth, reality, or validity about outcomes 
of a behaviour in a given situation) 
 
Constructs 
 Beliefs 
 Outcome expectancies 
 
 
 
X 
 
“One issue that springs to mind is… benzodiazepine prescribing, so you would 
have a cohort of elderly patients who have been prescribed benzodiazepines for a 
very long period of time, that you wouldn’t be in a position to be really thinking 
about stopping them, but certainly you would wonder if, certain events such as a 
fall, an episode of confusion, could be related to these particular medications.” 
(GP5) 
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 Characteristics of outcome expectancies 
 Anticipated regret 
 Consequents 
 
 
 
“One of the biggest problems at the moment is the generic substitution, it is 
confusing the hell out of all the elderly patients and that they are getting 
different pills, different capsules instead of pills and shapes and colours and sizes 
and names are all changing.” (GP3) 
7. Reinforcement  
(Increasing the probability of a response by arranging a 
dependent relationship, or contingency, between the 
response and a given stimulus)  
 
Constructs  
 Rewards (proximal/distal, valued/not valued, 
probable/improbable) 
 Incentives 
 Punishment 
 Consequents 
 Reinforcement 
 Contingencies 
 Sanctions 
 
 
 
 
 
 
 
 
“I’m pretty sure it’s out there somewhere that it’s the biggest source of litigation 
I think for GPs is prescribing or …. prescribing errors.” (GP13) 
 
“The other thing I suppose is whether this (educational training) will qualify for 
external CPD points. Because we’re all required to get 20 external points and 
internal points …, and certainly if it could be something that was worth internal 
and external points, I think it could be beneficial.” (GP5) 
 
 
8. Intentions  
(A conscious decision to perform a behaviour or a resolve to 
act in a certain way) 
 
Constructs  
 Stability of intentions 
 Stages of change model 
 Transtheoretical model and stages of change 
 
 
X 
 
“Sometimes it’s nearly easier to wait until the outpatient’s letter come and then 
start the medication.” (GP7) 
 
“But if it was something like methotrexate…even thinking about it now would 
give you the heebee jeebees … you’ve somebody elderly in front of you and your 
really not sure, I just don’t think you can prescribe it really you know.” (GP11) 
 
 
9. Goals  
(Mental representations of outcomes or end states that an 
individual wants to achieve) 
 
Constructs  
 Goals (distal/proximal) 
 Goal priority 
 Goal/target setting 
 
 
 
 
X 
 
 
“I think we are all in it for the side of the patient like what you want is a patient 
who’s prescribed appropriate drugs, at an appropriate dose for appropriate 
lengths of time.” (GP10) 
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 Goals (autonomous/controlled) 
 Action planning 
 Implementation intention 
“There are areas where I believe …for a pharmacist within the clinical 
environment. And I think that would work and certainly is one area we would 
love to trial and have tried to do before. It works in various areas in the UK. It’s 
been very successful.” (GP3) 
 
10. Memory, Attention and Decision Processes 
(The ability to retain information, focus selectively on 
aspects of the environment and choose between two or 
more alternatives) 
 
Constructs  
 Memory  
 Attention 
 Attention control 
 Decision making 
 Cognitive overload/tiredness 
 
 
 
 
“But if it was something like methotrexate …. even thinking about it now would 
give you the heebee jeebees… you’ve somebody elderly in front of you and you’re 
really not sure, I just don’t think you can prescribe it really you know.” (GP11)  
 
 
“… if you do need to use something … bearing in mind their cardiovascular risk, 
bearing in mind their falls risk that go with lots of the sedative medication, 
antipsychotics, sleeping tablets … I think that’s my biggest bugbear, difficulty.” 
(GP13) 
 
11. Environmental Context and Resources 
(Any circumstance of a person’s situation or environment 
that discourages or encourages the development of skills 
and abilities, independence, social competence and 
adaptive behaviour) 
 
Constructs  
 Environmental stressors 
 Resources/material resources 
 Organisational culture/climate 
 Salient events/critical incidents 
 Person x environment interaction 
 Barriers and facilitators 
 
 
 
 
 
 
 
 
“If you’re really busy sometimes and I’m just being honest, you just print off their 
last month’s prescription and you’ll keep going with that, you know.” (GP4) 
 
“We’re very lucky that we have a very good relationship with the local 
pharmacist here they are very, very good and so we would be on to them a 
number of times a day … particularly for people who come out from hospital 
whereas sometimes it isn’t clear what dose of medications they’re on.” (GP8) 
 
 
 
12. Social influences  
(Those interpersonal processes that can cause individuals to 
change their thoughts, feelings or behaviours) 
 
Constructs  
 Social pressure/Social norms/ Social comparisons 
 Group conformity/Group norms/Group identity 
 
 
 
 
 
 
 
“… so people do present saying I saw the ad on the telly (for an anticholinergic 
medication for urinary incontinence) and I have the overactive bladder and 
you’re thinking anticholinergics and you’re 75 …. but they still expect it you 
know.” (GP1) 
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 Social support 
 Power 
 Intergroup conflict 
 Alienation 
 Modelling 
“Any of those on the benzos you’d be trying to pull them all off it... Very hard, 
very hard.  …And in spite of you talking about the risk of falls and obviously 
slowly weaning off …but very hard to get patients off these tablets that are not 
essential really you know.” (GP7) 
 
13. Emotion 
(A complex reaction pattern, involving experiential, 
behavioural, and physiological elements, by which the 
individual attempts to deal with a personally significant 
matter or event) 
 
Constructs  
 Fear  
 Anxiety 
 Affect 
 Stress 
 Depression 
 Positive/negative affect 
 Burn-out 
 
 
 
 
X  
 
“I’m worried, I’m always worried about renal function, I’m worried about anti-
inflammatories and hypertension, I’m worried about risk of bleeding, I’m worried 
about side-effects, probably I should worry more about drug interaction and I 
don’t.” (GP15) 
 
 
“But as regards other people highlighting it (prescribing errors) I don’t mind, I’m 
just embarrassed really.” (GP11) 
 
14. Behavioural Regulation 
(Anything aimed at managing or changing objectively 
observed or measured actions) 
 
Constructs  
 Self-monitoring 
 Breaking habit 
 Action planning 
 
 
 
X 
 
“…you had a pharmacist coming in and doing an audit on your over 65s every 
month, that they came in and had access to your system. I think it would be a 
great system.” (GP7) 
 
“We have started actually about 4 or 5 months ago, a repeat prescribing protocol 
within the practice and as part of that we look at STOPP/START.” (GP15) 
 
(STOPP/START: Screening Tool of Older Persons Prescriptions/ Screening Tool to 
Alert doctors to Right Treatment criteria) 
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Important influences on GP prescribing behaviour identified using the TDF 
Knowledge/Skills 
 Although they are described separately in the TDF, it was decided to merge the 
domains “Knowledge” and “Skills” as the findings that emerged were overlapping 
and therefore are reported as a single domain. 
Participants reported the responsibility of prescribing for increasing numbers of 
complicated older patients as a burden. They voiced that they felt this would become 
even more demanding in the future. Participants reported a need to become more 
knowledgeable in pharmacology and drug interactions and they called for extra 
training in order to manage and treat these patients.  
“… it’s going to have a huge impact on general practice and GPs, I think we’ll need to 
try and continue to improve our skills in that area and I think… care of the elderly … 
will be a speciality … it’s going to present a lot of challenges in terms of knowing the 
pharmacology and interactions.” (GP11) 
Participants acknowledged the importance of their role as prescribers and suggested 
regular evaluation of their prescribing knowledge would motivate GPs to stay up-to-
date with their prescribing skills and in some cases, change the way they practice or 
enhance the care of their patients. 
“I personally think that we should have to every 6 or 12 months sit some kind of exam 
in prescribing … because prescribing is so desperately important and I think the only 
way I would actually change the way I practice is if there was some kind of 
revalidation …” (GP15) 
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Participants reported that they are influenced by information provided by 
pharmaceutical drug representatives despite viewing this information as biased. 
They called for alternative sources of succinct information that can be delivered in 
their practices, but is independent of the pharmaceutical industry and is evidence-
based. 
“Three times a week for 5 minutes I meet a drug rep … so while we take it with a pinch 
of salt, because we know it’s biased … we inevitably are influenced by drug reps …” 
(GP15) 
 
Reinforcement Participants viewed prescribing in older people as a potential source 
of litigation should a prescribing error arise. They reported that the risk of error is 
higher in these patients due to the medical complexity and the possible interactions 
and side effects associated with the use of multiple medicines. The fear of litigation 
made some GPs more cautious and acted as an incentive to optimize their prescribing 
for these patients.  
“I’m pretty sure it’s out there somewhere that it’s the biggest source of litigation I 
think for GPs is prescribing or … prescribing errors.” (GP13) 
  
Memory Attention and Decision Process 
 Participants actively considered various factors when prescribing medicines for 
example, when to start them, when to stop them, their side-effects, their potential 
for addiction, their potential adverse outcomes. The decision-making process can 
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become more complicated when a patient is already prescribed multiple medicines. 
This was mentioned as a particular issue when considering medicines with potential 
adverse effects, as they can lead to a prescribing cascade. 
 “If you do need to use something … bearing in mind their cardiovascular risk, bearing 
in mind their falls risk that go with lots of the sedative medication, antipsychotics, 
sleeping tablets … I think that’s my biggest bugbear, difficulty.” (GP13) 
Some participants were reluctant to prescribe potentially useful medicines such as 
methotrexate out of fear of their side effects in older, more vulnerable patients. It 
was also evident that there was a level of caution and uncertainty around the 
prescribing of these high-risk medicines.   
“But if it was something like methotrexate … even thinking about it now would give 
you the heebee jeebees… you’ve somebody elderly in front of you and you’re really 
not sure, I just don’t think you can prescribe it really you know.” (GP11)  
 
Environmental Context and Resources  
Although prescribing was seen as an important responsibility by participants, they 
did not always get time to review medications as thoroughly as they would like.  
“If you’re really busy sometimes and I’m just being honest, you just print off their last 
month’s prescription and you’ll keep going with that, you know.” (GP4) 
Pharmacists were described as a useful resource for GPs especially in cases where 
older patients were having compliance issues with their medicines by dispensing 
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medicines into weekly/monthly blister packs. Reviewing prescriptions, checking drug 
doses and identifying potential drug interactions and side effects were other roles 
where pharmacists were identified as being a valuable support to the GP.   Most 
participants reported a good working relationship with their local pharmacist.  
“We’re very lucky that we have a very good relationship with the local pharmacist 
here they are very, very good and so we would be on to them a number of times a 
day … particularly for people who come out from hospital whereas sometimes it isn’t 
clear what dose of medications they’re on.” (GP8) 
Participants reported that GPs and pharmacists collaborate successfully together on 
a regular basis.  However, it was suggested that the strengths of these existing 
relationships between GPs and pharmacists were not harnessed to their full 
potential. Maintaining and further enhancing the GP-pharmacist relationship was 
viewed as being an important strategy to improve prescribing and patient care.  
“Pharmacists and doctors work very successfully together on a daily routine basis, 
and that’s probably not recognised enough but there is a significant interaction 
between the two. And anytime there’s good positive interaction you’ll always get 
positive responses and positive outputs.” (GP3) 
Participants were asked to comment about the possibility of a service-orientated 
outreach educational intervention (such as academic detailing) provided by 
pharmacists to GPs in their surgeries. Participants welcomed the idea of an 
educational intervention delivered to individual practices rather than larger groups 
of GPs.  
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“It would probably be better to have a practice do it in isolation rather than two or 
three practices in the area doing it together. Because I’m not sure that all practices 
would like to be open with other practices about their prescribing. It’s kind of a 
personal thing, isn’t it?” (GP11) 
Participants were asked about using information technology systems such as clinical 
decision support systems to help optimise their prescribing. They acknowledged that 
as prescribing is a complicated process especially in older people, computerised 
systems would be of some benefit but only to inform clinical situations and not to 
dictate them.  
“… prescribing is so complicated in the elderly I’m not sure if a computer system could 
do it all. Now it might do a lot of it but at the end of the day you are still going to have 
to make a decision on the patient sitting in front of you.” (GP1) 
Social influences 
Participants reported that older patients can be influenced by the marketing of 
medications in the lay media. This can in turn influence patient requests and what 
GPs prescribe. For example, anticholinergic medicines are indicated for urinary 
incontinence, but GPs reported being reluctant to prescribe them for older people 
due to their side effects (i.e. falls, confusion and blurred vision). However, despite 
these reservations, GPs felt pressurised into prescribing these medicines due to 
patient expectations.  
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“… so people do present saying I saw the ad on the telly (for an anticholinergic 
medication for urinary incontinence) and I have the overactive bladder and you’re 
thinking anticholinergics and you’re 75 … but they still expect it you know.” (GP1) 
GPs experience difficulty in explaining why they are withholding such medications, 
particularly to an older person with hearing, visual or cognitive impairment. Stopping 
benzodiazepine medicines was another example of how patient preference 
conflicted with GPs’ knowledge about the risks of the medication.  
“Any of those on the benzos you’d be trying to pull them all off it ... Very hard, very 
hard. And … in spite of you talking about the risk of falls and obviously slowly weaning 
off … but very hard to get patients off these tablets that are not essential really you 
know.” (GP7) 
 
Social/Professional Role and Identity 
Overall, the collaborative relationship between primary and secondary care was 
described as very good. However, some participants reported a lack of appreciation 
by their secondary care colleagues for their role as a GP. A lack of support from 
secondary care was highlighted especially with the management of complex patients 
in general practice. 
 “I think some of the hospital sector, don’t fully understand the nature of general 
practice … I saw a person with a renal problem and I was in their house … I rang the 
Urology (team) because they had a nephrostomy tube and they were asking me what 
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his creatinine was… they just had no idea that you don’t have a portable creatinine 
monitor by your side …” (GP8) 
GPs described themselves as co-coordinators of care for patients, which was assisted 
by their detailed medical record for each of their patients.  
“As a GP, you have a role as a co-ordinator of care, and you’d have the most up to 
date record of everything that’s going on.” (GP5) 
 
Discussion  
This study revealed the determinants influencing GP prescribing behaviour for older 
adults in primary care and GPs’ views on potential intervention strategies to optimise 
prescribing for older often multi-morbid patients. A behaviour change theory was 
used to analyse the data and generate findings that could be used to inform 
intervention strategies. 
The domain “Knowledge and Skills” highlighted that the responsibility of prescribing 
for increasing numbers of complicated older patients was viewed as a burden for 
GPs. This echoed the findings of a qualitative study of twenty practising general 
internists and family practitioners in the United States, which aimed to gain a deeper 
understanding of why they found caring for older patients so challenging. Three 
major domains emerged: medical complexity and chronicity for example, older 
people were seen to have more medical conditions, prescribed more medicines, be 
more vulnerable to illnesses and more susceptible to adverse drug reactions (ADRs); 
personal and interpersonal challenges for example, hearing problems, cognitive 
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impairment and family members caring for these patients, and, administrative 
burden for example, time consuming, increased workload, risk of litigation. 
Contextual conditions such as the practice environment and the GPs’ training and 
personal values also influenced the care for these patients (157).  
From the domain “Environmental Context and Resources” lack of available time for 
GPs was cited as a major barrier during clinical practice. As a result, GPs were unable 
to carry out all their clinical roles for example, review patient’s monthly prescriptions 
upon renewal. Braddock et al.  argue that the issue of time has an ethical significance 
as it may result in GPs sacrificing duties that promote important features of the 
patient-GP relationship such as trust, respect and fidelity, act as a barrier to shared 
decision making and being unable to fulfil their obligations as patient advocates 
(158). 
Pharmacists were described as a reliable resource for GPs and many participants 
reported experiencing a good working relationship with their local pharmacist. In a 
qualitative study with 27 GPs and 31 pharmacists in the UK, GPs reported that 
knowing the pharmacist was an essential component of a successful GP-pharmacist 
collaboration. This professional familiarity was also considered an important factor 
in the provision of local pharmaceutical services pilots. Pharmacists experienced 
difficulty working in collaboration with large GP surgeries. GPs who were reluctant to 
collaborate expressed concerns about the standard of pharmacists’ qualifications 
and therefore questioned their professional ability. Collaboration between both 
HCPs was optimised with reciprocal communication. Conversely, one-way 
communication was associated with lower levels of collaboration (159). 
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Implications for research and/or practice 
Computerised decision support systems are widely used tools that optimise quality 
of care and patient outcomes (64). In practice, these systems may involve an alert 
system appearing at the end of a consultation or at the time of prescribing (9, 66, 
160). Participants in our study agreed that computerised decision support systems 
could be a useful resource for GP prescribing, however some were concerned they 
may dictate rather than inform a clinical situation.  In order for successful 
implementation of decision support systems in GP practices, software designers 
should consider  the following: the system should be incorporated into the practice 
workflow and existing computerised systems, involve all stakeholders during various 
stages of the implementation process and ensure alerts are straightforward and easy 
to understand (161). 
This study found that GPs feel they will need additional training in pharmacology and 
drug interactions as the older population increases. Prescribing for older people is a 
complex process and GPs welcomed supportive strategies to optimise the continuing 
care for this group of patients. One possible solution to optimise prescribing for this 
growing cohort of older patients prescribed multiple medications is academic 
detailing (AD). Academic detailers, who are usually pharmacists, nurses or doctors 
are trained to provide accurate, objective and up to date synthesis of the best 
available information on a clinical topic in an engaging format with GPs (162). This 
information often includes recommendations about alternative treatment regimens 
or non-pharmacological interventions (135). A pharmacist-led intervention 
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comprising AD demonstrated an improvement in statin prescribing in high-risk 
patients in primary care in the UK (137). A study in the United States found that two 
brief AD visits by clinical pharmacists to GPs reduced inappropriate prescribing by 
14% in comparison with controls (163).  
While clinical decision support systems and AD have been adopted in other countries 
these strategies are not routinely available in Irish general practice. 
A large body of research has been carried out on the role of pharmacists in optimising 
GP prescribing in primary care. However, much of this work shows limited or 
inconsistent results. A Cochrane review examined the evidence for pharmacist-led 
interventions aimed at improving appropriate polypharmacy for older people across 
different healthcare settings. The authors concluded, based on the 12 studies 
included in the review, that it was unclear whether the interventions led to clinically 
significant improvements (112). Another systematic review focused on the effect of 
pharmacist-led interventions in optimising prescribing in older adults in primary care. 
Although it appeared that these interventions improved prescribing appropriateness, 
it was unclear if they resulted in clinically significant improvements in patient 
outcomes (59).  
Despite these limited effects, our qualitative study shows that GPs still view the role 
of pharmacists and their own relationship with pharmacists in a positive way. It 
highlights that there is scope to harness the GP-pharmacist relationship to improve 
patient outcomes, and supports a need for intervention developers to consider other 
approaches to enhance the GP-pharmacist relationship in a way that will lead to 
meaningful and sustained improvements in prescribing. 
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Strengths and Limitations 
The findings of this study are underpinned by a theoretical model that was 
specifically designed for analysing HCPs behaviour, and thus offers a number of 
strengths (150, 164). The TDF facilitates comprehensive assessment of the possible 
influences on behaviour, and, lends clarity to these influences by characterising each 
domain with component constructs. (150). However, the TDF is a relatively new 
framework and is still undergoing refinement. We suggest that future iterations of 
this framework may recognise the similarity between some domains in certain 
contexts such as “Knowledge” and “Skills” for cognitive tasks such as prescribing.  
Prolonged engagement with the data was carried out as interviews were arranged 
with GPs over a five-month period, and were analysed on an iterative basis. The 
method developed by Francis  et al. was used systematically to determine data 
saturation (153). Data triangulation was not conducted in this study as there was only 
one group of research participants. As GPs are the main prescribers of medication in 
primary care they were identified as the key participants to answer the study 
question. Also, one means of data collection was used that is, semi-structured 
interviews. This interview method was chosen as it has the ability to achieve 
comprehensive coverage of the topic discussed. The validation technique of member 
checking was not used (165), as returning interview transcripts to participants can 
lead to changes being made to the transcripts which can influence the 
trustworthiness of any subsequent analysis. 
The transferability of the data may be limited by sampling GPs from one geographical 
region in Ireland. However, the broad inclusion criteria (requirement to be in active 
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practice) and the recruitment of GPs with a range of years of experience, gender, 
practice size and urban/rural locations may ensure that our findings reflect the most 
important factors that influence GP prescribing for older people in Ireland (166). 
Although data collection was only carried out by one researcher (D.O.R.), 
dependability was enhanced by using multidisciplinary team input for example,  
pharmacists (D.O.R., S.B., A.F.), GP (C.S.), physiotherapist (R.G.) and epidemiologist 
(P.K.) during data analysis (investigator triangulation). Additionally, D.O.R. 
maintained a reflective diary about his role and beliefs on the study topic during the 
course of the interviews and discussed this with other members of the team to help 
highlight any personal biases or challenges encountered. 
Conclusion 
This study has identified the key determinants that influence GP prescribing 
behaviour for older people in primary care. GPs are aware that prescribing for older 
people is a complex process that requires an increasing amount of their time and 
attention. GPs state that they require accurate, easily accessible sources of evidence-
based data about the effectiveness and safety of treatments to support their 
prescribing for older, complex patients. Future interventions should incorporate 
means of providing such information, for example academic detailing (AD), to ensure 
that GPs are provided with necessary evidence and are equipped with the necessary 
skills to prescribe safely for the growing cohort of older complex patients.  
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Abstract  
 
Background  
Academic detailing or educational outreach is a form of continuing medical education 
(CME) in which a trained health professional such a doctor or pharmacist visits 
prescribers in their practice to provide evidence-based information. While academic 
detailing has been adopted in Australia and the United States, this strategy is not 
routinely used in Ireland. The aim of this study was to assess the feasibility and 
acceptability of a pharmacist-led academic detailing intervention with a sample of 
practising GPs in Ireland. 
 
Design and setting   
A mixed methods feasibility study utilising quantitative data from patient medical 
records and qualitative focus groups with GPs in those ≥65 years with urinary 
incontinence in a region of Ireland.  
 
Method  
The intervention was delivered to GPs between June and September 2016. 
Qualitative focus groups were carried out with GPs who participated in the academic 
detailing intervention on urinary incontinence in older people. The focus groups were 
transcribed verbatim and analysed using thematic analysis. The medical records for 
all patients aged ≥65 years who were attending a participating GP with a diagnosis of 
urinary incontinence were retrieved and analysed using a before-after approach. The 
measures of prescribing assessed before and after the intervention were: LUTS-
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FORTA criteria; Drug Burden Index; Anticholinergic cognitive burden scale; and the 
Screening tool of older person’s prescriptions-screening tool to alert doctors to right 
treatment (STOPP/START) version 2 criteria.  
Results 
Twenty three GPs participated in the academic detailing intervention and 14 
attended focus groups. Participants reported that this topic was relevant and 
practical to general practice. They described the educational materials as being of 
high quality, clearly presented and easy to follow. Participants appreciated the 
succinct nature of the information but would have preferred a more easily 
retrievable format, such as an online version rather than paper-based. The medical 
records of 154 patients were analysed. The mean age (± SD) of patients was 75 (7.2) 
years. The proportion of females was 72.1%. There was minimal or no change in any 
of the prescribing measures used. 
Conclusion  
This study demonstrated that a pharmacist-led academic detailing intervention was 
acceptable to GPs in a selection of different types of general practice in Ireland. 
Overall, participants highly valued the evidence-based approach of AD. The findings 
from this study will inform the planning and design of larger studies enhancing their 
likelihood of success.  
Keywords: Academic detailing, older people, GPs, urinary incontinence, mixed 
methods, feasibility, primary care. 
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Introduction 
The International Continence Society (ICS) has defined urinary incontinence (UI) as 
“the complaint of any involuntary leakage of urine” (167).  It is a widespread medical 
problem that can cause a great deal of distress and embarrassment, as well as 
significant costs to individuals (168-170). More than 200 million people worldwide 
live with this condition. It is more common in women than in men due to a number 
of factors such as age, sex hormones, childbirth, hysterectomy, infection or other 
medical conditions (171). The severity of symptoms increases from middle age 
onwards (172). Despite the availability of evidence-based medicine, patients do not 
receive treatment because of their reluctance to report this condition or because for 
those in whom the condition is diagnosed are undertreated. In addition, when 
patients do seek help many doctors are not familiar with the latest information on 
the appropriate methods of evaluating and treating patients with this condition 
(173). 
Academic detailing (AD) is an interactive, convenient and user-friendly approach to 
delivering non-commercial evidence-based medical information to healthcare 
professionals (163). This quality-improvement intervention, also referred to as 
educational outreach can be effective in changing prescribing practices, medical 
decision making and ultimately improving patient care (69). Academic detailers, who 
are usually pharmacists, nurses or doctors are trained to provide accurate, balanced 
and up to date syntheses of the evidence on a clinical topic in an engaging format 
with healthcare professionals in their work environment (174). The information 
provided often includes recommendations about non-pharmacological and other 
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treatment options and indicates where these options are appropriate (175). Several 
important principles are key to a successful AD program. These include defining clear 
and focused objectives, identifying participant’s current knowledge and motivations, 
establishing credibility through a respected organisational identity and referencing 
evidence-based sources of information, using clearly presented graphic educational 
materials that are brief, engaging in two-way interaction, highlighting and re-
emphasising key messages and reinforcing best practice with follow-up visits (68).  
Previous studies have used a variety of methods to explore GPs experience of and 
satisfaction with AD in primary care. Frich et al. carried out focus group interviews to 
assess GPs and tutors experiences with peer group AD in Norway. It was reported 
that this educational approach was a suitable method to gain a better understanding 
of pharmacotherapy (176). Hartung et al. used short, written surveys to assess the 
effectiveness of and satisfaction with an AD pilot project with GPs in the United 
States. There was strong support and satisfaction among participants for the project. 
Participants preferred face-to-face approaches to distance interactions for example, 
video conference, online modules (174). 
 While AD has been adopted in other countries this strategy has not been tested as a 
sole intervention nor has it been adopted for use in Ireland. The OPTI-SCRIPT study 
(Optimizing Prescribing for Older People in Primary Care, a cluster-randomized 
controlled trial) was a complex, multi-faceted intervention conducted in primary care 
in Ireland. AD was one intervention component in this study. It involved a pharmacist 
carrying out a brief session with GPs discussing potentially inappropriate prescribing 
(PIP), a medicines review and web-based therapeutic treatment algorithms. The 
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results of this study were analysed using quantitative methods and demonstrated a 
reduction in PIP, particularly in modifying the prescribing of the proton pump 
inhibitors class of medicines (177). A further study reported a process evaluation of 
this intervention. Although participants reported their experience of the 
multifaceted  intervention, the AD component was not discussed in detail (178). To 
date, no studies have evaluated the feasibility and acceptability of an AD intervention 
with GPs in Ireland using mixed methods research. The premise of a mixed methods 
approach is that the use of quantitative and qualitative methods in combination, 
provides a better understanding of research problems than either approach alone 
(179). Eldridge et al. have defined a feasibility study as a study asking “whether 
something can be done, should we proceed with it, and if so, how”. These studies are 
divided into three subgroups: randomised pilot studies; non-randomised pilot 
studies and feasibility studies that are not pilot studies (180). They are used to 
estimate important parameters that are needed to design larger studies for example,  
feasibility of recruitment, number of eligible participants and selection of 
appropriate outcomes (181). Therefore, the aim of this study was to assess the 
feasibility and acceptability of a pharmacist-led AD intervention with a sample of 
practising GPs using a mixed methods approach. 
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Methods 
Study type 
Creswell and Plano Clark have defined mixed methods research as a method that 
focuses on collecting, analysing, and mixing both quantitative and qualitative data in 
a single study or series of studies (179). In this study, a convergent parallel mixed 
methods design was used. The aim was to collect, analyse and interpret integrated 
quantitative and qualitative data to assess the feasibility of an AD intervention with 
GPs in primary care. The quantitative prescribing patterns of the GPs and their 
qualitative responses from the focus groups were brought together and compared. 
The underlying logic of this approach is that the integration of both qualitative and 
quantitative data is greater than each method’s individual contribution (182, 183).  
 Convergent parallel design: the intent of the research is to collect both quantitative 
and qualitative data, analyse both datasets and then merge the results of the two 
data analyses with the purpose of comparing the results (Figure 6.1).  
Figure 6.1 Convergent design 
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Setting 
This study was carried out in six GP surgeries in County Cork, Ireland. The primary 
researcher (D.O.R.) arranged a meeting with the lead GP in each practice and a brief 
summary of the study was given. Other potential participants in each practice were 
contacted by telephone and invited to participate. Twenty three GPs participated in 
the intervention.  All GPs who participated in the study received a certificate of 
participation and a certificate for their continuous professional development (CPD) 
(See Appendix IV). 
 
Topic  
The AD sessions were supported using material developed by the Alosa Foundation. 
The Alosa Foundation in Boston is a nonprofit organization and is independent of the 
pharmaceutical industry. It produces educational materials and decision making 
tools for Academic Detailers, and provides training on AD internationally (184). The 
Alosa Foundation granted the authors permission to use their educational material 
for this study (See Appendix IV). Prior to commencing GP recruitment, D.O.R. met 
with three GPs to discuss a topic for the AD intervention. From the list of 24 Alosa 
topics with a summary brochure the GPs chose urinary incontinence. They 
highlighted that this topic was not discussed regularly among themselves and 
currently their only source of information is provided by pharmaceutical drug 
representatives. Therefore the topic of urinary incontinence was used for the AD 
intervention with the GPs. 
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Academic detailing training 
D.O.R. attended a two day AD training workshop at the National Resource Center for 
Academic Detailing (NaRCAD) in Boston, USA in May 2016. The workshop provided a 
critical foundation for the role as an academic detailer. It included sessions on the 
case for AD and evidence-based medicine, planning an AD visit, use of educational 
materials and role plays. This workshop helped to refine communication skills, 
improve clinical knowledge and gain confidence for attendees to carry out a 
successful educational visit.  
 
Piloting the intervention 
The AD intervention was piloted with three academic GPs in May 2016 before the 
study was launched. The GPs reported that they were very satisfied with this overall 
educational approach. The topic delivered and the educational materials used during 
the visit were also described as being very beneficial and relevant. The intervention 
was rolled out to participating GPs between June and September 2016. Figure 6.2 
shows the timeline of the study. 
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Figure 6.2 Timeline of the AD study 
  
AD intervention implemented 
with participating GPs (n= 23),          
June-September 2016.  
Ongoing quantitative data 
collection from patient medical 
records.  
Meet GPs (n=3) to choose topic 
for the AD intervention, March 
2016. 
Two day training workshop at 
NaRCAD, Boston, USA, May 
2016. 
Meet academic GPs (n=3) for 
pilot of the intervention, May 
2016.  
Refinement of AD intervention, 
June 2016.  
Qualitative focus groups with 
participating GPs (n= 14),             
July-November 2016. 
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Qualitative method 
Design 
After the intervention was delivered to participating GPs by D.O.R., qualitative focus 
groups were conducted with GPs to explore its feasibility and acceptability. This 
interview method was chosen due to its ability to generate data by interaction 
between group participants. Participants can present their own views and can listen 
to the contributions from others in the group. This allows additional material to be 
triggered in response to what is reported by others. There was also a shared 
background to the research topic among the GPs (152).   
 
Data collection 
The primary researcher (D.O.R.) did not carry out the focus groups as this may have 
resulted in respondent bias from participants. D.O.R had also carried out a previous 
study with most of the participants and had developed a professional relationship 
with them. Therefore, the focus groups were carried out by other researchers (E.H.), 
(C.S.) and (S.B.) between July and November 2016. Four of the focus groups were 
carried out at the GPs surgeries during lunchtime and one was carried out at a 
meeting room in a nearby hotel after surgery hours.  A topic guide was developed 
based on discussion and consensus agreement by all authors. It was iteratively 
refined after each focus group was transcribed and analysed to pursue emerging 
themes. Examples of the topic guide are provided as supplementary material to show 
its continuous development as the focus groups progressed (Appendix IV). The focus 
140 
 
groups were audio-recorded. All researchers recorded field notes immediately after 
each focus group and this facilitated preliminary familiarisation with emerging 
themes.  
Analysis 
All focus groups were anonymised and fully transcribed and saved in QSR 
Internationals NVivo Qualitative Data Analysis Software (V.10.22) to facilitate 
analysis (185).  The descriptions of GPs views were analysed using thematic analysis. 
This approach was used as it provides a flexible and useful research tool, which can 
potentially provide a rich and detailed account of the data (186). It consists of six 
phases of data analysis (186). The first phase involved several readings of the 
interview transcripts to ensure familiarity with the data. The second phase involved 
generating initial codes. The next phase which refocuses the analysis at the broader 
level of themes involved sorting the codes into potential themes. The fourth phase 
involved a refinement of the candidate themes. The fifth phase involved defining and 
naming themes. The last phase began with a set of clearly defined themes and 
involved final analysis and write-up. To enhance the credibility of the coding, three 
members of the research team (D.O.R., C.S. and S.B.) independently coded a sample 
of the transcripts. 
 
Quantitative method  
Study population 
This was an analysis of patient medical records (PMRs). All patients aged ≥65 years 
with urinary incontinence treated by GPs who participated in the AD study were 
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included. D.O.R. analysed their medical records at multiple time points before and 
after the intervention (six and three months before the intervention (T-6), (T-3), at the 
time of the intervention (T0) and three and six months after the intervention (T3), (T6). 
Community-dwelling patients aged ≥65 years with urinary incontinence were 
identified by searching GP databases and notes. D.O.R. recorded the following 
patient information using Microsoft Office Excel ® (2013), patient demographics (age, 
sex, medical card status and smoking history), body measurements (blood pressure 
[systolic and diastolic], cholesterol, weight, body mass index (BMI)) chronic 
prescription medicines and medical history.  
 
The following criteria were applied to the patient data recorded: 
LUTS-FORTA criteria 
Drugs to treat lower urinary tract symptoms (LUTS) regularly used in older people 
aged ≥65 years are classified on their appropriateness based on efficacy, safety and 
tolerability using the Fit fOR The Aged (FORTA) criteria. This criteria classifies drugs 
for the treatment of LUTS into four ordinal categories, A (absolutely: indispensable 
drug), B (beneficial: drugs with proven efficacy), C (careful: drugs with questionable 
efficacy/safety profiles) and D (don’t: avoid in older people) (49). 
 
The Drug Burden Index (DBI) 
The DBI was developed to measure the cumulative exposure to anticholinergic and 
sedative medicines in older people and its impact on physical and cognitive function 
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(50). The calculation of the DBI is based on a pharmacological equation that 
incorporates drug dose and the principles of dose response (51).  
DBI = Σ D / δ + D 
D is equal to the daily dose taken and δ is the recommended minimum dose 
recommended by a relevant formulary (50). For each drug the DBI ranges from 0-1, 
with 0 being no burden, 0.5 being exposure to the minimum daily dose and upwards 
to 1 as the dose is increased exponentially (52). The sum of these individual drugs 
(anticholinergic/sedative drugs) equals to the total drug burden. In this study, the list 
of drugs with clinically significant anticholinergic and sedative effects were defined 
from a composite list developed from a review by Duran et al. 2013, the 
anticholinergic cognitive burden scale developed by Boustani  et al. 2008 and from a 
study published by Ailabouni   et al. 2017 (56, 187, 188) . This composite list consisted 
of 133 drugs. The minimum geriatric dose of drugs were obtained from the British 
National Formulary Edition 71 (BNF) and reconciled with the drug Summary of 
Product Characteristics (SPC) as listed by the Health Products Regulatory Authority 
(HPRA) in Ireland (189). 
 
Anticholinergic cognitive burden scale (ACB) 
The cumulative effect of taking multiple medicines with anticholinergic properties is 
defined as the anticholinergic burden (53). Previous studies have demonstrated that 
the use of medicines with anticholinergic activity among older adults is associated 
with physical and cognitive decline (54, 55). The ACB is based on a systematic 
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literature review of medicines with known anticholinergic activity. The scale consists 
of 88 drugs with known anticholinergic activity and assesses individual drugs that 
have none, possible or definite anticholinergic properties with a score ranging from 
0 to 3. A cumulative score is generated if a patient is on multiple anticholinergic 
medicines (56).  
STOPP/START version 2 (V2) criteria 
An explicit screening tool was used to capture the prescribing appropriateness and 
compare it with other study populations within the thesis. Prescribing 
inappropriateness was assessed using The Screening Tool of Older Persons 
Prescriptions, Screening Tool to Alert doctors to Right Treatment (STOPP/START) 
criteria, a validated and explicit measure of potentially inappropriate prescribing 
(PIP) and potential prescribing omissions (PPOs) for use in older adults (≥ 65 years) in 
European countries (76). In 2014, the criteria were revised and updated. The revised 
set, STOPP/START version 2 (STOPP/START V2), consists of 80 STOPP and 34 START 
criteria (40). A subset of the criteria (62/80 STOPP, 22/34 START) were applied as 
some were not relevant to the data collected for example, the administration of 
vaccines. (See Appendix IV). 
D.O.R. applied the LUTS-FORTA, DBI, ACB and STOPP/START V2 criteria to patient 
related data retrieved from the electronic medical records. For validation purposes, 
the four types of criteria were applied independently by a second member of the 
research team to a random 10% sample of the data.  
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Outcomes  
The four outcomes of interest were the overall prevalence of LUTS-FORTA, DBI, ACB 
and PIP/PPOs in the patients.  
Statistical analysis 
Data analyses were performed using STATA ® version 13 (StataCorp, College Station, 
Tx, USA). Continuous variables were presented as mean with standard deviation (SD) 
and range, or median with interquartile range (IQR), as appropriate, and categorical 
variables as frequency (percentage). It is important to note that a feasibility study is 
not a hypothesis testing study (190). One of the key aspects of these studies is that 
they do not evaluate effectiveness as they are not powered to do so (191). The main 
focus of this feasibility study was to assess feasibility of the intervention, therefore 
the data were analysed using descriptive statistics. Statistical testing was not 
undertaken as the study did not aim to draw inferences from the data (192). 
However, this data may be informative for researchers planning similar work or 
planning definitive intervention studies (i.e. trials). 
Standardised reporting guidelines 
The Good Reporting of a Mixed Methods Study (GRAMMS) framework was used to 
inform reporting of the findings (193, 194). (See Appendix IV) 
Ethical approval 
Ethical approval for this study was granted by the Clinical Research Ethics Committee 
of the Cork University Teaching Hospitals, Cork (reference ECM 4 (s) 10/05/16 & ECM 
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3 (ddddd) 07/03/17) and the Mallow Primary Health Centre (MPHC), Cork ethics 
committee (See Appendix IX).  
 
Results 
Qualitative results  
Five focus groups were conducted in total. The focus groups ranged from 19 minutes 
to 48 minutes (median interview length (minutes), interquartile range (IQR), 21 (20, 
24)). The mean duration of medical experience of GPs’ that participated in the focus 
groups was 21 years (range 0 to 42). The number of GPs working in a practice ranged 
from 1 to 7. The characteristics of GPs interviewed are detailed below (Table 6.1).  
Table 6.1 Characteristics of GP participants in the focus group  
General 
Practitioner 
(GP) 
Gender  Years of 
medical 
experience 
No of GPs in 
the practice 
Participant 
number in 
focus group  
Focus group 
number 
1 M 27 4 1 1 
2 M 6 4 2 1 
3 M 35 5 3 1 
4 M 38 7 4 1 
5 M 42 7 5 2 
6 M 0* 7 6 2 
7 M 29 4 7 3 
8 F 1 5 8 3 
9 F 22 4 9 3 
10 M 24 7 10 4 
11 F 1 7 11 4 
12 F 21 1 12 5 
13 F 20 2 13 5 
14 M 22 2 14 5 
*GP registrar 
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Themes  
Theme 1: The academic detailing experience 
Subtheme: Convenience of academic detailing  
Participants highlighted the convenience of the AD session being carried out in their 
working environment. They welcomed this educational visit being delivered with 
little disturbance to their daily practice. They also reported that they are prepared to 
block out some of their working time to accommodate this source of evidence-based 
information. 
 “The whole process of somebody coming to the practice to somewhere like this, to a 
small group complements the brevity and concise nature of it and kind of the 
convenience in that respect of it is good. You can slot it into your day …and if you’re 
looking at trustworthy information presented in a similarly available kind of way, you 
are far prepared to… put 15-20 minutes of your time aside to kind of look at this.” 
(GP2 Focus group 1) 
This was in contrast to the alternative sources of evidence-based information that 
are currently available for GPs. Participants reported the frustration at not being able 
to attend courses of interest due to the demands of their work schedule.  
 “I mean it’s very hard. Even though you’d see stuff that might be on, it could be on a 
Saturday but you know you could be working Saturday surgery, it’s hard to attend 
everything so.” (GP11 Focus group 4) 
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Subtheme: The interaction 
Participants described the interaction between the GP and the academic detailer as 
being important to the success of the intervention. They reported that the session 
worked because it felt relaxed and free of pressure. This was in contrast to their 
experience with some pharmaceutical drug representatives who they described as 
having an aggressive approach combined with an overload of information, which 
seemed to aggravate participants. 
 “Relaxed, it wasn’t a, you didn’t feel pressurised. Sometimes when you get drug reps 
in they are selling. It’s a different conversation…I want you to prescribe my 
Tolterodine, or my Mirabegron or my, whatever you know. Where I’m going to tell 
you the forty reasons why and then I’m really going to p*** you off by pulling out 
something that you don’t want to see and I’m going to give you a study that we have 
produced.” (GP10 Focus group 4) 
 
Subtheme: The educational materials 
Participants said they liked the educational materials because they had a clear layout 
and were easy to follow. They reported that they valued the succinct nature of the 
key messages while the tables and figures were presented in a straightforward way. 
“First of all, well presented, clear, succinct, easy to read… and it got to the core 
messages quite well and it wasn’t over graphed or over too much stats, things that 
distract me. I thought it was quite well done.” (GP7 Focus group 3) 
 
148 
 
Subtheme: The topic: Urinary incontinence  
Participants reported a desire to become more knowledgeable in urinary 
incontinence however, it was not a topic that they seek out themselves.  
 “It’s something that you would like to know more about. It’s never on your radar to 
actually go out and read an article on overactive bladder.” (GP1 Focus group 1) 
The topic of urinary incontinence was agreed by a number of GPs prior to rolling out 
the study. Participants reported that this topic was relevant and suitable to general 
practice. The relevance of this topic facilitated the delivery of the intervention to GPs.  
 “I think this worked well cause we had input in actually what the topic was. So 
effectively it was something that would have been relevant and applicable so 
immediately that makes you less resistant.” (GP1 Focus group 1) 
 
Theme 2: Behaviour change 
Participants were asked whether this type of educational intervention would change 
their behaviour. They highlighted the importance of engaging with the academic 
detailer during the visit in order to optimise the possibility for behaviour change. 
“I would think the more input you have into it yourself, if somebody just comes in and 
talked to you and you’ve put nothing into it I don’t think it’s going to change 
anything.”   (GP12 Focus group 5) 
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Participants described the likelihood of changing their behaviour in treating patients 
with urinary incontinence following the intervention. However, this change in 
behaviour could be influenced by environmental resources such as the availability of 
primary care physiotherapists.  
 “Oh I’d say I’d change a bit you know. Provided you see that, stuff like physios and 
that kind of a thing are available but they’re not.” (GP5 Focus group 2) 
Subtheme: Knowledge gained 
Participants were asked if they had gained any knowledge from the intervention. 
Some participants were not aware of the important role that non-pharmacological 
methods play in treating urinary incontinence. These methods are often 
recommended first line and can be very effective in managing this condition. 
“Yeah I learned a lot… I didn’t realise that the non-pharmacological methods would 
be as good or better than the pharmacological methods … to use them as your first 
line and only when a failure of… kegel muscle exercises, or … bladder diaries and only 
when that fails would you go to  pharmacological treatment. I thought that was 
interesting.” (GP6 Focus group 2) 
For some participants, the intervention served to refresh their knowledge with the 
topic rather than gain new knowledge as some of the treatment options may be more 
commonly used than others. 
 “I suppose it more refreshed my knowledge of it rather than gave me new knowledge 
so it just made me more aware of the treatment options that were there, some come 
on your radar and some come off your radar over time.” (GP14 Focus group 5) 
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Theme 3: Sustainability  
Subtheme:  Academic detailing ownership 
Participants were asked how this type of educational intervention could be rolled out 
to a wider group of GPs in Ireland. Some suggested that it could be affiliated with the 
Irish College of General Practitioners (ICGP), the professional and educational body 
for general practice in Ireland. The association with this recognised body could 
enhance the credibility of AD among GPs. 
“I think if it can be affiliated with the Irish college it would probably be more 
important being honest because that gives a bit of a imprimatur and it kind of gets 
people more receptive to it because if the Irish college are involved and they’ve 
tailored it to general practice…”  (GP 14 Focus group 5) 
However, some participants were reluctant for regulatory bodies such as the Health 
Information and Quality Authority (HIQA) being involved. 
 “Not HIQA.” (GP11 Focus group 4) 
 “Not HIQA. Don’t mention that word here.” (GP10 Focus group 4) 
 
Subtheme: Online educational material 
Participants suggested an online version of the educational material, which would be 
easier for them to manage in a setting where print materials over-accumulate or go 
missing.  
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 “I think an online pack is a good idea, even like relevant, like I know he gave us the 
cards but you see the cards, where do you put the cards, you can’t stick up every card 
all over your wall but you need something that just pops up in front of you, so even if 
there is a handy pack literally with the summary page and you know advised drugs.” 
(GP11 Focus group 4) 
 
Subtheme: Advance notice of the visit 
Participants suggested that advanced notice of the visit could help to optimise the 
AD session with the detailer. This would give the GP the chance to prepare for the 
visit by thinking about how they manage their patients regarding the topic or 
information related to the latest treatments.  
 “If you know someone is coming in say on a Thursday. On a particular topic. You 
certainly think of patients coming in to you and you know that kind of focuses you a 
little bit so yeah I think that would probably be good. Even an email or a just a 
reminder … that this is happening and anything that you may want to consider in 
relation to difficult patients to treat or other things, newer treatments or whatever.” 
(GP 14 Focus group 5) 
 
Subtheme: Desire for practice staff involvement 
Participants highlighted the importance of incorporating the wider members of the 
practice team in the AD sessions. This is especially significant given the expanded role 
of nurses in primary care.  
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“I’d be quite keen to involve the practices nurses… because they, say with urine 
incontinence, with lots of other topics… patients …sometimes tell nurses things that 
they don’t tell doctors …realistically long term they’re going to be doing an awful lot 
of the chronic disease management sort of stuff...”. (GP14 Focus group 5) 
Subtheme: Participation format 
Participants were asked whether these educational sessions should be delivered one- 
to-one or in a group setting. They suggested that group sessions would work well as 
GPs might also then learn from each other, however group sessions were not tested 
in this study. 
 “Small group I’d say works well. You might get more relevance out of a small group 
and that the interaction between people and different emphasis and that type of 
thing. I think that interaction leads to more learning anyway.” (GP3 Focus group 1) 
However, some participants said they viewed the one-to-one format as preferential 
as it facilitates greater information exchange between academic detailer and 
prescriber. They also felt that one-to-one sessions were less susceptible to 
distractions.  
 “When you are together with the presenter you get much more information and you 
are really focusing on what he’s speaking compared to when you are in a group.” 
(GP8 Focus group 3) 
Participants were asked if they would be interested in participating in future AD 
studies. All indicated a willingness to do so. 
“Yes very interested.” (GP9 Focus group 3) 
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“Yeah, I would absolutely yeah.” (GP11 Focus group 4) 
Quantitative results 
The characteristics of 154 patients diagnosed with urinary incontinence included in 
the study are detailed in Table 6.2. The mean age (± SD) of patients was 75 (7.2) years. 
The proportion of females was 72.1%. The median number of drugs (IQR) prescribed 
to patients was 7 (5, 10). The proportion of patients with urge incontinence was 32%. 
The documentation of Pelvic floor muscle training (PFMT) was reported in 15% of 
PMRs at one time point in the study (T-6). 
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Table 6.2 Baseline characteristics   
Population characteristics Total (n=154) 
Mean age (years) (± SD), range 75 (7.2), 65-93 
Female, n (%) 111 (72.1) 
*GMS medical card holder, n (%) 122 (79.2) 
Current smokers, n (%) 7 (4.5) 
Mean blood pressure (± SD) 136/76 (17.1/10.3) 
Mean total cholesterol (± SD) 4.8 (1.1) 
Mean BMI (± SD) 28.1 (4.9) 
Median number of drugs prescribed per patient, 
interquartile range (IQR) 
7 (5,10) 
Median number of all comorbidities per patient, 
interquartile range (IQR) 
6 (4,9) 
Type of incontinence  
Stress,  
Urge,  
Mixed,  
Unknown, n (%) 
 
13 (8%), 
49 (32%), 
24 (16%), 
68 (44%) 
*GMS (General medical services) is a means-tested scheme that entitles those who qualify to have 
access to public health services, free of charge.  
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LUTS-FORTA score  
Figure 6.3 shows the LUTS-FORTA score in patients over time. According to the 
criteria, no drug was rated in category A. Patients prescribed drugs in category C 
showed an increase over time, while patients prescribed drugs in category B and D 
showed no change. Appendix IV shows the drugs that were identified by the LUTS-
FORTA criteria. 
 
 Figure 6.3 The LUTS-FORTA score in patients over time  
 
Drug Burden Index 
Almost 65% (100/154) of patients did not show any change in drug burden over time. 
While, 14% (21/154) showed a decrease in DBI score and 21% (33/154) showed an 
increase. Table 6.3 shows the DBI score in patients over time. 
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Table 6.3 DBI score in patients over time   
 
DBI  score T-6 n (%) T-3 n (%) T0 n (%) T3 n (%) T6 n (%) 
No burden 36 (23) 31 (20) 31 (20) 31 (20) 27 (18) 
0.01 to 0.5 29 (19) 28 (18) 30 (20) 28 (18) 31 (20) 
0.51 to 1.0 32 (21) 37(24) 35 (23) 33 (21) 31 (20) 
More than 1.01 57 (37) 58 (38) 58 (38) 62 (40) 65 (42) 
 
 
 
 
Anticholinergic cognitive burden (ACB) scale  
Figure 6.4 shows the ACB score in patients over time. This scale assesses individual 
drugs that have none, possible or definite anticholinergic properties with a score 
ranging from 0 to 3. In this study some patients received a score of 4 or more. Thirty-
four per cent of patients at T-6 months and 31% of patients at T6 months had an ACB 
score of 0. Twenty five percent of patients had an ACB score of zero at the start and 
end of the study (T-6, T6). The number of patients with ACB scores of 1, 4 and ≥5 
showed an increase from the time of the intervention (T0) up to three (T3) and six (T6) 
months after.  
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Figure 6.4 The ACB score in patients over time (n=154) 
 
STOPP/START  
Table 6.4 shows the overall PIP/PPO prevalence and the most common examples of 
PIP and PPO throughout the study. The overall prevalence of PIP/PPOs was defined 
as the proportion of participants having at least one PIP or PPO according to the 
STOPP/START V2 criteria among all participants included in this analysis. The overall 
prevalence of PIP changed from 37% at T-6 to 39.6% at T6 (95% CI -0.1-0.01). The 
overall prevalence of PPOs changed from 30.5% at T-6 to 27.9% at T6 (95% CI -0.01-
0.1). Approximately 51% of patients did not have any PIP/PPO issues at T-6, while 50% 
of patients did not have any PIP/PPO issues at T6. The most frequent PIP in patients 
were any drug prescribed beyond the recommended duration; the prescribing of 
benzodiazepines and the prescribing of hypnotic Z-drugs. The most frequent PPOs in 
patients were vitamin D and calcium supplements in patients with osteoporosis; 
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Angiotensin Converting Enzyme (ACE) inhibitor with systolic heart failure and/or 
documented coronary artery disease and laxatives in patients receiving opioids 
regularly. 
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Table 6.4  PIP/PPO prevalence and the most common examples of PIP and PPO throughout the study 
Timeframe 
(Months) 
PIP prevalence 
 (%) 
PPO prevalence 
(%) 
Most common PIP (%) Most common PPO (%) 
T-6 37.0 30.5 1. STOPP 2 A2 (11.0) 
2. STOPP 2 K1 (9.7) 
3. STOPP 2 K4 (9.7) 
1. START 2 E3 (9.1) 
2. START 2 A6 (8.4) 
3. START 2 H2 (7.8) 
T-3 37.0 29.2 1. STOPP 2 A2 (11.0) 
2. STOPP 2 K1 (9.7) 
3. STOPP 2 K4 (9.7) 
1. START 2 E3 (7.8) 
2. START 2 A6 (7.8) 
3. START 2 H2 (6.5) 
T0 37.7 28.6 1. STOPP 2 A2 (11.0) 
2. STOPP 2 K4 (10.4) 
3. STOPP 2 K1 (9.7) 
1. START 2 E3 (8.4) 
2. START 2 A6 (7.8) 
3. START 2 H2 (6.5) 
T3 40.9 27.9 1. STOPP 2 K4 (11.7) 
2. STOPP 2 A2 (10.4)  
3. STOPP 2 K1 (9.1) 
1. START 2 E3 (7.8) 
2. START 2 A6 (7.1) 
3. START 2 H2 (7.1) 
T6 39.6 27.9 1. STOPP 2 K4 (11.7) 
2. STOPP 2 A2 (10.4) 
3. STOPP 2 K1 (9.1) 
1. START 2 E3 (7.8) 
2. START 2 A6 (7.1) 
3. START 2 H2 (7.1) 
STOPP2 A2: Any drug prescribed beyond the recommended duration, where treatment duration is well defined; STOPP2 K1: Benzodiazepines; STOPP2 K4: Hypnotic 
Z-drugs e.g. zopiclone, zolpidem, zaleplon. START2 E3: Vitamin D and calcium supplements in patients with known osteoporosis; START2 A6: Angiotensin 
Converting Enzyme (ACE) inhibitor with systolic heart failure and/or documented coronary artery disease; START2 H2: Laxatives in patients receiving opioids 
regularly.
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Discussion 
This study used a mixed-methods approach to 1) qualitatively explore the feasibility 
and acceptability of an AD intervention among GPs in primary care and 2) 
quantitatively evaluate the ability of measuring an impact of the intervention.   
A feasibility study that is not a pilot study was used in this research. They are defined 
as studies in which researchers attempt to identify whether an element of the future 
trial can be performed but do not implement the intervention to be evaluated or 
other systems to be undertaken in a future trial, although intervention development 
may be addressed in some way (180).  
The prescribing outcomes LUTS-FORTA, DBI, ACB and STOPP/START V2 criteria were 
described over the study time points. Drugs in category C of the LUTS-FORTA score 
showed a slight increase over time, while those in categories B and D showed no 
change. Regarding the DBI, the majority of patients showed no change in drug burden 
over time. The number of patients with ACB scores of 1, 4 and ≥5 increased from the 
time of the intervention (T0) until the end of the study. Although the prevalence of 
PIP and PPOs was high in this study, the prevalence of both outcomes did not change 
dramatically over the different time points. The involvement of GPs in the choice of 
topic was seen to be a key factor in the success of the intervention. However, 
although some participants from the focus groups reported a desire to become more 
knowledgeable on urinary incontinence, they also highlighted that it was not a topic 
that they actively seek out. Urinary incontinence may not have been high on their list 
of priorities compared to topics such as cardiovascular disease or diabetes. This may 
be reflected in the minimal change in measures of prescribing assessed in the study. 
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Participants also described the possibility of behaviour change following the 
intervention however, this was dependent on the availability of primary care 
resources such as physiotherapists. In Ireland, GMS patients are often on a waiting 
list to attend primary care physiotherapists. PFMT is an effective treatment for 
women with urinary incontinence and these exercises are often demonstrated by 
physiotherapists. If there is a lack of these healthcare professionals then GPs may 
have no option but to treat patients with medicines. This can increase the prescribing 
cascade if patients are already on multiple medicines. PFMT was reported in 15% of 
PMRs at one time point (T-6) in the study. Participants described the educational 
materials as being high quality. These materials contain evidence-based information 
on the prevalence of urinary incontinence, an overview of the interventions and cost 
of drugs to treat the condition and key messages which may be very beneficial for 
GPs. However, if this information is not easily retrievable for GPs then they may not 
be used as a treatment resource during a patient consultation. This may have limited 
the change in prescribing outcomes in the study. Participants called for these 
materials to become available as an online resource as they could be of value in 
optimising the diagnosis and management of urinary incontinence.  
 
Comparison with existing literature 
Allen et al. used a mixed methods study (a questionnaire and semi-structured 
telephone interviews) to explore family physician perceptions of AD and the factors 
that affect their use. Several factors were identified that encourage the use of AD. 
They were, the relevance of the topic, the evidence-based approach adopted and the 
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educational material used (195). These findings are similar to those in our study. The 
GPs selected the topic of urinary incontinence for the intervention and described it 
as relevant. They welcomed the idea of evidence-based information being presented 
to them in their practice and they also described the educational material used as 
being of high quality. Soumerai recommends that educational materials should be 
brief and clearly presented (68). In this study a one-to-one detailing model was used. 
However, participants reported that they would be willing to participate in small 
group detailing. Evidence suggests this format of detailing is effective at optimising 
prescribing. Van Eijk et al. showed that individual and group AD visits improved the 
prescribing appropriateness of anticholinergic depressants (196). However, Figueiras   
et al. found that the one-to-one format was more effective than group education at 
improving the prescribing of non-steroidal anti-inflammatory drugs (NSAIDs) (197). 
Participants reported that the more input they had into the session the more likely it 
would change their behaviour. They also reported that environmental factors would 
also influence their behaviour. Hatung et al. found that clinicians who participated in 
face-to-face detailing reported a higher likelihood of changing their behaviour (174). 
For this intervention, all GPs received one visit from the detailer, however research 
has indicated that frequent reinforcement visits can optimise behaviour change 
(198). In this study, GPs indicated a willingness to participate in future AD studies. 
Hartung et al. also reported similar findings (174). Habraken et al. highlighted that 
Belgian physicians highly rated AD visits and approximately 90% of those surveyed 
were willing to use this service again (70).  
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The measures of prescribing assessed: the LUTS-FORTA, DBI, ACB and STOPP/START 
showed minimal or no change in their scores following the intervention. However, it 
is important to highlight that this study was not designed or powered to demonstrate 
effectiveness. Also the key focus of this study was to optimise the diagnosis and 
management of urinary incontinence and not to change the impact of prescribing. 
Other AD studies have evaluated efficacy. A cluster randomised, stepped-wedge trial 
consisting of an AD component of a complex intervention reduced the rate of high 
risk prescribing of antiplatelet medicines and NSAIDs in the UK (199). A randomised 
control trial carried out in the United States found that two face-to-face visits by 
clinical pharmacists to GPs reduced inappropriate prescribing by 14% compared to 
the control group (200). 
 
Strengths and limitations  
The qualitative data supplemented the quantitative data by identifying convergence 
and divergence between the two datasets (179). The information extracted from the 
PMRs for example, patient demographics, co-morbidities and medication facilitated 
a comprehensive analysis of the prescribing outcomes. To enhance the validity of the 
quantitative results, a sample of the data were independently reviewed by two 
healthcare professionals. The focus groups were arranged with GPs over a five-
month period and this facilitated prolonged engagement with the data. Qualitative 
data collection was carried out by three researchers (E.H., C.S. and S.B.) and 
dependability was enhanced by using a multidisciplinary team input for example, 
pharmacists, GP, physiotherapist and epidemiologist during data analysis.  
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Although 23 GPs participated in the intervention only 14 were available to attend the 
focus groups. All participating GPs were contacted in advance about the focus 
groups, however, some were on holidays on the scheduled date while others who 
agreed to participate had to cancel at the last minute due to time constraints during 
work or emergency situations that arose with patients. There was no control group 
used in the study and as a result this limited the comparison between the GPs who 
received the intervention and those who didn’t.  
The findings from this study may be beneficial to other researchers when developing 
their own study designs as they may enhance their approach or avoid similar pitfalls 
(201). Future studies could evaluate the impact of newly diagnosed incontinence 
patients with an intervention and control group. A follow up visit could be arranged 
with the GPs after four to six weeks to reinforce the key messages from the first visit 
and to identify if they have been successfully implementing any suggested changes. 
It would also give the academic detailer an opportunity to answer any additional 
questions that the GPs may have. Qualitative work could also be carried out with 
Urologists to identify their views on the management of urinary incontinence in 
primary care. Although the academic detailing training took place in the United 
States, a “train the trainer” approach could be utilised to make it more feasible for 
an Irish context. Instructors could train their colleagues and this would help to build 
a pool of competent academic detailers. Finally, large randomised control trials that 
have clear objectives, explicit criteria, are methodologically robust and have a long 
duration of follow-up should be considered.  
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Conclusion 
This mixed-methods study explored the feasibility and satisfaction of a pharmacist-
led AD intervention with GPs. Overall, participants highly valued this evidence-based 
approach and welcomed further visits. Selecting a relevant topic was considered 
important. The printed educational materials were reported as being of high quality, 
however an online version was preferred. Although there was minimal or no change 
in the measures of prescribing assessed, we believe that publishing these results are 
important for researchers planning similar studies. Further research is needed in a 
larger population evaluating the impact and cost effectiveness of AD to optimise 
patient care.  
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Chapter 7. Discussion 
 
The overall aim of this thesis was to understand the potential role of the pharmacist 
in optimising prescribing for older people in primary care.  
This chapter highlights the findings from each individual chapter to create an overall 
summary of the evidence. Firstly, Chapter 3 sets the scene by highlighting the 
prevalence of PIP and PPOs across three European countries. Secondly, Chapter 4 
summarises the evidence of pharmacist-led interventions in optimising prescribing 
in older adults in primary care. Thirdly, Chapter 5 reveals the determinants of GP 
prescribing behaviour for older adults in primary care and elicits GPs’ views on the 
potential role for broad intervention strategies involving pharmacists and/or 
information technology systems in general practice. Finally, these findings have 
informed the pharmacist-led academic detailing (AD) intervention with GPs in 
Chapter 6. The feasibility of this study was evaluated using a mixed methods 
approach. The strengths and limitations of the thesis are explained. The policy 
implications of the thesis findings are also outlined in addition to highlighting areas 
for further research. 
 
7.1 Summary of findings for the cross-sectional study 
This study estimated and compared the prevalence and type of PIP and PPOs 
amongst community-dwelling older adults (≥65 years) in three European populations 
using STOPP/START V2 criteria. Overall, the prevalence of PIP was 12.9% (n=69) and 
was similar in the Irish, Swiss and Dutch participants. The overall prevalence of PPOs 
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in the three populations was 22.2% (n=118) and was higher in the Swiss and Dutch 
than in the Irish participants. Participants at the Swiss and Dutch sites were at 
increased odds of any PIP and PPOs after adjusting for age, sex, multimorbidity and 
polypharmacy compared to participants at the Irish site. A greater understanding of 
PIP was gained from this study by highlighting its prevalence across three European 
populations. This study also offered the opportunity to compare the characteristics 
of trial participants recruited by sites in different countries, and to compare 
prescribing behaviours internationally. For example, the prescribing of 
benzodiazepines in Ireland was lower compared to Switzerland and the Netherlands. 
The use of national benzodiazepine audits, with individual practice feedback, may 
have optimised the prescribing of these medicines among Irish GPs (89). This study 
also described the role of the GP across the three countries. Therefore, by 
highlighting and comparing the prevalence of prescribing issues, this study illustrated 
the need to identify a potential pharmacist-led intervention to optimise prescribing 
appropriateness in older people in primary care.  
 
7.2 Summary of findings from the systematic review 
This review systematically evaluated studies of pharmacist-led interventions on 
potentially inappropriate prescribing among community-dwelling older adults 
receiving primary care to identify the components of a successful intervention. Five 
studies met the inclusion criteria. Four studies involved a pharmacist conducting a 
medication review and providing feedback to patients or their family physician. One 
RCT evaluated the effect of a computerised tool that alerted pharmacists when 
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elderly patients were newly prescribed potentially inappropriate medications (PIMs). 
Four studies were associated with an improvement in prescribing appropriateness. 
Overall, it demonstrated that pharmacist-led interventions may improve prescribing 
appropriateness in community-dwelling older adults. However the quality of 
evidence is low. 
In an update of this systematic review conducted in May 2017, two additional studies 
were found, the results of which were consistent with the previously included 
studies, and thus did not change the conclusion of the review. Haag et al. evaluated 
the impact of a pharmacist-provided telephonic medication therapy management 
(MTM) on care quality in a care transition program (CTP) from a hospital to home for 
high-risk older adults. In this prospective, randomised, controlled study, patients 
were randomised to the pharmacist intervention or usual care which consisted of a 
nurse practitioner reviewing the patient’s medications. The primary outcome was to 
identify PIP and PPOs using STOPP/START V1 criteria. No significant differences were 
found between the two groups in medicines using the criteria. The small sample size 
of the study (n=25 patients) may have limited the possibility of detecting a difference 
between the groups (202). Campins et al. assessed the safety and effectiveness of a 
pharmacist-led medication evaluation programme for community-dwelling 
polymedicated (≥ 8 medicines) older people. The pharmacist review of medications 
included recommendations to the patient’s physician. This was a randomised, open-
label, multicentre, parallel-arm clinical trial with a one year follow-up that used the 
STOPP/START V1 criteria to assess medication appropriateness. The control group 
patients received the usual standard of care from their physicians. Approximately 
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26.5% of prescriptions were rated as potentially inappropriate and 21.5% were 
changed following the pharmacist’s recommendations (203).  
 
7.3 Summary of findings from the qualitative study 
The aim of this study was firstly to reveal the determinants of GP prescribing 
behaviour for older adults in primary care and secondly to elicit GPs’ views on the 
potential role for broad intervention strategies involving pharmacists and/or 
information technology systems in general practice. Semi-structured qualitative 
interviews were carried out with 16 GPs with emerging themes mapped to the TDF.  
This study highlighted the complexities of behavioural determinants of prescribing 
for older people in primary care in Ireland and the need for additional supports to 
optimise prescribing for this growing cohort of patients. It also showed that GPs still 
view the role of pharmacists and their own relationship with pharmacists in a positive 
way. Participants suggested that there is scope to harness the GP-pharmacist 
relationship to improve patient outcomes. One approach that could enhance this 
relationship in a way that may lead to meaningful and sustained improvements in 
prescribing is AD.  
The findings from the cross-sectional study, systematic review and qualitative study 
informed the AD educational intervention for the next phase of the thesis. The cross-
sectional study sets the scene by highlighting the prevalence and type of prescribing 
issues among older adults in primary care. These study findings then informed the 
systematic review as we wanted to evaluate the most appropriate pharmacist-led 
intervention to improve prescribing appropriateness. Having reviewed these 
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interventions, the next step was to carry out a qualitative study with GPs to obtain 
their experience of prescribing for older people in primary care and to elicit their 
views on the potential role for broad intervention strategies involving pharmacists 
and/or information technology systems in general practice. It identified AD as an 
approach to optimise prescribing for older people in primary care. 
7.4 Summary of findings from the mixed methods study 
This study assessed the feasibility and acceptability of a pharmacist-led academic 
detailing intervention with a sample of practising GPs using a mixed methods 
approach. Qualitative focus groups were carried out with 14 GPs who participated in 
the AD intervention on urinary incontinence in older people. The medical records for 
all patients aged ≥65 years who were attending a participating GP with a diagnosis of 
urinary incontinence were retrieved and analysed using a before-after approach. The 
intervention was well received by GPs, who deemed it acceptable and appropriate to 
the context of general practice. They were also willing to participate in future AD 
studies. Habraken et al. highlighted that Belgian physicians highly rated AD visits and 
approximately 90% of those surveyed were willing to use this service again (70). 
Hartung et al. reported strong support and satisfaction for the AD program among 
participating clinicians and almost all indicated that they would continue to 
participate in future educational sessions (174). 
There was minimal or no change in the reported prescribing outcomes of the LUTS-
FORTA criteria, DBI, ACB scale and the STOPP/START V2 criteria before and after the 
intervention. However, these findings are of value as they can provide information 
on possible effect sizes which can help to determine the sample size in subsequent 
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larger studies. This may be particularly useful where there are no data from previous 
studies to inform this process. The findings can also evaluate appropriate outcome 
measures for future trials. It is envisaged that the publication of the mixed methods 
study will inform and benefit other researchers planning future definitive larger 
studies. 
 
7.5 Strengths and limitations  
This section provides a synopsis of the overall strengths and limitations of this thesis. 
The strengths and limitations of the individual studies have been previously 
addressed in each chapter. 
The thesis was designed in a structured and systematic way to identify the most 
appropriate intervention to be used. The cross-sectional study in the thesis sets the 
scene and has multiple strengths. To the best of our knowledge that was one of the 
first studies that used the updated STOPP/START criteria. Data comparing the 
prevalence of PIP and PPOs across different European sites was also scarce. Twenty 
researchers with various academic disciplines from three different countries 
contributed to this study for example, conceiving and designing the study, carrying 
out statistical analysis and reviewing subsequent drafts of the manuscript. This cross-
disciplinary, multi-authored and multi-institutional approach added to the credibility 
and reliability of the study. However, the study population is relatively small (532 
participants) and may limit the generalisability and insights about prescribing 
nationally across three countries.  
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The value of the systematic review is supported by the use of an explicit research 
question, robust methodology that included comprehensive and exhaustive search 
strategies, clearly defined inclusion and exclusion criteria, the use of transparent 
quality appraisal tools and clear reporting of results. The five included studies were 
conducted in the United States, the UK and New Zealand. This facilitated a cross 
country comparison of each study findings. Due to the heterogeneity of the 
interventions and outcome measures reported a narrative synthesis was carried out. 
A meta-analysis would have enhanced the findings of the review. Despite updating 
the search in May 2017 only two additional studies were relevant to the review. This 
highlights the lack of high quality studies on this topic.  
The qualitative study obtained rich data on the challenges that GPs face when 
prescribing for older people in primary care in Ireland. It also informed the 
intervention for the mixed methods study. The framework method facilitated a 
systematic approach to data analysis. However, this method is more time consuming 
compared to the other approaches of qualitative analysis.  
Triangulating the data from the qualitative focus groups and quantitative measures 
of prescribing allowed a richer analysis of the findings. It also afforded an opportunity 
to gain a more complete insight into the research topic (204).  I had previously carried 
out qualitative work (Chapter 5) with most of the GPs who participated in the 
feasibility study and as a result, this helped to develop a professional relationship 
between us. The GPs may have been less resistant to participating in the intervention 
as they were familiar with the detailer who was delivering it.  Attending the two day 
academic detailing training workshop in Boston in 2016 added rigour and consistency 
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to the educational approach.  Permission was granted by the Alosa Foundation to use 
their educational materials for this study. This highlights the transferability of AD data 
across countries with different health systems and supports future sustainability and 
practicability of AD interventions. The high quality of the materials were 
acknowledged by the GPs in the qualitative focus groups.  This study was carried out 
with a sample of GPs in a region of Ireland, however it remains to be seen if the 
potential benefits of the intervention will be observed in other geographical areas or 
in a larger population.  
 
7.6 Policy implications 
In 2004, the WHO commissioned a report “Knowledge for Better Health, 
Strengthening Health Systems”. This report recommended incorporating high quality 
research into the policy making process as a key approach to optimising international 
health systems (205). 
I believe that the analysis of PIP and PPOs among older adults in Chapter 3 is 
important and that the between country comparisons may provide insight on 
important differences about the effect of guidelines and incentives at national level 
that could inform policy. Another factor that could optimise the uptake of this 
research into policy is the publication of the systematic review. This source of 
evidence has been suggested as a useful tool in policy development (206). During the 
focus groups of the mixed methods study, participants were asked how the AD 
intervention could be rolled out to GPs nationwide. Some participants highlighted 
that one way of communicating this research to a wider group of GPs in Ireland would 
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be to publish an article on the study in the GP magazine Forum.  The Forum magazine 
is published by the ICGP.  
“It might be interesting if you wrote into FORUM, that’s our GP magazine… they can 
do the middle page where the educational updates every month, write into that.”                                 
(GP11 Focus group 4).  
In October 2016 I emailed the editor of the journal about submitting an article on the 
feasibility study. The editor suggested a short communication on the study, which 
was submitted a month later and was published in the January 2017 issue of the 
magazine. The publication of the short communication was a first step towards 
communicating my research for policy.  This short communication is available in 
Appendix V.                                                                                                                
Finally, I have also disseminated the research from my PhD at various national and 
international conferences (See Appendix VII). The use of social media especially 
Twitter can play an important role as a communication channel to an audience that 
is interested in my research. This could lead to increased collaborations with other 
academics outside my usual networks and communication with other healthcare 
professionals (207). 
7.7 Future research 
The next step of the feasibility study is to move to a large scale evaluation of the 
intervention. The overall impression from the study is that this educational service is 
feasible and acceptable to GPs. Up-scaling the intervention to a large scale 
randomised control trial would allow an assessment of its effectiveness. In order to 
increase the acceptability of any future interventions it would be important to 
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collaborate with the ICGP. Participants from the focus groups highlighted that if a 
future intervention was affiliated with this professional body it would optimise its 
approval among GPs. 
“that gives a bit of an imprimatur and it … gets people more receptive to it.”                               
(GP14 Focus group 5). 
Another option would be an affiliation with a university body for example, the School 
of Pharmacy or Medicine e.g. the Department of General Practice in UCC. This would 
formalise the intervention and the relevant institution could become a “centre of 
excellence” for academic detailing in Ireland. The literature has also highlighted the 
importance of establishing credibility through a respected organisational identity 
(68). It might also be worthwhile attending CME meetings for GPs or the annual ICGP 
conference. A brief presentation could be given to attendees on the case for AD. It 
would also provide an opportunity to answer any questions relating to this 
educational technique.  Linking academic detailing to CME credits may incentivise 
GPs to participate in future studies. Topic selection and educational material 
development should involve GPs to ensure relevance to general practice. 
Interventions that are tailored to participants can be powerful predictors of 
effectiveness (197, 208). This study involved a single visit to GPs, however, when AD 
interventions are sustained over time, participants have an opportunity to develop a 
relationship with the detailer. Regular, repeated visits would allow the detailer to 
understand individual participant and practice needs and provide educational and 
organisational support accordingly. This may result in different findings and should 
be further explored in future studies (209). AD studies with other healthcare 
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professionals such as hospital doctors and nurses should be considered. Finally, 
future efforts evaluating the economic benefits of AD should also be explored. 
 
7.8 Conclusion 
This thesis presents a comprehensive and detailed body of research exploring the 
role of the pharmacist in optimising prescribing for older people in primary care. The 
range of methodological approaches used, combined with a multidisciplinary, 
collaborative team effort throughout adds to the reliability and rigour of the thesis. 
The prevalence study highlighted that PIP and PPOs are prevalent among a sample 
of community-dwelling older people enrolled to a clinical trial in three European 
countries. The systematic review demonstrated that pharmacist-led interventions 
may improve prescribing appropriateness in community-dwelling older adults. 
However, the quality of evidence is low. While the qualitative study highlighted the 
complexities of behavioural determinants of prescribing for older people in primary 
care and the need for additional supports to optimise prescribing for this growing 
cohort of patients. At the end of this series of studies, a pharmacist-led AD 
intervention with GPs was identified as being potentially useful for improving 
prescribing behaviour. The results of the research indicate that this intervention was 
relevant and practical to general practice in Ireland. The evidence-based approach of 
AD was also highly valued by the participating GPs in the study. Going forward, AD 
should be up-scaled to large intervention studies and include a wider number of 
healthcare providers i.e. hospital doctors, dentists, nurses to assess its effectiveness. 
AD, which offers a pragmatic approach that can potentially optimise prescribing 
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practices, prevent adverse effects and improve patient health outcomes, is worthy 
of further investigation in an Irish context.  
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Appendix I. Supplementary material for Chapter 3. 
Supplementary material 1. STOPP/START criteria version 2 applied to the TRUST dataset 
 
Physiological system Criteria Criteria 
included  
Number (%)  of 
criteria included out of total 
criteria  
 STOPP criteria 
Indication of medication A1. Any drug prescribed without an evidence-based clinical indication. 
 
A2. Any drug prescribed beyond the recommended duration, where treatment duration is well defined. 
 
A3. Any duplicate drug class prescription i.e. two concurrent NSAIDs, SSRIs, loop diuretics, ACE inhibitors, 
anticoagulants (optimisation of monotherapy within a single drug class should be observed prior to considering a 
new agent). 
X 
 
X 
 
 
 
 
1/3 (33.3) 
Cardiovascular system B1. Digoxin for heart failure with preserved systolic ventricular function (no clear evidence of benefit) 
 
B2. Verapamil or diltiazem with NYHA Class III or IV heart failure (may worsen heart failure). 
 
B3. Beta-blocker in combination with verapamil or diltiazem (risk of heart block). 
 
B4. Beta blocker with symptomatic bradycardia (< 50/min), type II heart block or complete heart block (risk of 
profound hypotension, asystole). 
 
B5. Amiodarone as first-line antiarrhythmic therapy in supraventricular tachyarrhythmias (higher risk of side-effects 
than beta-blockers, digoxin, verapamil or diltiazem) 
 
B6. Loop diuretic as first-line treatment for hypertension (safer, more effective alternatives available). 
 
B7. Loop diuretic for dependent ankle oedema without clinical, biochemical evidence or radiological evidence of 
heart failure, liver failure, nephrotic syndrome or renal failure (leg elevation and /or compression hosiery usually 
more appropriate). 
 
B8. Thiazide diuretic with current significant hypokalaemia (i.e. serum K+ < 3.0 mmol/l), hyponatraemia (i.e. serum 
Na+ < 130 mmol/l) hypercalcaemia (i.e. corrected serum calcium > 2.65 mmol/l) or with a history of gout 
(hypokalaemia, hyponatraemia, hypercalcaemia and gout can be precipitated by thiazide diuretic). 
X 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
 
 
X 
 
 
7/13 (53.8) 
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B9. Loop diuretic for treatment of hypertension with concurrent urinary incontinence (may exacerbate 
incontinence). 
 
B10. Centrally-acting antihypertensives (i.e. methyldopa, clonidine, moxonidine, rilmenidine, guanfacine), unless 
clear intolerance of, or lack of efficacy with, other classes of antihypertensives (centrally-active antihypertensives 
are generally less well tolerated by older people than younger people). 
 
B11. ACE inhibitors or Angiotensin Receptor Blockers in patients with hyperkalaemia. 
 
B12. Aldosterone antagonists (i.e. spironolactone, eplerenone) with concurrent potassium-conserving  drugs (i.e. 
ACEI’s, ARB’s, amiloride, triamterene) without monitoring of serum potassium (risk of dangerous hyperkalaemia i.e. 
> 6.0 mmol/l – serum K should be monitored regularly, i.e. at least every 6 months). 
 
B13. Phosphodiesterase type-5 inhibitors (i.e. sildenafil, tadalafil, vardenafil) in severe heart failure characterised by 
hypotension i.e. systolic BP < 90 mmHg, or concurrent daily nitrate therapy for angina (risk of cardiovascular 
collapse). 
 
 
 
 
 
X 
 
 
 
X 
 
 
 
X 
 
 
 
Antiplatelet/Anticoagulant drugs C1. Long-term aspirin at doses greater than 160mg per day (increased risk of bleeding, no evidence for increased 
efficacy). 
 
C2. Aspirin with a past history of peptic ulcer disease without concomitant PPI (risk of recurrent peptic ulcer). 
 
C3. Aspirin, clopidogrel, dipyridamole, vitamin K antagonists, direct thrombin inhibitors or factor Xa inhibitors with 
concurrent significant  bleeding risk, i.e. uncontrolled severe hypertension, bleeding diathesis, recent non-trivial 
spontaneous bleeding) (high risk of bleeding). 
 
C4. Aspirin plus clopidogrel as secondary stroke prevention, unless the patient has a coronary stent(s) inserted in 
the previous 12 months or concurrent acute coronary syndrome or has a high grade symptomatic carotid arterial 
stenosis (no evidence of added benefit over clopidogrel monotherapy) 
 
 
X 
 
 
 
 
 
 
 
 
 
X 
7/11 (63.6) 
C5. Aspirin in combination with vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors in patients 
with chronic atrial fibrillation without a clear indication for aspirin (no added benefit from aspirin). 
 
C6. Antiplatelet agents with vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors in patients with 
stable coronary, cerebrovascular or peripheral arterial disease without a clear indication for anticoagulant therapy 
(no added benefit from dual therapy). 
 
 
 
 
 
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C7. Ticlopidine in any circumstances (clopidogrel and prasugrel have similar efficacy, stronger evidence and fewer 
side-effects). 
 
C8. Vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors for first deep venous thrombosis without 
continuing provoking risk factors (i.e. thrombophilia) for > 6 months, (no proven added benefit). 
 
C9. Vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors for first pulmonary embolus without 
continuing provoking risk factors (i.e. thrombophilia) for > 12 months (no proven added benefit). 
 
C10. NSAID and vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors in combination (risk of 
gastrointestinal bleeding). 
 
C11. NSAID with concurrent antiplatelet agent(s) without PPI prophylaxis (increased risk of peptic ulcer disease). 
 
 
 
 
X 
 
 
X 
 
 
 
 
 
 
CNS & Psychotropic drugs D1. Tricyclic antidepressants with dementia, narrow angle glaucoma, cardiac conduction abnormalities, prostatism, 
or prior history of urinary retention (risk of worsening these conditions). 
 
D2. Initiation of tricyclic antidepressants as first-line antidepressant treatment (higher risk of adverse drug reactions 
with TCAs than with SSRIs or SNRIs). 
 
D3. Neuroleptics with moderate-marked antimuscarinic/anticholinergic effects (chlorpromazine, clozapine, 
flupenthixol, fluphenzine, pipothiazine, promazine, zuclopenthixol) with a history of prostatism or previous urinary 
retention (high risk of urinary retention). 
 
D4. Selective serotonin re-uptake inhibitors (SSRI’s) with current or recent significant hyponatraemia i.e. serum Na+ 
< 130 mmol/l (risk of exacerbating or precipitating hyponatraemia). 
 
D5. Benzodiazepines for ≥ 4 weeks (no indication for longer treatment; risk of prolonged sedation, confusion, 
impaired balance, falls, road traffic accidents; all benzodiazepines should be withdrawn gradually if taken for > 2 
weeks as there is a risk of causing a benzodiazepine withdrawal syndrome if stopped abruptly). 
 
D6. Antipsychotics (i.e. other than quetiapine or clozapine) in those with parkinsonism or Lewy Body Disease (risk of 
severe extra-pyramidal symptoms). 
 
D7. Anticholinergics/antimuscarinics to treat extra-pyramidal side-effects of neuroleptic medications (risk of 
anticholinergic toxicity). 
 
D8. Anticholinergics/antimuscarinics in patients with delirium or dementia (risk of exacerbation of cognitive 
impairment). 
 
 
 
 
X 
 
 
 
 
 
 
X 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
8/14 (57.1) 
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D9. Neuroleptic antipsychotic in patients with behavioural and psychological symptoms of dementia (BPSD) unless 
symptoms are severe and other non-pharmacological treatments have failed (increased risk of stroke). 
 
D10. Neuroleptics as hypnotics, unless sleep disorder is due to psychosis or dementia (risk of confusion, 
hypotension, extra-pyramidal side effects, falls). 
 
D11. Acetylcholinesterase inhibitors with a known history of persistent bradycardia (< 60 beats/min.), heart block 
or recurrent unexplained syncope or concurrent treatment with drugs that reduce heart rate such as beta-blockers, 
digoxin, diltiazem, verapamil (risk of cardiac conduction failure, syncope and injury). 
 
D12. Phenothiazines as  first-line treatment, since safer and more efficacious alternatives exist (phenothiazines are 
sedative, have significant anti-muscarinic toxicity in older people, with the exception of prochlorperazine for 
nausea/vomiting/vertigo, chlorpromazine for relief of persistent hiccoughs and levomepromazine as an anti-emetic 
in  palliative care). 
 
D13. Levodopa or dopamine agonists for benign essential tremor (no evidence of efficacy). 
 
D14. First-generation antihistamines (safer, less toxic antihistamines now widely available). 
 
X 
 
 
X 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
 
 
Renal system E1. Digoxin at a long-term dose greater than 125µg/day if eGFR < 30 ml/min/1.73m2 (risk of digoxin toxicity if 
plasma levels not measured).  
 
E2. Direct thrombin inhibitors (i.e. dabigatran) if eGFR < 30 ml/min/1.73m2 (risk of bleeding). 
 
E3. Factor Xa inhibitors (i.e. rivaroxaban, apixaban) if eGFR < 15 ml/min/1.73m2 (risk of bleeding). 
 
E4. NSAID’s if eGFR < 50 ml/min/1.73m2 (risk of deterioration in renal function). 
 
E5. Colchicine if eGFR < 10 ml/min/1.73m2 (risk of colchicine toxicity). 
 
E6. Metformin if eGFR < 30 ml/min/1.73m2 (risk of lactic acidosis). 
 
 
X 
 
 
X 
 
X 
 
X 
 
X 
 
X 
 
 
0/6 (0) 
Gastrointestinal system F1. Prochlorperazine or metoclopramide with Parkinsonism (risk of exacerbating Parkinsonian symptoms). 
 
F2.  PPI for uncomplicated peptic ulcer disease or erosive peptic oesophagitis at full therapeutic dosage for > 8 
weeks (dose reduction or earlier discontinuation indicated). 
 
 
 
X 
 
 
 
 
2/4 (50) 
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F3. Drugs likely to cause constipation (i.e. antimuscarinic/anticholinergic drugs, oral iron, opioids, verapamil, 
aluminium antacids) in patients with chronic constipation where non-constipating alternatives are available (risk of 
exacerbation of constipation). 
 
F4. Oral elemental iron doses greater than 200 mg daily (i.e. ferrous fumarate> 600 mg/day, ferrous sulphate > 600 
mg/day, ferrous gluconate> 1800 mg/day; no evidence of enhanced iron absorption above these doses). 
 
 
 
X 
Respiratory system G1. Theophylline as monotherapy for COPD (safer, more effective alternative; risk of adverse effects due to narrow 
therapeutic index). 
 
G2. Systemic corticosteroids instead of inhaled corticosteroids for maintenance therapy in moderate-severe COPD 
(unnecessary exposure to long-term side-effects of systemic corticosteroids and effective inhaled therapies are 
available). 
 
G3. Antimuscarinic bronchodilators (i.e. ipratropium, tiotropium) with a history of narrow angle glaucoma (may 
exacerbate glaucoma) or bladder outflow obstruction (may cause urinary retention). 
 
G4. Non-selective beta-blocker (whether oral or topical for glaucoma) with a history of asthma requiring treatment 
(risk of increased bronchospasm). 
 
G5. Benzodiazepines with acute or chronic respiratory failure i.e. pO2 < 8.0 kPa ± pCO2 > 6.5 kPa (risk of 
exacerbation of respiratory failure). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
4/5 (80) 
Musculoskeletal system H1. Non-steroidal anti-inflammatory drug (NSAID) other than COX-2 selective agents with history of peptic ulcer 
disease or gastrointestinal bleeding, unless with concurrent PPI or H2 antagonist (risk of peptic ulcer relapse). 
 
H2. NSAID with severe hypertension (risk of exacerbation of hypertension) or severe heart failure (risk of 
exacerbation of heart failure). 
 
H3. Long-term use of NSAID (>3 months) for symptom relief of osteoarthritis pain where paracetamol has not been 
tried (simple analgesics preferable and usually as effective for pain relief). 
 
H4. Long-term corticosteroids (>3 months) as monotherapy for rheumatoid arthrtitis (risk of systemic corticosteroid 
side-effects). 
 
H5.  Corticosteroids (other than periodic intra-articular injections for mono-articular pain) for osteoarthritis (risk of 
systemic corticosteroid side-effects). 
 
 
 
 
 
 
 
 
X 
 
 
X 
 
 
 
 
 
 
6/9 (66.7) 
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H6. Long-term NSAID or colchicine (> 3 months) for chronic treatment of gout where there is no contraindication to 
a xanthine-oxidase inhibitor i.e. allopurinol, febuxostat (xanthine-oxidase inhibitors are first choice prophylactic 
drugs in gout). 
 
H7. COX-2 selective NSAIDs with concurrent cardiovascular disease (increased risk of myocardial infarction and 
stroke). 
 
H8. NSAID with concurrent corticosteroids without PPI prophylaxis (increased risk of peptic ulcer disease). 
 
H9. Oral bisphosphonates in patients with a current or recent history of upper gastrointestinal disease i.e. 
dysphagia, oesophagitis, gastritis, duodenitis, or peptic ulcer disease, or upper gastrointestinal bleeding (risk of 
relapse/exacerbation of oesophagitis, oesophageal ulcer, oesophageal stricture). 
X 
 
 
 
 
 
 
 
 
 
 
Urogenital system I1. Antimuscarinic drugs with dementia, or chronic cognitive impairment (risk of increased confusion, agitation) or 
narrow-angle glaucoma (risk of acute exacerbation of glaucoma), or chronic prostatism (risk of urinary retention). 
 
I2. Selective alpha-1 selective alpha blockers in those with symptomatic orthostatic hypotension or micturition 
syncope (risk of precipitating recurrent syncope) 
 
 
 
 
2/2 (100) 
Endocrine system J1. Sulphonylureas with a long duration of action (i.e. glibenclamide, chlorpropamide, glimepiride) with type 2 
diabetes mellitus (risk of prolonged hypoglycaemia). 
 
J2. Thiazolidenediones (i.e. rosiglitazone, pioglitazone) in patients with heart failure (risk of exacerbation of heart 
failure). 
 
J3. Beta-blockers in diabetes mellitus with frequent hypoglycaemic episodes (risk of suppressing hypoglycaemic 
symptoms). 
 
J4. Oestrogens with a history of breast cancer or venous thromboembolism (increased risk of recurrence). 
 
J5. Oral oestrogens without progestogen in patients with intact uterus (risk of endometrial cancer). 
 
J6. Androgens (male sex hormones) in the absence of primary or secondary hypogonadism (risk of androgen 
toxicity; no proven benefit outside of hypogonadismindication). 
 
 
 
 
 
 
X 
 
 
 
 
 
 
 
5/6 (83.3) 
Drugs that predictably increase the 
risk of falls in older people 
K1. Benzodiazepines (sedative, may cause reduced sensorium, impair balance). 
 
K2. Neuroleptic drugs (may cause gait dyspraxia, Parkinsonism). 
 
K3. Vasodilator drugs (i.e. alpha-1 receptor blockers, calcium channel blockers, long-acting nitrates, ACE inhibitors, 
angiotensin I receptor blockers, diazoxide, minoxidil, hydralazine) with persistent postural hypotension i.e. 
recurrent drop in systolic blood pressure ≥ 20mmHg (risk of syncope, falls). 
 
 
 
 
 
X 
 
 
 
3/4 (75) 
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K4. Hypnotic Z-drugs i.e. zopiclone, zolpidem, zaleplon (may cause protracted daytime sedation, ataxia).  
Analgesic drugs L1. Use of oral or transdermal strong opioids (morphine, oxycodone, fentanyl, buprenorphine, diamorphine, 
methadone, tramadol, pethidine, pentazocine) as first line therapy for mild pain (WHO analgesic ladder not 
observed). 
 
L2. Use of regular (as distinct from PRN) opioids without concomitant laxative (risk of severe constipation). 
 
L3. Long-acting opioids without short-acting opioids for break-through pain (risk of persistence of severe pain). 
X 
 
 
 
 
 
 
2/3 (66.7) 
Antimuscarinic/Anticholinergic drug 
burden  
N. Concomitant use of two or more drugs with antimuscarinic/anticholinergic properties (i.e. bladder 
antispasmodics, intestinal antispasmodics, tricyclic antidepressants, first generation antihistamines) (risk of 
increased antimuscarinic/anticholinergic toxicity). 
 1/1 (100) 
Total STOPP criteria n=80  
 
 48/80 (60) 
 
 START criteria 
Cardiovascular system A1. Vitamin K antagonists or direct thrombin inhibitors or factor Xa inhibitors in the presence of chronic atrial 
fibrillation. 
 
A2. Aspirin (75 mg – 160 mg once daily) in the presence of chronic atrial fibrillation, where Vitamin K antagonists or 
direct thrombin inhibitors or factor Xa inhibitors are contraindicated. 
 
A3. Antiplatelet therapy (aspirin or clopidogrel or prasugrel or ticagrelor) with a documented history of coronary, 
cerebral or peripheral vascular disease. 
 
A4. Antihypertensive therapy where systolic blood pressure consistently > 160 mmHg and/or diastolic blood 
pressure consistently > 90 mmHg; if systolic blood pressure > 140 mmHg and /or diastolic blood pressure > 90 
mmHg, if diabetic. 
 
A5. Statin therapy with a documented history of coronary, cerebral or peripheral vascular disease, unless the 
patient’s status is end-of-life or age is > 85 years. 
 
A6. Angiotensin Converting Enzyme (ACE) inhibitor with systolic heart failure and/or documented coronary artery 
disease. 
 
A7. Beta-blocker with ischaemic heart disease. 
 
A8. Appropriate beta-blocker (bisoprolol, nebivolol, metoprololorcarvedilol) with stable systolic heart failure. 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
7/8 (87.5) 
Respiratory system B1. Regular inhaled beta 2 agonist or antimuscarinic bronchodilator (i.e. ipratropium, tiotropium) for mild to 
moderate asthma or COPD. 
 
 
 
 
1/3 (33.3) 
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B2. Regular inhaled corticosteroid for moderate-severe asthma or COPD, where FEV1 <50% of predicted value and 
repeated exacerbations requiring treatment with oral corticosteroids. 
 
B3. Home continuous oxygen with documented chronic hypoxaemia (i.e. pO2 < 8.0 kPa or 60 mmHg or SaO2 < 
89%). 
 
X 
 
 
X 
Central nervous system & Eyes C1. L-DOPA or a dopamine agonist in idiopathic Parkinson’s disease with functional impairment and resultant 
disability. 
 
C2. Non-TCA antidepressant drug in the presence of persistent major depressive symptoms. 
 
C3. Acetylcholinesterase inhibitor (i.e. donepezil, rivastigmine, galantamine) for mild-moderate Alzheimer’s 
dementia or Lewy Body dementia (rivastigmine). 
 
C4. Topical prostaglandin, prostamide or beta-blocker for primary open-angle glaucoma. 
 
C5. Selective serotonin reuptake inhibitor (or SNRI or pregabalin if SSRI contraindicated) for persistent severe 
anxiety that interferes with independent functioning. 
 
C6. Dopamine agonist (ropinirole or pramipexole or rotigotine) for Restless Legs Syndrome, once iron deficiency 
and severe renal failure have been excluded. 
 
 
 
X 
 
 
 
 
 
 
X 
 
 
 
X 
3/6 (50) 
Gastrointestinal system D1. Proton Pump Inhibitor with severe gastro-oesophageal reflux disease or peptic stricture requiring dilatation. 
 
D2. Fibre supplements (i.e. bran, ispaghula, methylcellulose, sterculia) for diverticulosis with a history of 
constipation. 
 
 
 
2/2 (100) 
Musculoskeletal system E1. Disease-modifying anti-rheumatic drug (DMARD) with active, disabling rheumatoid disease. 
 
E2. Bisphosphonates and vitamin D and calcium in patients taking long-term systemic corticosteroid therapy. 
 
E3. Vitamin D and calcium supplement in patients with known osteoporosis and/or previous fragility fracture(s) 
and/or (Bone Mineral Density T-scores more than -2.5 in multiple sites). 
 
E4. Bone anti-resorptive or anabolic therapy (i.e. bisphosphonate, strontium ranelate, teriparatide, denosumab) in 
patients with documented osteoporosis, where no pharmacological or clinical status contraindication exists (Bone 
Mineral Density T-scores -> 2.5 in multiple sites) and/or previous history of fragility fracture(s). 
 
E5. Vitamin D supplement in older people who are housebound or experiencing falls or with osteopenia (Bone 
Mineral Density T-score is > -1.0 but < -2.5 in multiple sites). 
 
E6. Xanthine-oxidase inhibitors (i.e. allopurinol, febuxostat) with a history of recurrent episodes of gout. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7/7 (100) 
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E7. Folic acid supplement in patients taking methotexate.  
Endocrine system F1. ACE inhibitor or Angiotensin Receptor Blocker (if intolerant of ACE inhibitor) in diabetes with evidence of renal 
disease i.e. overt dipstick proteinuria or microalbuminuria (>30mg/24 hours) with or without serum biochemical 
renal impairment. 
X 0/1 (0) 
Urogenital system G1. Alpha-1 receptor blocker with symptomatic prostatism, where prostatectomy is not considered necessary. 
 
G2. 5-alpha reductase inhibitor with symptomatic prostatism, where prostatectomy is not considered necessary. 
 
G3. Topical vaginal oestrogen or vaginal oestrogen pessary for symptomatic atrophic vaginitis. 
X 
 
X 
 
 
1/3 (33.3) 
Analgesics H1. High-potency opioids in moderate-severe pain, where paracetamol, NSAIDs or low-potency opioids are not 
appropriate to the pain severity or have been ineffective. 
 
H2. Laxatives in patients receiving opioids regularly. 
X 
 
 
 
1/2 (50) 
Vaccines I1: Seasonal trivalent influenza vaccine annually. 
 
I2: Pneumococcal vaccine every 5 years, according to national guidelines 
 
X 
 
X 
0/2 (0) 
Total START criteria n=34   22/34 (64.7) 
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Supplementary material 2. STROBE statement 
 
Section/topic 
Item 
no 
Recommendation 
Reported on 
page no 
Title  
Title 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract. 38 
Abstract   
Structured summary  1 (b) Provide in the abstract an informative and balanced summary of what was done and what was found. 39-40 
Introduction  
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported. 42-43 
Objectives  3 State specific objectives, including any prespecified hypotheses. 43 
Methods  
Study design 4 Present key elements of study design early in the paper. 44 
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection. 44-48 
Participants 6 (a) Give the eligibility criteria, and the sources and methods of selection of participants. 44-48 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if 
applicable. 
44-48 
Data sources/ 
measurement 
8* For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of 
assessment methods if there is more than one group. 
44-48 
Bias 9 Describe any efforts to address potential sources of bias. 44-48 
Study size 10 Explain how the study size was arrived at. 44-48 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why. 44-48 
Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding. 44-48 
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(b) Describe any methods used to examine subgroups and interactions. 
(c) Explain how missing data were addressed. 
(d) If applicable, describe analytical methods taking account of sampling strategy. 
(e) Describe any sensitivity analyses. 
Results   
Participants 13* (a) Report numbers of individuals at each stage of study i.e. numbers potentially eligible, examined for eligibility, confirmed eligible, 
included in the study, completing follow-up, and analysed. 
(b) Give reasons for non-participation at each stage. 
(c) Consider use of a flow diagram. 
48-49 
Descriptive data 14* (a) Give characteristics of study participants (i.e. demographic, clinical, social) and information on exposures and potential 
confounders. 
(b) Indicate number of participants with missing data for each variable of interest. 
48-49 
Outcome data 15* Report numbers of outcome events or summary measures. 48-58 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (i.e., 95% confidence interval). 
Make clear which confounders were adjusted for and why they were included. 
(b) Report category boundaries when continuous variables were categorized. 
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period. 
48-58 
Other analyses 17 Report other analyses done—i.e. analyses of subgroups and interactions, and sensitivity analyses. 48-58 
Discussion  
Key results 18 Summarise key results with reference to study objectives. 59 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude 
of any potential bias. 
64-66 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar 
studies, and other relevant evidence. 
59-64 
Generalisability 21 Discuss the generalisability (external validity) of the study results. 59-64 
Other information     
Funding  22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the 
present article is based. 
67-68 
*Give information separately for exposed and unexposed groups. 
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Appendix II. Supplementary material for Chapter 4. 
 
Supplementary material 3. Table of databases and search terms applied.  
Database Search terms applied 
 
CINAHL AGED OR aged, 65 and over OR middle aged OR elderly AND Primary care OR primary health care OR community AND Pharmacist* AND Prescription 
OR prescribing 
 
ClinicalTrials.gov 
 
(pharmacist or pharmacists) AND (prescribing OR prescription) AND (inappropriate OR strategy OR strategies OR improving OR improve OR optimise 
OR optimize) AND (primary care OR primary health care OR community OR outpatient care) | Adult, Senior 
 
Cochrane Database of 
Systematic Reviews 
"aged" or " aged, over 65" or "middle aged" or "elderly" AND prescribing or prescription or "inappropriate prescribing" AND  "primary care" or 
"primary health care" or "outpatient care" or "community" AND  
pharmacist* or "pharmaceutical care" or pharmacist* intervention 
 
Embase  'aged' OR 'aged' OR 'middle aged' OR 'middle aged' OR 'aged, over 65' OR 'elderly' OR ‘elderly’ AND  
'primary care' OR 'primary health care' OR 'outpatient care' AND prescribing OR prescription*  AND     
 pharmacist* OR 'pharmaceutical care'        
 
Medline (through OVID)  
 
(prescribing or prescription) AND  (aged or middle aged or elderly) AND (primary care or primary health care or elderly care or outpatient care) AND 
(pharmacist* or pharmaceutical care) 
 
metaRegister of Controlled 
Trials (mRCT) 
(pharmacist or pharmacists) AND (prescribing OR prescription) AND (inappropriate OR improving OR improve OR optimise OR optimize ) AND (primary 
care OR primary health care OR outpatient care OR community OR general practice) 
 
ProQuest Dissertations & Theses 
 
(aged or elderly OR “middle aged”) AND (“primary care” or “primary health care” OR community or “outpatient care”) AND (prescribing or “drug 
prescribing “ OR prescription* or “drug prescription*”) AND (pharmacist* or clinical pharmacist* OR “pharmaceutical care” OR “pharmacy 
intervention” or “clinical intervention” OR “pharmacist intervention” or “clinical pharmacist intervention”) 
 
PubMed 
 
((("primary care" or "primary health care" or "outpatient care"))) AND ((prescribing or prescription*))) AND (("aged" or "middle aged" or elderly))) AND 
((pharmacist* or "pharmaceutical care")) 
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Database Search terms applied 
ScienceDirect aged OR "middle aged" OR "elderly" AND "primary care" OR "primary health care" OR community OR "outpatient care" AND prescribing OR 
prescription* OR "appropriate prescribing" OR "inappropriate prescribing" OR “potentially inappropriate prescribing” AND “clinical pharmacist” OR 
pharmacist* OR "pharmaceutical care" OR "pharmacy intervention" or "clinical intervention" OR “pharmacist intervention” or “clinical pharmacist 
intervention”[All Sources(Medicine and Dentistry, Nursing and Health Professions, Pharmacology, Toxicology and Pharmaceutical Science)]. 
Trip "(title: aged OR middle aged OR elderly AND primary care OR primary health care OR outpatient care)(title: pharmacist* OR pharmaceutical care)(title: 
usual care OR control)(prescribing OR prescription)", by quality 
University of York Centre for 
Reviews and Dissemination 
(aged ) OR (“middle aged”) OR (elderly) AND (prescribing or prescription* or “drug prescribing” or “drug prescription*”) AND (“primary care”) OR 
(“primary health care”) OR (“outpatient care”) AND (pharmacist* or "clinical pharmacist*" or "pharmaceutical care" OR "pharmacist* intervention" OR 
"clinical pharmacist* intervention") 
ISI Web of Science ("aged " or "middle aged" or elderly) Timespan=All years, Search language=Auto  AND  ("primary care" or "primary health care" or "outpatient care")  
Timespan=All years, Search language=Auto AND (prescribing or prescription*)  Timespan=All years, Search language=Auto AND  (pharmacist* or 
"pharmaceutical care")  Timespan=All years, Search language=Auto 
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Supplementary material 4. Table of ongoing and excluded articles reviewed and reasons for exclusion 
Study 
Number 
Article Reason for exclusion 
1.  Developing Pharmacist-led Research to Educate and Sensitive Community 
Residents to the Inappropriate Prescription Burden in the Elderly.  
Source: Clinicaltrials.gov 
This study is currently ongoing. 
Study Start Date: March 2014 
Estimated Study Completion Date: September 2016 
2.  Inappropriate Prescription in Elderly and Polypharmacy Patients in 
Primary Care. PHARM-PC Trial.  
Source: Clinicaltrials.gov 
This study is not yet open for participant recruitment. 
Study Start Date: October 2014 
Estimated Study Completion Date: April 2016 
3.  A Pilot Study to Reduce Inappropriate Anticholinergic Prescribing in the 
Elderly. 
Source: Clinicaltrials.gov 
This study is currently recruiting participants 
Study Start Date: September 2014 
Estimated Study Completion Date: December 2015 
4.  Educational Intervention to Reduce Drug-related Hospitalizations in 
Elderly Primary Health Care Patients.Source: Clinicaltrials.gov 
Emailed author for full paper. 12/12/14 10.50am. No  reply  
Emailed author again on 13/01/15 11.35am. No reply 
5.  Minimizing Risk and Maximizing Outcomes in Geriatric Patients Through 
Integrated Clinical Pharmacy Services in an Innovative Model of 
Community Practice. 
Source: Clinicaltrials.gov 
The recruitment status of this study is unknown because the information has not 
been verified recently. Observational study 
6.  Study of Whether Educational Visits to Primary Care Professionals 
Improves the Quality of Care They Provide. 
Source: Clinicaltrials.gov 
 
Not relevant. The intervention was  evaluated using Prescribing Analysis and Cost 
(PACT) data for antidepressant drugs 
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7.  An Intervention Study to Reduce the Use and Impact of Potentially 
Inappropriate Medications Among Older Adults. 
Source: Clinicaltrials.gov 
Emailed author for full paper 12/12/14, 11.55am. 
Author replied 12/12/14, 5pm with the following statement 
“Unfortunately our trial did not involve a pharmacist intervention so would not be 
relevant for your review” 
8.  Pharmacist-led Medicines Management Outpatient Service 
 Source: Clinicaltrials.gov 
Emailed author for full paper 12/12/14 12.05pm.                   
 Author replied 05/01/15 with the following comment “The Medicines Management 
Outpatient Service research is currently in progress therefore, unfortunately it is not 
possible to share details at this stage”  
9.  Rationalisation of Polypharmacy in the Elderly by the RASP Instrument 
Source: Clinicaltrials.gov 
Emailed author for full paper 12/12/14 12.24pm.  
Author replied on 13/01/15 with following comment “I am afraid that our manuscript 
concerning the RASP study in hospital setting is still in the makings. We are currently 
finishing it as we speak.  
Afterwards we will normally finish a short proof-of-concept study, which was 
performed in primary care” 
10.  Randomized Controlled Trial of Enhanced Pharmacy Care in Older 
Veteran Outpatients 
Source: Clinicaltrials.gov 
Emailed author for full paper 12/12/14 12.30pm. No response 
Emailed author again on 13/01/15 at 11.50am. No response 
11.  Preventing Falls Through Enhanced Pharmaceutical Care 
Source: Clinicaltrials.gov 
 
Full article obtained.  
The purpose of this study was to assess the effects of a community pharmacy-based 
falls-prevention Program. 
12.  The impact of clinical pharmacists' consultations on physicians' geriatric 
drug prescribing. A randomized controlled trial. Lipton, H, Bero, L, Joyce, 
Bird, A, McPhee, S: McPhee.  Medical Care 1992.Vol. 30, No. 7 (Jul., 
1992), pp. 646-658 
Full article obtained 
Intervention in secondary care. 
Not a validated tool in 1992 
13.  Elderly people still given inappropriate drugs. Pharmaceutical Journal. 
2006.  276, 7384. 62 
Report from the Pharmaceutical Journal 
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14.  Pharmacist-based medication review reduces potential drug-related 
problems in the elderly: the SMOG controlled trial. Vinks, T, Egberts, T, De 
Lange, T, De Koning F. Drugs and Aging.  2009.26 (2) 123-133 
Full article obtained.  
No screening tool used. 
Medication review used. Drug Related Problems were identified and validated by 
reference to national prescribing guidelines such as the Practice Standards of Dutch 
GPs as well as  therapeutic handbooks 
15.  Efficacy of a clinical medication review on the number of potentially 
inappropriate prescriptions prescribed for community-dwelling elderly 
people. Allard, J, Hebert, R, Rioux, Voyer, L. Canadian Medical Association 
journal. 2001. 164. 9. 1291-6.  
 
Full article obtained. 
Potentially Inappropriate Prescriptions (PIPs) were identified from a list of PIPs 
developed by the Quebec Committee on Drug Use in the Elderly. Although generated 
by a panel of experts, this list has never been validated with empirical data. 
16.  The MEDMAN study: A randomized controlled trial of community 
pharmacy-led medicines management for patients with coronary heart 
disease. The Community Pharmacy Medicines Management Project 
Evaluation Team. Family Practice. 2007. 24, 189-200. 
Full article obtained 
No screening tool used. 
17.  Drug Burden Index and potentially inappropriate medications in 
community-dwelling older people: the impact of Home Medicines 
Review. Castelino RL, Hilmer SN, Bajorek BV, Nishtala P, Chen TF. Drugs 
and Aging. 2010; 27(2):135-48. 
From abstract:  A retrospective analysis of medication reviews. No control group.  
Full article not required. 
18.  The cost-effectiveness of a clinical pharmacist intervention among elderly 
outpatients. Cowper PA, Weinberger M, Hanlon JT, Landsman PB, Samsa 
GP, Uttech KM, et al. Pharmacotherapy. 1998 Mar-Apr;18(2):327-32 
 
Full article obtained 
Cost analysis of a previously reported randomised controlled trial (A randomised 
controlled trial of a clinical pharmacist intervention to improve inappropriate 
prescribing in elderly outpatients with polypharmacy. Hanlon et al. 1996. This paper 
was included in our final review) 
19.  Retrospective evaluation of medication appropriateness and clinical 
pharmacist drug therapy recommendations for home-based primary care 
veterans. Davis RG, Hepfinger CA, Sauer KA, Wilhardt MS. American 
Journal of Geriatric Pharmacotherapy. 2007 3//; 5(1):40-7 
Full article obtained: Hard copy only  
Retrospective analysis. 
No control group. 
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20.  Treatment reviews of older people on polypharmacy in primary care: 
cluster controlled trial comparing two approaches. Denneboom W, 
Dautzenberg MG, Grol R, De Smet PA. British Journal of General Practice. 
2007. 57(542):723-31 
Full article obtained 
Treatment review only. 
No screening tool used. 
21.  Pharmaceutical care for elderly patients in community pharmacy: analysis 
and evaluation of community pharmacist interventions in the 
Randomised Evaluation of Shared Prescribing for Elderly People in the 
Community over Time (RESPECT) Study. Faya S. Ann Arbor: University of 
Bradford (United Kingdom); 2009. 
Paper produced as part of PhD thesis. Thesis obtained 
22.  Effect of nurse practitioner and pharmacist counselling on inappropriate 
medication use in family practice. Fletcher J, Hogg W, Farrell B, Woodend 
K, Dahrouge S, Lemelin J, et al. Canadian Family Physician. 2012; 
58(8):862-8. 
Full article obtained 
This study had no control group 
23.  Appropriate medications: prescription and use in primary care. Goodyear-
Smith F. Journal of primary health care. 2013 Sep; 5(3):178-9. 
Full article obtained 
Not relevant: Editorial review 
24.  Impact of a pharmaceutical care model for non-institutionalised elderly: 
Results of a randomised, controlled trial. Grymonpre RE, Williamson DA, 
Montgomery PR. International Journal of Pharmacy Practice. 2001:9:235-
41.  
Full article obtained 
Not related to inappropriate prescribing 
25.  Description and process evaluation of pharmacists' interventions in a 
pharmacist-led information technology-enabled multicentre cluster 
randomised controlled trial for reducing medication errors in general 
practice (PINCER trial). Howard R, Rodgers S, Avery AJ, Sheikh A. 
International Journal of Pharmacy Practice. 2014; 22(1):59-68.  
Full article obtained 
Pharmacist’s recommendations to manage individual cases of hazardous medicines 
management. 
No screening tool used. 
26.  Effect of prescriber education on the use of medications contraindicated 
in older adults in a managed Medicare population. Kaufman MB, Brodin 
KA, Sarafian A. Journal of Managed Care Pharmacy. 2005 Apr; 11(3):211-
9. 
 
Full article obtained 
This was a before and after study. No control group 
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27.  Pharmacist-led medication review in patients over 65: A randomized, 
controlled trial in primary care. Krska J, Cromarty JA, Arris F, Jamieson D, 
Hansford D, Duffus PRS, et al. Age and Ageing. 2001; 30(3):205-11. 
Full article obtained 
The study identified pharmaceutical care issues using medication reviews, however 
no screening tool used. 
28.  The effect of home medication review on the resolution of drug related 
problems and health-related quality of life. Kwint HF, Faber A, Bouvy ML. 
International Journal of Clinical Pharmacy. 2013;35(5):896 
Article obtained 
 Poster presented at 41st European Society of Clinical Pharmacy symposium on 
clinical pharmacy: Barcelona, Spain. 29–31 October 2012 
29.  Effects of medication review on drug-related problems in patients using 
automated drug-dispensing systems: A pragmatic randomized controlled 
study. Kwint HF, Faber A, Gussekloo J, Bouvy ML. Drugs and Aging. 2011; 
28(4):305-14. 
 
Full article obtained 
Medication review. Implicit and explicit criteria used. Explicit criteria consisted of a 
list of clinical rules based on Dutch treatment and prescription guidelines. Implicit 
criteria for identifying Drug Related Problems were based on a structural assessment 
by Cipolle according to a rational order of indication, effectiveness, safety and 
compliance. 
30.  Assessing the appropriateness of physician prescribing for geriatric 
outpatients: Development and testing of an instrument. Lipton HL, Bird 
JA, Bero LA, McPhee SJ. Journal of Pharmacy Technology. 1993; 9(3):107-
13. 
Full article obtained: Hard copy only. 
 This study was carried out in secondary care. It involved the development and testing 
of an instrument for drug therapy prescribing problems for geriatric patients. 
31.  Inappropriate prescribing predicts adverse drug events in older adults. 
Lund BC, Carnahan RM, Egge JA, Chrischilles EA, Kaboli PJ. The Annals of 
pharmacotherapy. 2010 Jun; 44(6):957-63. 
 
Full article obtained 
Study utilised data from a previous study (The Veterans Affairs Enhanced Pharmacy 
Outpatient Clinic (EPOC) study: a randomised controlled pharmacist- physician 
intervention trial. Kaboli et al. 2004). Objective: To determine whether an implicit 
measure of inappropriate prescribing can predict ADE risk.  
MAI score not segregated between control and intervention group. 
32.  An educational intervention to reduce the use of potentially 
inappropriate medications among older adults (EMPOWER study): 
protocol for a cluster randomized trial. Martin P, Tamblyn R, Ahmed S, 
Tannenbaum C. Trials. 2013, 14:80. 1-11.  
 
Full article obtained. 
Educational intervention. Outcome:  Cessation of benzodiazepines in the 6 months 
following receipt of the intervention.  
Trial ongoing currently recruiting patients.   
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33.  Improving the quality of pharmacotherapy in elderly primary care 
patients through medication reviews: a randomised controlled study. 
Milos V, Rekman E, Bondesson A, Eriksson T, Jakobsson U, Westerlund T, 
et al. Drugs & Aging. 2013 Apr;30(4):235-46 
Full article obtained. 
 The majority of the patients in the present study were living in nursing homes. The 
goal of medication reviews has been improved patient safety and quality of 
medication use, according to the Swedish National Board of Health and Welfare’s 
indicators for good drug therapy in the elderly. 
34.  Physicians and pharmacists: collaboration to improve the quality of 
prescriptions in primary care in Mexico. Mino-Leon D, Reyes-Morales H, 
Jasso L, Douvoba SV. International Journal of Clinical Pharmacy. 2012 Jun; 
34(3):475-80. 
Full article obtained.  
Aim to reduce prescription errors for patients with diabetes and/or hypertension. No 
screening tool used. 
35.  Inappropriate Drug Prescribing and Polypharmacy Are Major Causes of 
Poor Outcomes in Long-Term Care. Morley JE. Journal of the American 
Medical Directors Association. 2014 11//; 15(11):780-2. 
Not relevant:  
Study carried out in Long term care i.e. nursing homes 
36.  Evaluation of studies investigating the effectiveness of pharmacists' 
clinical services (Structured abstract). Morrison A, Wertheimer AI.  
American Journal of Health-System Pharmacy. 58. 7. 569-577 
Not relevant: systematic review 
37.  Implantation of a program for polymedicated patients within the 
framework of the Galician Strategy for Integrated Chronic Care. 
Reboredo-Garcia S, Mateo CG, Casal-Llorente C. Atencion Primaria. 2014; 
46 Suppl 3:33-40. 
 
Full article obtained 
Published in Spanish. (A native Spanish speaker was recruited to translate the article 
into English, Dec 2014.)   
No control study 
38.  Polypharmacy and health beliefs in older outpatients. Rossi MI, Young A, 
Maher R, Rodriguez KL, Appelt CJ, Perera S, et al. American Journal 
Geriatric Pharmacotherapy. 2007; 5(4):317-23. 
Abstract only.  
This study contained no control group.  
39.  Effects of geriatric evaluation and management on adverse drug reactions 
and suboptimal prescribing in the frail elderly. Schmader KE, Hanlon JT, 
Pieper CF, Sloane R, Ruby CM, Twersky J, et al. The American Journal of 
Medicine. 2004 3/15/; 116(6):394-401. 
 
Full article obtained 
Analysed same patients as inpatient and outpatients. 
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40.  A randomized controlled trial of a pharmacist consultation program for 
family physicians and their elderly patients (Structured abstract). Sellors J, 
Kaczorowski J, Sellors C, Dolovich L, Woodward C, Willan A, et al. 
Canadian Medical Association Journal. 2003; 169(1):17-22 
Full article obtained. 
The intervention focused on drug related problems. The primary end-point measure 
was a reduction in the daily units of medication taken, as a surrogate for optimized 
drug therapy. 
41.  Potentially Inappropriate Medications in Community-Dwelling Older 
Adults. Shade MY, Berger AM, Chaperon C. Research in Gerontological 
Nursing. 7. 4. 178-192 
Full article obtained 
This is a systematic review. 
42.  Implementation of medication reviews in community pharmacies and 
their effect on potentially inappropriate drug use in elderly patients. 
Teichert M, Luijben SN, Wereldsma A, Schalk T, Janssen J, Wensing M, et 
al. International Journal of Clinical Pharmacy. 2013; 35(5):719-26. 
Full article obtained.  
Specifically developed algorithms were used to identify nine potentially inappropriate 
medicines (PIMs) from the HARM study 
43.  Pharmaceutical care for elderly patients shared between community 
pharmacists and general practitioners: a randomised evaluation. RESPECT 
(Randomised Evaluation of Shared Prescribing for Elderly people in the 
Community over Time. Wong I, Campion P, Coulton S, Cross B, 
Edmondson H, Farrin A, et al. BMC Health Services Research.. 2004. 4(1). 
11 
Full article obtained 
This paper describes a proposed randomised multiple interrupted time series trial 
design. 
44.  Clinical medication review by a pharmacist of patients on repeat 
prescriptions in general practice: a randomised controlled trial. 
Zermansky AG, Petty DR, Raynor DK, Lowe CJ, Freemantle N, Vail A. 
Health Technology Assessment (Winchester, England). 2002; 6(20):1-86. 
Full article obtained 
Primary outcome: the number of repeat medication changes per patient over a 12 
month period. Secondary outcome was the effect on the medication costs. 
45.  
 
 
Impact of an enhanced pharmacy discharge service on prescribing 
appropriateness criteria: a randomised controlled trial. Basger B.J, Moles 
R.J, Chen T.F. International Journal of Clinical Pharmacy. (2015). 37: 1194-
1205. 
Full article obtained. 
This study was performed in a small private hospital. (Not a primary care study). 
46.  The WestGem study; Medication management in the elderly. Rose O, 
Waltering I, John C, Mertens-Keller D, Richling I, Koeberlein-Neu J. 
International Journal of Clinical Pharmacy. 2015; 37(2):405-6. 
Abstract only obtained. 
The WestGem-Study is still going on, results will be published by the end of 2015. 
47.  Majority of drug-related problems identified during medication review 
are not associated with STOPP/START criteria. Verdoorn S, Kwint HF, 
Faber A, Gussekloo J, Bouvy ML. European Journal of Clinical 
Pharmacology. 2015 Oct; 71(10):1255-62. 
 Full article obtained.  
This study has no control group. 
225 
 
48.  Combined intervention programme reduces inappropriate prescribing in 
elderly patients exposed to polypharmacy in primary care. Bregnhøj  L, 
Thirstrup S,  Kristensen  MB,  Bjerrum L, Sonne J. European Journal of 
Clinical Pharmacology. (2009) 65:199–207. 
 
 
 
 Full article obtained 
This was not a pharmacist-led study. The pharmacist analysed the patients’ 
prescription and medical history and proposed changes in their medication. The 
pharmacist and clinical pharmacologist discussed these recommendations, however it 
was the responsibility of the clinical pharmacologist what was finally recommended. 
The pharmacist forwarded the feedback to the physicians. The clinical 
pharmacologists contacted the physicians by telephone to discuss any uncertainties 
concerning the recommendations given. The clinical pharmacologists delivered the 
interactive educational interventions. 
49.  Improving prescribing patterns for the elderly through an online drug 
utilization review intervention. A System Linking the Physician, 
Pharmacist, and Computer. Monane, M, Matthias, D, Nagle, B, Kelly, M.  
Journal of the American Medical Association.  1998;280(14):1249-1252 
*Hand searched 
Full article obtained.   
This study has no control group. 
50.  A randomized study to decrease the use of potentially inappropriate 
medicines among community-dwelling older adults in a south-eastern 
managed care organisation. Fick DM, Maclean JR, Rodriguez NA, Short L, 
Heuvel RV, Waller JL, Rogers RL. American Journal of Managed Care.  
2004 Nov; 10(11 Pt 1):761-8.  
*Hand searched 
Full article obtained.  
Pharmacists suggested a list of potentially inappropriate medicine alternative 
medicines and performed a peer review of the drugs to be included in the 
intervention and their corresponding alternative medications.  
Not a pharmacist led intervention. 
 
51.  Pharmacist's contribution in a heart function clinic: patient perception 
and medication appropriateness. Bucci, C, Jackevicius, C, McFarlane, K, 
Liu, P. Canadian Journal of Cardiology 2003; 19(4):391–6.  
*Hand searched 
Full article obtained.  
This pharmacist intervention was carried out at the heart function clinic at Toronto 
General Hospital. Interventions carried out in secondary care were not included in 
the review 
52.  Meredith S, Feldman P, Frey D, Giammarco L, Hall K, Arnold K, et al.  
Improving medication use in newly admitted home healthcare patients: A 
randomized controlled trial. Journal of the American Geriatric Society. 
2002; 50:1484-1491. 
*Hand searched 
Full article obtained  
There was no validated screening tool used in this study and potentially inappropriate 
prescribing was not measured as an outcome.  
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53.   Avorn J, Soumerai SB.  Improving drug-therapy decisions through 
educational outreach. A randomized controlled trial of academically 
based "detailing". New England Journal of Medicine. 1983 Jun 16; 
308(24):1457-63. 
*Hand searched 
 
Full article obtained 
The three target drugs were selected on the basis of an analysis of national 
prescribing practices i.e. Medicaid prescribing records and evidence from published 
controlled clinical trials. There was no screening tool used in the intervention and the 
target population was not specifically aimed at those aged 65 and older. 
 
 
 
 
 
 
 
 
 
 
 
 
227 
 
Supplementary material 5. PRISMA Checklist 
Section/topic  # Checklist item  
Reported on 
page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  69 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, 
and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; 
systematic review registration number.  
70-71 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  72-74 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, 
and study design (PICOS).  
74 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (i.e., Web address), and, if available, provide registration 
information including registration number.  
N/A 
Eligibility criteria  6 Specify study characteristics (i.e., PICOS, length of follow-up) and report characteristics (i.e., years considered, language, 
publication status) used as criteria for eligibility, giving rationale.  
75-76 
Information sources  7 Describe all information sources (i.e., databases with dates of coverage, contact with study authors to identify additional studies) 
in the search and date last searched.  
74-75 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.  74-75 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the 
meta-analysis).  
75-77 
Data collection 
process  
10 Describe method of data extraction from reports (i.e., piloted forms, independently, in duplicate) and any processes for obtaining 
and confirming data from investigators.  
75-77 
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Data items  11 List and define all variables for which data were sought (i.e., PICOS, funding sources) and any assumptions and simplifications 
made.  
75-77 
Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the 
study or outcome level), and how this information is to be used in any data synthesis.  
77 
Summary measures  13 State the principal summary measures (i.e. risk ratio, difference in means).  N/A 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (i.e., I2) for 
each meta-analysis.  
N/A 
 
Page 1 of 2  
Section/topic  # Checklist item  
Reported on 
page #  
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence (i.e., publication bias, selective reporting within 
studies).  
N/A 
Additional analyses  16 Describe methods of additional analyses (i.e., sensitivity or subgroup analyses, meta-regression), if done, indicating which 
were pre-specified.  
N/A 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each 
stage, ideally with a flow diagram.  
77-78 
Study characteristics  18 For each study, present characteristics for which data were extracted (i.e., study size, PICOS, follow-up period) and provide 
the citations.  
79-88 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  89-91 
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group 
(b) effect estimates and confidence intervals, ideally with a forest plot.  
89-91 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  N/A 
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  N/A 
Additional analysis  23 Give results of additional analyses, if done (i.e., sensitivity or subgroup analyses, meta-regression [see Item 16]).  
 
N/A 
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DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key 
groups (i.e., healthcare providers, users, and policy makers).  
92-93 
Limitations  25 Discuss limitations at study and outcome level (i.e., risk of bias), and at review-level (i.e., incomplete retrieval of identified 
research, reporting bias).  
99 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  100 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (i.e., supply of data); role of funders for the 
systematic review.  
N/A 
Page 2 of 2  
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Appendix III. Supplementary material for Chapter 5. 
 
Supplementary material 6.  Example of topic guides 
The topic guide was iteratively refined as the study progressed to pursue emerging 
themes. Examples of topic guides 1 and 7 are presented below. 
 
 Topic guide 1 
   
1.  How do you think prescribing for patient’s aged 65 and older differs 
from prescribing for the general adult population? 
2.  What resources would you use for prescribing in this group of patients? 
3.  What are the challenges you face to prescribing for those over 65? 
4.  What are the adverse consequences to prescribing to those over 65? 
5.  Do you think that prescribing in general practice can impact on your 
relationship with other healthcare professionals?  Can you think of an 
example? 
6.  Would you use other healthcare professionals as resources when 
prescribing for this group of patients? Would you seek the opinion of 
other healthcare professionals?  
When is this useful? 
When is it not useful? 
7.  What kind of strategies do you think could assist your prescribing in 
general practice?   
What do you think of Clinical Decision Support Systems (CDSS)? 
8.  How could the pharmacist have a role in optimising prescribing in 
primary care? 
9.  How could pharmacist’s and GPs work together when it comes to 
prescribing in ≥ 65 years? 
10.  Any further comments? 
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Topic guide 7 
 
  
1.  How do you think prescribing for patient’s aged 65 and older differs 
from prescribing for the general adult population? 
2.  As you know, the population of older people is increasing. How do you 
think this is going to affect your role as a GP in the future? 
3.  From your experience does your surrounding environment impact on 
your prescribing for older patients? Can you give an example?  Prompts 
i.e. Time constraints, patient education etc. 
4.  When you are prescribing for older patients, what are you thinking 
about and considering? Some GPs have mentioned that prescribing 
benzodiazepines or sleeping tablets can be an issue? 
5.  What sources of information would you use for prescribing in older 
patients? Where would you look for prescribing information? I.e. 
guidelines   
6.  Would you use other healthcare professionals as resources when 
prescribing for this group of patients? Would you seek the opinion of 
other healthcare professionals?  
When is this useful? 
When is it not useful? 
7.  Do you think that prescribing in general practice can impact on your 
relationship with other healthcare professionals? If so, how? 
8.  Do you think that other healthcare professionals form a judgement on 
your prescribing for older patients? Is this a concern for you? 
9.  How would you feel if a prescribing mistake was highlighted to you by 
another healthcare professional? Would you feel comfortable changing 
it? 
10.  What would you think of an educational presentation delivered by 
community pharmacists to GPs to highlight their prescribing patterns in 
primary care? Would you find it beneficial?  I.e. Academic detailing? 
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11.  How could the community pharmacist have a role in optimising 
prescribing in primary care? I.e. carrying out medication reviews. 
12.  How would you feel if the role of the community pharmacist was 
expanded in primary care? 
13.  How could pharmacist’s and GPs work together when it comes to 
prescribing in those ≥ 65 years? 
14.  Any further comments? 
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Supplementary material 7. Table of consolidated criteria for reporting qualitative 
studies (COREQ) checklist. 
Item No  Guide 
questions/description 
Response  
Domain 1 : Research team and 
reflexivity 
  
Personal characteristics   
1. Interviewer Which author/s conducted 
the interview? 
The primary author D.O.R. 
conducted the interviews.  
 
2. Credentials What were the researcher’s 
credentials? I.e. PhD 
D.O.R. is a research 
pharmacist/PhD student.   
 
3. Occupation What was their occupation 
at the time of the study? 
Full time research pharmacist in 
Clinical Pharmacy in an academic 
institution. 
 
4. Gender Was the researcher male or 
female? 
 
Male  
5. Experience & training What experience or training 
did the researcher have? 
D.O.R. received training at the 
Health Experience Research 
Group, Oxford University and 
completed training in NVivo 
computer assisted qualitative 
data management. 
 
Relationship with participants   
6. Relationship established prior 
to study commencement 
Was a relationship 
established prior to study 
commencement? 
 
No  
7. Participant knowledge of the 
interviewer 
What did the participants 
know about the researcher? 
Yes in a minority of cases    (2 
GPs). 
 
8. Interviewer characteristics What characteristics were 
reported about the 
interviewer? i.e. 
Bias, assumptions, reasons 
and 
interests in the research 
topic 
 
Not addressed. 
Domain 2: Study design   
Theoretical framework   
9. Methodological orientation & 
theory 
What methodological 
orientation was stated to 
underpin the study? 
Open coding mapped to the 
TDF*. 
 
 
Participant selection   
10. Sampling How were participants 
selected? i.e. purposive, 
convenience, consecutive, 
snowball 
Purposive sampling was 
complemented by snowball 
sampling where necessary.  
 
 
11. Method of approach How were participants 
approached? i.e. face-to-
face, telephone, mail, email 
D.O.R. contacted potential 
participants by telephone and a 
brief summary of the study was 
given. 
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12. Sample size How many participants 
were in the study? 
 
16  
13. Non-participation How many people refused 
to participate or dropped 
out? Reasons? 
 
Not applicable: participation was 
voluntary. 
14. Setting of data collection Where was the data 
collected? i.e. home, clinic, 
workplace 
 
In the GP participants surgeries. 
15. Presence of non-participants Was anyone else present 
besides the participants and 
researchers? 
 
No 
16. Description of sample What are the important 
characteristics of the 
sample? I.e. demographic 
data, date. 
 
See Table 5.1. 
Data collection   
17. Interview guide Were questions, prompts, 
guides provided by the 
authors? Was it pilot 
tested? 
The first two interviews were 
reviewed for interview 
technique. The topic guide was 
reviewed after each interview.  
 
18. Repeat interviews Were repeat interviews 
carried out? If yes, how 
many? 
 
No 
19. Audio/visual recording Did the researcher use 
audio or visual recording to 
collect the data? 
 
Data were audio recorded using 
a digital voice recorder. 
20. Field notes Were field notes made 
during and/or after the 
interview?  
Yes. Field notes were taken 
immediately after each 
interview.  
 
21. Duration What was the duration of 
the interviews? 
The mean interview length was 
19 min (Range 9-31 min). 
 
22. Data saturation Was data saturation 
discussed? 
Data saturation was reached at 
interview number 16. 
 
23. Transcripts returned Were transcripts returned 
to participants for 
comment?  
 
No, but they were available to 
participants on request. 
 
Domain 3: analysis and findings   
Data analysis   
24. Number of data coders How many data coders 
coded the data? 
 
Three coders coded the data. 
25. Description of coding tree Did authors provide a 
description of the coding 
tree? 
No coding tree was developed 
but all the researchers discussed 
and agreed on the framework 
analysis approach a priori. 
 
26. Derivation of themes Were themes identified in 
advance or derived from the 
data? 
Themes were derived from the 
data by open coding and then 
mapped to the TDF. 
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27. Software What software, if 
applicable, was used to 
manage the data? 
 
 NVivo Qualitative Data Analysis 
Software V.10.22 was used.  
28. Participant checking Did participants provide 
feedback on the findings? 
 
No  
 
Reporting   
29. Quotations presented Were participant quotations 
presented to illustrate the 
themes/findings? 
 
Yes. Supporting quotations from 
GPs are presented. 
30. Data and findings consistent Was there consistency 
between the data presented 
and the findings? 
 Quotes are embedded in text 
and are used to illustrate our 
findings in participants own 
language as much as possible. 
 
31. Clarity of major themes Were major themes clearly 
presented in the findings? 
Major themes are presented in 
the results section.  
 
32. Clarity of minor themes Is there a description of 
diverse cases or discussion 
of minor themes? 
 
Variations in views and themes 
and minor themes are presented. 
*TDF= Theoretical Domains Framework  
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Appendix IV. Supplementary material for Chapter 6 
 
Supplementary material 8. GP certificate of participation  
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Supplementary material 9. CPD certificate 
  
 
CONTINUING PROFESSIONAL DEVELOPMENT: RESEARCH POINTS 
Name of GP:  Dr X  
Name of Researcher: Mr David O Riordan, research pharmacist, University College Cork. 
Date of research meeting Purpose of research meeting Duration of meeting GP Signature 
8th July 2016 Participation in an educational outreach visit on urinary 
incontinence in older people.  
15 minutes  
21st July 2016 Participation in a qualitative focus group to assess the feasibility 
and satisfaction of the educational outreach visit.  
25 minutes  
 
CONTINUING PROFESSIONAL DEVELOPMENT: INTERNAL POINTS 
Internal CPD Activity: Clinical chart review of diagnoses and treatments for urinary incontinence in older people. 
Date of chart review Patient initials/ date of birth Duration of review GP Signature 
    
1 hour of activity = 1 CPD point 
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Supplementary material 10. Alosa educational urinary incontinence material 
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Supplementary material 11. Academic detailing training certificate 
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Supplementary material 12. Examples of topic guides 
The topic guide was iteratively refined as the study progressed to pursue emerging 
themes. Examples of topic guides 1 and 5 are presented below. 
 
Topic guide 1 
1. What were your initial thoughts when you heard about the academic 
detailing (AD)/educational visit being carried out in MPHC?  
2. Have any of you any previous experience with academic detailing/educational 
visit before? If so how did it compare with the one delivered in MPHC?  
3. What did you think of the process of organising the visit in MPHC?  
4. What did you think of the topic delivered i.e. urinary incontinence (this topic 
was agreed with Dr Andrew Clare and Dr Tony Heffernan in advance of the 
visit) 
5. How did you feel about this one on one interaction?  
6. Do you think there was sufficient time allocated for the visit? Why?  
7. What do you think of a pharmacist conducting these visits as opposed to 
other health care professionals?  
8. How did you find the pharmacist’s knowledge on the topic? 
9. How did you find the pharmacist’s ability to answer any of your questions on 
this topic? 
10. What did you think of the printed material? I.e. was the content useful? Was 
it accurate and up to date?  
11. What did you know at the end of the educational visit that you didn’t know 
at the beginning of it? If anything?  
12. Have you used any of the information discussed during the visit in the 
management of your incontinence patients? If so, how? 
13. Do you think academic detailing/educational visit would impact on your 
management of patients with urinary incontinence? Can you visualise a case?  
14. What would your response be if another educational visit was organised in 
the future? 
15. Have you any further comments? 
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Topic guide 5  
1. What were your initial thoughts when you heard about the educational visit 
being carried out in your practice?  
2. Have any of you any previous experience with educational visits before? If so 
how did it compare with the one delivered in your practice?  
3. What did you think of the topic delivered i.e. urinary incontinence (this topic 
was agreed with GPs in another practice)? Was it relevant?  
4. What other topics do you think might be relevant?  
5. How did you find this one on one educational interaction?  
a. Do you think this style of interaction has advantages or disadvantages 
over routine educational types? If so, how?  
6. Do you think there was sufficient time allocated for the visit? Some GPs 
mentioned the word brevity in relation to the visit.  
7. If you had to explain to a colleague of yours what this educational visit is. 
What are the words that you’d use to describe it? 
8. What do you think of a pharmacist conducting these visits as opposed to 
other health care professionals?  
9. How did you find the pharmacist’s knowledge on the topic? 
10. What did you think of the printed material? I.e. was it relevant? Was it of good 
quality? What about the content? 
a. Some GPs mentioned that it was visually appealing and easy to 
understand. 
11. What did you know at the end of the educational visit that you didn’t know 
at the beginning of it? If anything?  
12. How effective do you think this type of educational visit is? Somebody sitting 
down with a GP for 10 or 15 minutes and going through the evidence relating 
to a clinical topic. Do you think that it would change your behaviour? How? 
13. Is there anything that could be done differently to make the visit more 
beneficial for you?  
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a. Some GPs had mentioned completing an assessment i.e. a series of 
MCQ’s in their spare time after the educational visit was carried out 
to assess their knowledge.  
b. Some GPs mentioned having an electronic form of the material on the 
computer desktop would allow it to be more readily accessible.  
14. How could this type of educational visit be rolled out to other GP practices? 
Do you think it is a practical program that can be delivered with GPs?  
a. Some GPs mentioned delivering it at CME meetings.  
b. Some GPs suggested promoting it in a GP magazine i.e. Forum.  
15. Some GPs had mentioned that the educational visit should have an academic 
input. What are your thoughts on that?  
16. What would your response be if you were asked to participate in another 
educational visit? 
17. Have you any further comments? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
254 
 
Supplementary material 13. GRAMMS framework. 
The GRAMMS includes the following set of quality guidelines: 
 
1. Describe the justification for using a mixed methods approach to the research 
question. 
To date, no studies have evaluated the feasibility and acceptability of an academic 
detailing intervention with GPs in Ireland using mixed methods research. Therefore, 
the aim of this study was to assess the feasibility and acceptability of a pharmacist-
led academic detailing intervention with a sample of practising GPs using a mixed 
methods approach. 
2. Describe the design in terms of the purpose, priority and sequence of methods. 
In this study a convergent parallel mixed method design was adopted as the 
qualitative and quantitative data were collected and analysed separately. Data were 
collected from the qualitative focus groups while quantitative data were collected 
from patient medical records (PMRs) on the GP practice database. The results of the 
qualitative and quantitative data analyses were then merged and interpreted.  
 
3. Describe each method in terms of sampling, data collection and analysis. 
Qualitative focus groups were conducted with GPs to explore the feasibility and 
acceptability of the intervention. This interview method was chosen due to its ability 
to generate data by interaction between group participants. Participants can present 
their own views and can listen to the contributions from others in the group. This 
allows additional material to be triggered in response to what is reported by others. 
There was also a shared background to the research topic among the GPs (urinary 
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incontinence). The descriptions of the GPs views were analysed using thematic 
analysis. This approach was used as it provides a flexible and useful research tool, 
which can potentially provide a rich and detailed account of the data. The medical 
records for all patients aged ≥65 years who were attending a participating GP with a 
diagnosis of urinary incontinence were retrieved and analysed using a before-after 
approach. Their medical records were analysed at multiple time points before and 
after the intervention (six and three months before the intervention (T-6), (T-3), at the 
time of the intervention (T0) and three and six months after the intervention (T3), (T6). 
The following patient information were recorded for each patient: patient 
demographics, body measurements, chronic prescription medicines and medical 
history. The following criteria were then applied to the data: 
 LUTS-FORTA criteria. These criteria were applied as they are the only criteria 
that review drugs to treat lower urinary tract symptoms.  
 The Drug Burden Index (DBI). These criteria were applied as they measure the 
cumulative exposure to anticholinergic and sedative medicines in older 
people and its impact on physical and cognitive function. 
 Anticholinergic cognitive burden scale (ACB). These criteria were applied to 
measure the cumulative effect of taking multiple medicines with 
anticholinergic properties. 
 STOPP/START V2 criteria. Applying these criteria would capture how 
complicated these patients are in relation to their comorbidities and 
medicines prescribed.  
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4. Describe where integration has occurred, how it has occurred and who has 
participated in it. 
This study used a mixed-methods approach to 1) qualitatively explore the feasibility 
and acceptability of an AD intervention among GPs in primary care and 2) 
quantitatively evaluate the ability of measuring an impact of the intervention.  The 
integration of the qualitative and quantitative data occurred in the discussion section 
of the manuscript.  
5. Describe any limitation of one method associated with the presence of the other 
method. 
Combining and analysing the qualitative and quantitative approaches in the study 
was time consuming as equal weight had to be given to both sets of data. 
6. Describe any insights gained from mixing or integrating methods. 
The qualitative data supplemented the quantitative data by identifying convergence 
and divergence between the two datasets. 
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Supplementary material 14. Drugs identified by the LUTS-FORTA criteria 
 
 
Drug class Agent FORTA class Drugs identified by LUTS-
FORTA in the study  
5α-reductase 
inhibitors 
Dutasteride B √ 
Finasteride B X 
α1-blockers Alfuzosin 
 
D X 
Doxazosin D X 
Sildosin C √ 
Tamsulosin C √ 
Terazosin D X 
Antimuscarinics Darifenacin C X 
Fesoterodine B √ 
Oxybutynin standard 
dose/immediate 
release 
D √ 
Oxybutynin low 
dose/extended 
release 
C √ 
Propiverine D √ 
Solifenacin C √ 
Tolterodine C √ 
Trospium C √ 
β3-agonist Mirabegron C √ 
PDE5 inhibitor Tadalafil  C X 
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Supplementary material 15. STOPP/START V2 criteria applied to the data 
 
Physiological system Criteria Criteria 
included  
Number (%)  of 
criteria included out of total 
criteria  
 STOPP criteria 
Indication of medication A1. Any drug prescribed without an evidence-based clinical indication. 
 
A2. Any drug prescribed beyond the recommended duration, where treatment duration is well defined. 
 
A3. Any duplicate drug class prescription i.e. two concurrent NSAIDs, SSRIs, loop diuretics, ACE inhibitors, 
anticoagulants (optimisation of monotherapy within a single drug class should be observed prior to considering a 
new agent). 
 
 
 
 
 
 
 
 
3/3 (100) 
Cardiovascular system B1. Digoxin for heart failure with preserved systolic ventricular function (no clear evidence of benefit) 
 
B2. Verapamil or diltiazem with NYHA Class III or IV heart failure (may worsen heart failure). 
 
B3. Beta-blocker in combination with verapamil or diltiazem (risk of heart block). 
 
B4. Beta blocker with symptomatic bradycardia (< 50/min), type II heart block or complete heart block (risk of 
profound hypotension, asystole). 
 
B5. Amiodarone as first-line antiarrhythmic therapy in supraventricular tachyarrhythmias (higher risk of side-effects 
than beta-blockers, digoxin, verapamil or diltiazem) 
 
B6. Loop diuretic as first-line treatment for hypertension (safer, more effective alternatives available). 
 
B7. Loop diuretic for dependent ankle oedema without clinical, biochemical evidence or radiological evidence of 
heart failure, liver failure, nephrotic syndrome or renal failure (leg elevation and /or compression hosiery usually 
more appropriate). 
 
B8. Thiazide diuretic with current significant hypokalaemia (i.e. serum K+ < 3.0 mmol/l), hyponatraemia (i.e. serum 
Na+ < 130 mmol/l) hypercalcaemia (i.e. corrected serum calcium > 2.65 mmol/l) or with a history of gout 
(hypokalaemia, hyponatraemia, hypercalcaemia and gout can be precipitated by thiazide diuretic). 
 
 
 
 
 
 
 
 
 
 
X 
 
 
X 
 
 
 
 
 
 
X 
 
 
 
7/13 (53.8) 
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B9. Loop diuretic for treatment of hypertension with concurrent urinary incontinence (may exacerbate 
incontinence). 
 
B10. Centrally-acting antihypertensives (i.e. methyldopa, clonidine, moxonidine, rilmenidine, guanfacine), unless 
clear intolerance of, or lack of efficacy with, other classes of antihypertensives (centrally-active antihypertensives 
are generally less well tolerated by older people than younger people). 
 
B11. ACE inhibitors or Angiotensin Receptor Blockers in patients with hyperkalaemia. 
 
B12. Aldosterone antagonists (i.e. spironolactone, eplerenone) with concurrent potassium-conserving  drugs (i.e. 
ACEI’s, ARB’s, amiloride, triamterene) without monitoring of serum potassium (risk of dangerous hyperkalaemia i.e. 
> 6.0 mmol/l – serum K should be monitored regularly, i.e. at least every 6 months). 
 
B13. Phosphodiesterase type-5 inhibitors (i.e. sildenafil, tadalafil, vardenafil) in severe heart failure characterised 
by hypotension i.e. systolic BP < 90 mmHg, or concurrent daily nitrate therapy for angina (risk of cardiovascular 
collapse). 
 
 
 
 
 
 
X 
 
 
 
X 
 
 
X 
 
 
 
 
Antiplatelet/Anticoagulant drugs C1. Long-term aspirin at doses greater than 160mg per day (increased risk of bleeding, no evidence for increased 
efficacy). 
 
C2. Aspirin with a past history of peptic ulcer disease without concomitant PPI (risk of recurrent peptic ulcer). 
 
C3. Aspirin, clopidogrel, dipyridamole, vitamin K antagonists, direct thrombin inhibitors or factor Xa inhibitors with 
concurrent significant  bleeding risk, i.e. uncontrolled severe hypertension, bleeding diathesis, recent non-trivial 
spontaneous bleeding) (high risk of bleeding). 
 
C4. Aspirin plus clopidogrel as secondary stroke prevention, unless the patient has a coronary stent(s) inserted in 
the previous 12 months or concurrent acute coronary syndrome or has a high grade symptomatic carotid arterial 
stenosis (no evidence of added benefit over clopidogrel monotherapy) 
 
 
 
 
 
 
 
 
 
 
 
X 
8/11 (72.7) 
C5. Aspirin in combination with vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors in patients 
with chronic atrial fibrillation without a clear indication for aspirin (no added benefit from aspirin). 
 
C6. Antiplatelet agents with vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors in patients with 
stable coronary, cerebrovascular or peripheral arterial disease without a clear indication for anticoagulant therapy 
(no added benefit from dual therapy). 
 
 
 
 
 
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C7. Ticlopidine in any circumstances (clopidogrel and prasugrel have similar efficacy, stronger evidence and fewer 
side-effects). 
 
C8. Vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors for first deep venous thrombosis without 
continuing provoking risk factors (i.e. thrombophilia) for > 6 months, (no proven added benefit). 
 
C9. Vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors for first pulmonary embolus without 
continuing provoking risk factors (i.e. thrombophilia) for > 12 months (no proven added benefit). 
 
C10. NSAID and vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors in combination (risk of 
gastrointestinal bleeding). 
 
C11. NSAID with concurrent antiplatelet agent(s) without PPI prophylaxis (increased risk of peptic ulcer disease). 
 
 
 
 
 
X 
 
 
X 
 
 
 
 
 
CNS & Psychotropic drugs D1. Tricyclic antidepressants with dementia, narrow angle glaucoma, cardiac conduction abnormalities, prostatism, 
or prior history of urinary retention (risk of worsening these conditions). 
 
D2. Initiation of tricyclic antidepressants as first-line antidepressant treatment (higher risk of adverse drug 
reactions with TCAs than with SSRIs or SNRIs). 
 
D3. Neuroleptics with moderate-marked antimuscarinic/anticholinergic effects (chlorpromazine, clozapine, 
flupenthixol, fluphenzine, pipothiazine, promazine, zuclopenthixol) with a history of prostatism or previous urinary 
retention (high risk of urinary retention). 
 
D4. Selective serotonin re-uptake inhibitors (SSRI’s) with current or recent significant hyponatraemia i.e. serum Na+ 
< 130 mmol/l (risk of exacerbating or precipitating hyponatraemia). 
 
D5. Benzodiazepines for ≥ 4 weeks (no indication for longer treatment; risk of prolonged sedation, confusion, 
impaired balance, falls, road traffic accidents; all benzodiazepines should be withdrawn gradually if taken for > 2 
weeks as there is a risk of causing a benzodiazepine withdrawal syndrome if stopped abruptly). 
 
D6. Antipsychotics (i.e. other than quetiapine or clozapine) in those with parkinsonism or Lewy Body Disease (risk 
of severe extra-pyramidal symptoms). 
 
D7. Anticholinergics/antimuscarinics to treat extra-pyramidal side-effects of neuroleptic medications (risk of 
anticholinergic toxicity). 
 
D8. Anticholinergics/antimuscarinics in patients with delirium or dementia (risk of exacerbation of cognitive 
impairment). 
 
 
 
 
X 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10/14 (71.4) 
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D9. Neuroleptic antipsychotic in patients with behavioural and psychological symptoms of dementia (BPSD) unless 
symptoms are severe and other non-pharmacological treatments have failed (increased risk of stroke). 
 
D10. Neuroleptics as hypnotics, unless sleep disorder is due to psychosis or dementia (risk of confusion, 
hypotension, extra-pyramidal side effects, falls). 
 
D11. Acetylcholinesterase inhibitors with a known history of persistent bradycardia (< 60 beats/min.), heart block 
or recurrent unexplained syncope or concurrent treatment with drugs that reduce heart rate such as beta-blockers, 
digoxin, diltiazem, verapamil (risk of cardiac conduction failure, syncope and injury). 
 
D12. Phenothiazines as  first-line treatment, since safer and more efficacious alternatives exist (phenothiazines are 
sedative, have significant anti-muscarinic toxicity in older people, with the exception of prochlorperazine for 
nausea/vomiting/vertigo, chlorpromazine for relief of persistent hiccoughs and levomepromazine as an anti-emetic 
in  palliative care). 
 
D13. Levodopa or dopamine agonists for benign essential tremor (no evidence of efficacy). 
 
D14. First-generation antihistamines (safer, less toxic antihistamines now widely available). 
 
X 
 
 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
 
 
 
Renal system E1. Digoxin at a long-term dose greater than 125µg/day if eGFR < 30 ml/min/1.73m2 (risk of digoxin toxicity if 
plasma levels not measured).  
 
E2. Direct thrombin inhibitors (i.e. dabigatran) if eGFR < 30 ml/min/1.73m2 (risk of bleeding). 
 
E3. Factor Xa inhibitors (i.e. rivaroxaban, apixaban) if eGFR < 15 ml/min/1.73m2 (risk of bleeding). 
 
E4. NSAID’s if eGFR < 50 ml/min/1.73m2 (risk of deterioration in renal function). 
 
E5. Colchicine if eGFR < 10 ml/min/1.73m2 (risk of colchicine toxicity). 
 
E6. Metformin if eGFR < 30 ml/min/1.73m2 (risk of lactic acidosis). 
 
 
X 
 
 
X 
 
X 
 
X 
 
X 
 
X 
 
0/6 (0) 
Gastrointestinal system F1. Prochlorperazine or metoclopramide with Parkinsonism (risk of exacerbating Parkinsonian symptoms). 
 
F2.  PPI for uncomplicated peptic ulcer disease or erosive peptic oesophagitis at full therapeutic dosage for > 8 
weeks (dose reduction or earlier discontinuation indicated). 
 
 
 
 
 
 
 
4/4 (100) 
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F3. Drugs likely to cause constipation (i.e. antimuscarinic/anticholinergic drugs, oral iron, opioids, verapamil, 
aluminium antacids) in patients with chronic constipation where non-constipating alternatives are available (risk of 
exacerbation of constipation). 
 
F4. Oral elemental iron doses greater than 200 mg daily (i.e. ferrous fumarate> 600 mg/day, ferrous sulphate > 600 
mg/day, ferrous gluconate> 1800 mg/day; no evidence of enhanced iron absorption above these doses). 
 
 
 
 
 
 
 
Respiratory system G1. Theophylline as monotherapy for COPD (safer, more effective alternative; risk of adverse effects due to narrow 
therapeutic index). 
 
G2. Systemic corticosteroids instead of inhaled corticosteroids for maintenance therapy in moderate-severe COPD 
(unnecessary exposure to long-term side-effects of systemic corticosteroids and effective inhaled therapies are 
available). 
 
G3. Antimuscarinic bronchodilators (i.e. ipratropium, tiotropium) with a history of narrow angle glaucoma (may 
exacerbate glaucoma) or bladder outflow obstruction (may cause urinary retention). 
 
G4. Non-selective beta-blocker (whether oral or topical for glaucoma) with a history of asthma requiring treatment 
(risk of increased bronchospasm). 
 
G5. Benzodiazepines with acute or chronic respiratory failure i.e. pO2 < 8.0 kPa ± pCO2 > 6.5 kPa (risk of 
exacerbation of respiratory failure). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
4/5 (80) 
Musculoskeletal system H1. Non-steroidal anti-inflammatory drug (NSAID) other than COX-2 selective agents with history of peptic ulcer 
disease or gastrointestinal bleeding, unless with concurrent PPI or H2 antagonist (risk of peptic ulcer relapse). 
 
H2. NSAID with severe hypertension (risk of exacerbation of hypertension) or severe heart failure (risk of 
exacerbation of heart failure). 
 
H3. Long-term use of NSAID (>3 months) for symptom relief of osteoarthritis pain where paracetamol has not been 
tried (simple analgesics preferable and usually as effective for pain relief). 
 
H4. Long-term corticosteroids (>3 months) as monotherapy for rheumatoid arthrtitis (risk of systemic 
corticosteroid side-effects). 
 
H5.  Corticosteroids (other than periodic intra-articular injections for mono-articular pain) for osteoarthritis (risk of 
systemic corticosteroid side-effects). 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
 
 
 
 
8/9 (88.9) 
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H6. Long-term NSAID or colchicine (> 3 months) for chronic treatment of gout where there is no contraindication to 
a xanthine-oxidase inhibitor i.e. allopurinol, febuxostat (xanthine-oxidase inhibitors are first choice prophylactic 
drugs in gout). 
 
H7. COX-2 selective NSAIDs with concurrent cardiovascular disease (increased risk of myocardial infarction and 
stroke). 
 
H8. NSAID with concurrent corticosteroids without PPI prophylaxis (increased risk of peptic ulcer disease). 
 
H9. Oral bisphosphonates in patients with a current or recent history of upper gastrointestinal disease i.e. 
dysphagia, oesophagitis, gastritis, duodenitis, or peptic ulcer disease, or upper gastrointestinal bleeding (risk of 
relapse/exacerbation of oesophagitis, oesophageal ulcer, oesophageal stricture). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Urogenital system I1. Antimuscarinic drugs with dementia, or chronic cognitive impairment (risk of increased confusion, agitation) or 
narrow-angle glaucoma (risk of acute exacerbation of glaucoma), or chronic prostatism (risk of urinary retention). 
 
I2. Selective alpha-1 selective alpha blockers in those with symptomatic orthostatic hypotension or micturition 
syncope (risk of precipitating recurrent syncope) 
 
 
 
 
2/2 (100) 
Endocrine system J1. Sulphonylureas with a long duration of action (i.e. glibenclamide, chlorpropamide, glimepiride) with type 2 
diabetes mellitus (risk of prolonged hypoglycaemia). 
 
J2. Thiazolidenediones (i.e. rosiglitazone, pioglitazone) in patients with heart failure (risk of exacerbation of heart 
failure). 
J3. Beta-blockers in diabetes mellitus with frequent hypoglycaemic episodes (risk of suppressing hypoglycaemic 
symptoms). 
 
J4. Oestrogens with a history of breast cancer or venous thromboembolism (increased risk of recurrence). 
 
J5. Oral oestrogens without progestogen in patients with intact uterus (risk of endometrial cancer). 
 
J6. Androgens (male sex hormones) in the absence of primary or secondary hypogonadism (risk of androgen 
toxicity; no proven benefit outside of hypogonadismindication). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6/6 (100) 
Drugs that predictably increase the 
risk of falls in older people 
K1. Benzodiazepines (sedative, may cause reduced sensorium, impair balance). 
 
K2. Neuroleptic drugs (may cause gait dyspraxia, Parkinsonism). 
 
K3. Vasodilator drugs (i.e. alpha-1 receptor blockers, calcium channel blockers, long-acting nitrates, ACE inhibitors, 
angiotensin I receptor blockers, diazoxide, minoxidil, hydralazine) with persistent postural hypotension i.e. 
recurrent drop in systolic blood pressure ≥ 20mmHg (risk of syncope, falls). 
 
 
 
 
 
 
X 
 
 
3/4 (75) 
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K4. Hypnotic Z-drugs i.e. zopiclone, zolpidem, zaleplon (may cause protracted daytime sedation, ataxia).  
Analgesic drugs L1. Use of oral or transdermal strong opioids (morphine, oxycodone, fentanyl, buprenorphine, diamorphine, 
methadone, tramadol, pethidine, pentazocine) as first line therapy for mild pain (WHO analgesic ladder not 
observed). 
 
L2. Use of regular (as distinct from PRN) opioids without concomitant laxative (risk of severe constipation). 
 
L3. Long-acting opioids without short-acting opioids for break-through pain (risk of persistence of severe pain). 
X 
 
 
 
 
 
 
2/3 (66.7) 
Antimuscarinic/Anticholinergic drug 
burden  
N. Concomitant use of two or more drugs with antimuscarinic/anticholinergic properties (i.e. bladder 
antispasmodics, intestinal antispasmodics, tricyclic antidepressants, first generation antihistamines) (risk of 
increased antimuscarinic/anticholinergic toxicity). 
 1/1 (100) 
Total STOPP criteria n=80  
 
 
 58/80 (72.5) 
 
 START criteria 
Cardiovascular system A1. Vitamin K antagonists or direct thrombin inhibitors or factor Xa inhibitors in the presence of chronic atrial 
fibrillation. 
 
A2. Aspirin (75 mg – 160 mg once daily) in the presence of chronic atrial fibrillation, where Vitamin K antagonists or 
direct thrombin inhibitors or factor Xa inhibitors are contraindicated. 
 
A3. Antiplatelet therapy (aspirin or clopidogrel or prasugrel or ticagrelor) with a documented history of coronary, 
cerebral or peripheral vascular disease. 
 
A4. Antihypertensive therapy where systolic blood pressure consistently > 160 mmHg and/or diastolic blood 
pressure consistently > 90 mmHg; if systolic blood pressure > 140 mmHg and /or diastolic blood pressure > 90 
mmHg, if diabetic. 
 
A5. Statin therapy with a documented history of coronary, cerebral or peripheral vascular disease, unless the 
patient’s status is end-of-life or age is > 85 years. 
 
A6. Angiotensin Converting Enzyme (ACE) inhibitor with systolic heart failure and/or documented coronary artery 
disease. 
 
A7. Beta-blocker with ischaemic heart disease. 
 
A8. Appropriate beta-blocker (bisoprolol, nebivolol, metoprololorcarvedilol) with stable systolic heart failure. 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
7/8 (87.5) 
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Respiratory system B1. Regular inhaled beta 2 agonist or antimuscarinic bronchodilator (i.e. ipratropium, tiotropium) for mild to 
moderate asthma or COPD. 
 
B2. Regular inhaled corticosteroid for moderate-severe asthma or COPD, where FEV1 <50% of predicted value and 
repeated exacerbations requiring treatment with oral corticosteroids. 
 
B3. Home continuous oxygen with documented chronic hypoxaemia (i.e. pO2 < 8.0 kPa or 60 mmHg or SaO2 < 
89%). 
 
 
 
 
X 
 
 
 
X 
1/3 (33.3) 
Central nervous system & Eyes C1. L-DOPA or a dopamine agonist in idiopathic Parkinson’s disease with functional impairment and resultant 
disability. 
 
C2. Non-TCA antidepressant drug in the presence of persistent major depressive symptoms. 
 
C3. Acetylcholinesterase inhibitor (i.e. donepezil, rivastigmine, galantamine) for mild-moderate Alzheimer’s 
dementia or Lewy Body dementia (rivastigmine). 
 
C4. Topical prostaglandin, prostamide or beta-blocker for primary open-angle glaucoma. 
 
C5. Selective serotonin reuptake inhibitor (or SNRI or pregabalin if SSRI contraindicated) for persistent severe 
anxiety that interferes with independent functioning. 
 
C6. Dopamine agonist (ropinirole or pramipexole or rotigotine) for Restless Legs Syndrome, once iron deficiency 
and severe renal failure have been excluded. 
 
 
 
X 
 
 
 
 
 
 
X 
 
 
 
X 
3/6 (50) 
Gastrointestinal system D1. Proton Pump Inhibitor with severe gastro-oesophageal reflux disease or peptic stricture requiring dilatation. 
 
D2. Fibre supplements (i.e. bran, ispaghula, methylcellulose, sterculia) for diverticulosis with a history of 
constipation. 
 
 
 
 
2/2 (100) 
Musculoskeletal system E1. Disease-modifying anti-rheumatic drug (DMARD) with active, disabling rheumatoid disease. 
 
E2. Bisphosphonates and vitamin D and calcium in patients taking long-term systemic corticosteroid therapy. 
 
E3. Vitamin D and calcium supplement in patients with known osteoporosis and/or previous fragility fracture(s) 
and/or (Bone Mineral Density T-scores more than -2.5 in multiple sites). 
 
E4. Bone anti-resorptive or anabolic therapy (i.e. bisphosphonate, strontium ranelate, teriparatide, denosumab) in 
patients with documented osteoporosis, where no pharmacological or clinical status contraindication exists (Bone 
Mineral Density T-scores -> 2.5 in multiple sites) and/or previous history of fragility fracture(s). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7/7 (100) 
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E5. Vitamin D supplement in older people who are housebound or experiencing falls or with osteopenia (Bone 
Mineral Density T-score is > -1.0 but < -2.5 in multiple sites). 
 
E6. Xanthine-oxidase inhibitors (i.e. allopurinol, febuxostat) with a history of recurrent episodes of gout. 
 
E7. Folic acid supplement in patients taking methotexate. 
 
 
 
 
 
 
 
Endocrine system F1. ACE inhibitor or Angiotensin Receptor Blocker (if intolerant of ACE inhibitor) in diabetes with evidence of renal 
disease i.e. overt dipstick proteinuria or microalbuminuria (>30mg/24 hours) with or without serum biochemical 
renal impairment. 
 
X 0/1 (0) 
Urogenital system G1. Alpha-1 receptor blocker with symptomatic prostatism, where prostatectomy is not considered necessary. 
 
G2. 5-alpha reductase inhibitor with symptomatic prostatism, where prostatectomy is not considered necessary. 
 
G3. Topical vaginal oestrogen or vaginal oestrogen pessary for symptomatic atrophic vaginitis. 
X 
 
X 
 
 
1/3 (33.3) 
Analgesics H1. High-potency opioids in moderate-severe pain, where paracetamol, NSAIDs or low-potency opioids are not 
appropriate to the pain severity or have been ineffective. 
 
H2. Laxatives in patients receiving opioids regularly. 
 
X 
 
 
 
1/2 (50) 
Vaccines I1: Seasonal trivalent influenza vaccine annually. 
 
I2: Pneumococcal vaccine every 5 years, according to national guidelines. 
 
 
X 
 
X 
0/2 (0) 
Total START criteria n=34   22/34 (64.7) 
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Appendix V. Supplementary material for Chapter 7. 
 
Supplementary material 16. FORUM article. 
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Appendix VI. Education and training undertaken during the PhD 
 
Date Education and training 
October 2013-
September 2015 
SPHeRE Scholars Programme in Health Services Research. The following modules were undertaken: 
 EH7003: Evidence Synthesis and Clinical Trials (5 credits). 
 EH7005: Introduction to Health Economics and Econometrics (10 credits). 
 EH7009: Population and Individual Health (10 credits). 
 EH7010: Health Systems, Policy and Informatics (10 credits). 
 EH7011: Integrated Epidemiology/Biostatistics (10 credits). 
 EH7014: National work placement: 8 week placement with the TRUST trial (5 credits). 
 OH7013: Quantitative and Qualitative Research Methods (10 credits). 
 PG7016: Systematic Reviews for the Health Sciences (5 credits). 
 EH7012: Research Development and Academic writing (5 credits). 
 EH7013: International placement: 4 week placement at Inselspital, Bern University Hospital, Switzerland (5 credits). 
May 2014  Presentation skills, Irish Times training, Royal College of Surgeons Ireland (RCSI). 
May 2014  The importance of academic feedback, Dr Carlos Bruen, RCSI. 
May 2014  Research prioritisation and impact, Dr Carlos Bruen, RCSI. 
October 2014  Completing ethics applications, Professor Anne Hickey, RCSI. 
October 2014  Research troubleshooting, Professor Anne Hickey, RCSI. 
November 2014  NVivo 2 day Training Course, Mr Ben Meehan, University College Cork. 
February 2015  What Contribution will your PhD make? Dr Sarah Barry, Dr Niamh Humphries, RCSI. 
February 2015  Introduction to analysing qualitative interviews, Health Experiences Research Group at the University of Oxford. 
March 2015  Code of good practice, Dr Niamh Humphries, RCSI. 
April 2015  Writing skills, Professor Ivan Perry, UCC. 
April 2015  Behaviour change interventions, Dr Molly Byrne, RCSI. 
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Date Education and training 
April 2015  Qualitative troubleshooting, Dr Sarah Barry, RCSI. 
November 2015  Publishing in a peer review journal, Dr Trish Groves, Head of Research, BMJ & Editor-in-chief, BMJ Open, UCC. 
January 2016  Getting research into policy, Professor Ruairi Brugha, RCSI.  
March 2016  Leadership, Professor Patricia Kearney, RCSI. 
March 2016  Grant writing, Professor Kathleen Bennett, RCSI. 
March 2016  Managing a career in Population Health and Health Services Research (PHHSR), Dr Eithne Sexton, Dr Lisa Mellon, Dr Niamh Humphries, Dr Richard Layte, RCSI. 
May 2016  Academic detailing (AD) training workshop, National Resource Center for Academic Detailing (NARCAD) in Boston, USA. 
March 2017  Communicating your research for policy, Dr Carlos Bruen, Dr Sara McAleese, Dr Conor Keegan, RCSI. 
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